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ABSTRACT 
JENNA MARIE CURRIER: Novel Biomarkers for the Risk Assessment of Exposure to 
Arsenic in Drinking Water 
 (Under the direction of Miroslav Stýblo) 
 
The toxic methylated trivalent metabolites of inorganic arsenic (iAs), 
methylarsonite (MAs
III
) and dimethylarsinite (DMAs
III
), play an important role in the 
etiology of As-induced diseases, including diabetes mellitus. However, the rapid 
oxidation of DMAs
III
 and, to a lesser extent, MAs
III
 leads to difficulties in the analysis of 
these metabolites in biological samples and assessment of the risk associated with As 
exposure. The goal of this project was to determine if a recently optimized analytical 
technique, hydride generation-cryotrapping-atomic absorption spectroscopy (HG-CT-
AAS), can be used to quantitate trivalent As species in complex biological matrices, and 
determine whether concentrations of these species in biological systems can predict 
susceptibility to the diabetogenic effects of As exposure.  
First, we established that HG-CT-AAS is suitable for the quantification of MAs
III
 
and DMAs
III
 and that these species are relatively stable in cells and tissues. We then used 
HG-CT-AAS to compare As speciation in tissues of wild-type (WT) mice that methylate 
As and mice null for As (3+ oxidation state) methyltransferase (As3mt-KO), the key 
enzyme in the pathway for As methylation, focusing on tissues regulating glucose 
homeostasis, including liver, pancreas, skeletal muscle, and adipose tissue. In WT mice, 
MAs
III
 and DMAs
III
 were extensively retained in these tissues, while iAs
III
 and iAs
V
 were 
iv 
 
predominantly retained in tissues of As3mt-KO mice. Lastly, we used HG-CT-
inductively coupled plasma-mass spectrometry, which provides lower detection limits, to 
examine concentrations of tri- and pentavalent As species retained in bladder exfoliated 
cells (BECs) recovered from individuals exposed to iAs in drinking water, and 
determined associations between the concentrations of As species in BECs and urine and 
the individual risk of developing diabetes. As species retained in BECs were positively 
correlated with other markers of exposure. More importantly, iAs
III
 and MAs
III
 retained in 
BECs were positively associated with risk of diabetes. Taken together, this work 
demonstrates the robustness of the optimized HG-CT-based techniques for the oxidation 
state specific analysis of As species in a variety of biological samples, and provides the 
first evidence that measurements of trivalent arsenicals in these samples can provide 
sensitive markers for assessment of health risks associated with iAs exposure.  
v 
 
 
To those who trudge the road of happy destiny. 
  
vi 
 
 
ACKNOWLEDGEMENTS 
The path to completing this dissertation has been filled with amazing peers, 
mentors, friends, loved ones, colleagues and collaborators. It would take pages to 
properly acknowledge and thank everyone that has supported my growth as a scientist. 
Thus, the following is by no means an exhaustive list. 
I would like to thank my mentor, Dr. Miroslav Stýblo, for welcoming me into his 
laboratory and providing me with a well-rounded graduate career over the last four years. 
I am also grateful for my committee members for assessing my work and encouraging me 
to expand my knowledge and critical thinking skills.  
I would like to thank my family, specifically, my mother, Laurie, and father, Don, 
for facilitating my interest in math and science from such an early age. I owe my partner, 
Stephan, a world of gratitude for experiencing this journey by my side, even through the 
rough times. Moreover, I am eternally grateful for my vast support network of friends 
that keep me grounded. 
Finally, I am eternally indebted to the baristas at my favorite coffee shops that 
have brewed me endless cups of coffee and sometimes patiently listened during the more 
stressful times in my graduate career.   
   
vii 
 
 
TABLE OF CONTENTS 
 
LIST OF FIGURES ....................................................................................................... xiv 
LIST OF ABBREVIATIONS ...................................................................................... xvii 
CHAPTER I: Introduction ...............................................................................................1 
1.1 Biomarkers of Arsenic exposure and disease susceptibility ...................................1 
1.2 Human As exposure ................................................................................................2 
1.2.1 Ingestion of As in drinking water ...................................................................4 
1.2.2 As exposure through food ...............................................................................5 
1.2.3 Occupational and other exposures ..................................................................6 
1.2.4 Current medical uses for As ............................................................................7 
1.3 As Metabolism ........................................................................................................7 
1.3.1 As uptake and transport ..................................................................................7 
1.3.2 Biotransformation ...........................................................................................8 
1.3.2.1 Genetic factors affecting As biotransformation ......................................11 
1.3.2.2 Dietary factors affecting As biotransformation .......................................11 
1.3.3 As retention, and excretion ...........................................................................12 
1.4 As and Diabetes ....................................................................................................13 
1.4.1 Epidemiological evidence for associations between As and 
diabetes ..................................................................................................................15 
1.4.2 Effects of As on glucose metabolism and homeostasis: laboratory 
evidence .................................................................................................................18 
1.5 As Speciation Analysis .........................................................................................19 
viii 
 
1.5.2 Separation of As species ...............................................................................20 
1.5.3 Analytical detectors ......................................................................................24 
1.5.4 Biological matrices .......................................................................................25 
1.6 Conclusions...........................................................................................................26 
CHAPTER II: Direct Analysis of Methylated Trivalent Arsenicals in 
Mouse Liver by Hydride Generation-Cryotrapping-Atomic Absorption 
Spectrometry ....................................................................................................................27 
2.1 Overview ...............................................................................................................27 
2.2 Introduction ...........................................................................................................27 
2.3 Materials and Methods .........................................................................................29 
2.3.1 Arsenicals ......................................................................................................29 
2.3.2 Speciation Analysis of As .............................................................................30 
2.3.3 Animals .........................................................................................................31 
2.3.4 Tissues...........................................................................................................31 
2.3.5 Statistical Analyses .......................................................................................32 
2.4 Results and Discussion .........................................................................................32 
CHAPTER III: Direct Analysis and Stability of Methylated Trivalent 
Arsenic Metabolites in Cells and Tissues .......................................................................39 
3.1 Overview ...............................................................................................................39 
3.2 Introduction ...........................................................................................................40 
3.3 Methods ................................................................................................................43 
3.3.1 Arsenicals ......................................................................................................43 
3.3.2 Mice and treatments ......................................................................................43 
3.3.3 Cultured cells and treatments ........................................................................44 
3.3.4 Depletion of intracellular GSH .....................................................................45 
3.3.5 Speciation analysis of As by HG-CT-AAS ..................................................45 
ix 
 
3.3.6 Acid digestion ...............................................................................................46 
3.3.7 Statistical analysis .........................................................................................46 
3.4 Results and discussion ..........................................................................................47 
3.4.1 Speciation analysis of As in biological matrices ..........................................47 
3.4.2 Optimization of HG-CT-AAS for analysis of slurries ..................................48 
3.4.3 Stability of trivalent arsenicals in mouse liver homogenates........................53 
3.4.4 Generation and stability of DMAs
III
 in UROtsa/F35 cells............................55 
3.5 Conclusions...........................................................................................................62 
CHAPTER IV: Comparative Oxidation State Specific Analysis of Arsenic 
by High-Performance Liquid Chromatography-Inductively Coupled 
Plasma-Mass Spectrometry and Hydride Generation-Cryotrapping-
Atomic Absorption Spectrometry ..................................................................................63 
4.1 Overview ...............................................................................................................63 
4.2 Introduction ...........................................................................................................64 
4.3 Experimental .........................................................................................................68 
4.3.1 Arsenicals ......................................................................................................68 
4.3.2 Instrumentation .............................................................................................68 
4.3.2.1 HG-CT-AAS .............................................................................................68 
4.3.2.2 HPLC-ICP-MS ........................................................................................69 
4.3.3 In vitro methylation mixture .........................................................................70 
4.3.4 Ultrafiltration ................................................................................................71 
4.3.5 Statistical Analysis ........................................................................................72 
4.4 Results and discussion ..........................................................................................72 
4.4.1 Method optimization .....................................................................................72 
4.4.1.1 HG-CT-AAS .............................................................................................72 
4.4.1.2 HPLC-ICP-MS ........................................................................................73 
x 
 
4.4.2 Calibration.....................................................................................................74 
4.4.2.1 HG-CT-AAS .............................................................................................75 
4.4.2.2 HPLC-ICP-MS ........................................................................................76 
4.4.3 Limits of detection (LODs) ...........................................................................77 
4.4.4 Speciation analysis of As in the in vitro methylation mixture ......................77 
4.4.4.1 Analysis of the reaction mixture incubated with iAs
III
 .............................78 
4.4.4.2 Analysis of the reaction mixture incubated with MAs
III
 ..........................80 
4.4.5 Interactions of As
III
 species with the components of the 
methylation mixture ...............................................................................................82 
4.4.6 Binding of As
III
 species to AS3MT ..............................................................85 
4.5 Conclusions...........................................................................................................88 
4.6 Acknowledgements ...............................................................................................89 
CHAPTER V: Oxidation State Specific Analysis of Arsenic Species in 
Tissues of Wild-type and Arsenic (+3 oxidation state) Methyltransferase 
(As3mt) Knockout Mice ...................................................................................................91 
5.1 Overview ...............................................................................................................91 
5.2 Introduction ...........................................................................................................92 
5.3 Methods ................................................................................................................95 
5.3.1 Arsenicals ......................................................................................................95 
5.3.2 Mice and Treatments.....................................................................................96 
5.3.3 Speciation analysis of As by HG-CT-AAS ..................................................97 
5.3.5 Statistical Analysis ........................................................................................98 
5.4 Results and Discussion .........................................................................................98 
5.4.1 Water consumption and body weights ..........................................................98 
5.4.2 Effect of genotype on As speciation in tissues ...........................................101 
5.4.3 Recovery of speciated As during direct analysis ........................................108 
xi 
 
5.4.4 Comparison of the internal of As ................................................................109 
5.5 Conclusions.........................................................................................................111 
5.6 Acknowledgements .............................................................................................112 
CHAPTER VI: Retention of Trivalent Arsenic Metabolites in Urothelial 
Cells is Associated with Markers of iAs Exposure and Diabetes...............................113 
6.1 Overview .............................................................................................................113 
6.2 Introduction .........................................................................................................114 
6.3 Methods ..............................................................................................................117 
6.3.1 Study Population .........................................................................................117 
6.3.2 Sample Collection .......................................................................................118 
6.3.3 Diagnosis of Diabetes .................................................................................119 
6.3.4 Analyses of As in Urine and BECs .............................................................120 
6.3.5 Statistical Analysis ......................................................................................122 
6.4 Results and Discussion .......................................................................................123 
6.4.1 Study Population Characteristics ................................................................123 
6.4.2 Markers of iAs Exposure ............................................................................125 
6.4.3 Gender Differences in BECs As Retention .................................................132 
6.4.4 Associations of iAs Exposure and Diabetes ...............................................136 
6.4.4.1 Associations of Diabetes with iAs in Drinking Water ...........................136 
6.4.4.2 Associations of Diabetes with Metabolites of iAs in BECs and 
Urine ..................................................................................................................138 
6.4.4.3 Associations between Diabetes and iAs Exposure Based on 
Linear Regression Analysis ...............................................................................140 
6.5 Conclusions.........................................................................................................144 
CHAPTER VII: Synthesis .............................................................................................145 
7.1 Introduction .........................................................................................................145 
xii 
 
7.2 Findings and Implications ...................................................................................146 
7.3 Future Studies .....................................................................................................149 
7.4 Conclusions.........................................................................................................152 
REFERENCES ...............................................................................................................153 
 
  
xiii 
 
LIST OF TABLES 
Table 2.1:   Characteristics of the calibration curves for As
V
 standards 
spiked into DIW or 10% liver homogenate ...............................................33 
Table 2.2:   The instrumental and tissue detection limits for analysis of 
As
III
 and As
III+V
 species in mouse liver homogenate .................................35 
Table 2.3:   The concentration of As species in one section of the liver 
from a mouse exposed to iAs
III
 in drinking water (50 ppm 
As) for 9 days .............................................................................................36 
Table 4.1:    HG-CT-AAS and HPLC-ICP-MS operating conditions........................... 70 
Table 4.2:   The slopes of calibration curves generated by HG-CT-AAS 
and HPLC-ICP-MS for As standards .........................................................76 
Table 4.3:    Limits of detection for the analysis of As species by HPLC-
ICP-MS and HG-CT-AAS .........................................................................77 
Table 5.1:  Recovery of speciated As during direct analysis .................................... 109 
Table 5.2:  Determination of equivalent internal As doses in tissues 
critical for glucose homeostasis ...............................................................111 
Table 6.1:  Characteristics of the study population ................................................... 123 
Table 6.2:  Descriptive statistics for exposure to iAs in drinking water 
and iAs metabolites in BECs and urine ...................................................125 
Table 6.3:  Association of diabetes with exposure to iAs in drinking 
water and iAs metabolites in BECs and urine adjusted for 
age, sex, and BMI ....................................................................................141 
Table 6.4:  Association of log-transformed FPG and 2HPG with iAs in 
drinking water and iAs metabolites in BECs and urine 
adjusted for age, sex, and BMI. ...............................................................143 
.  
  
xiv 
 
LIST OF FIGURES 
Figure 1.1:  An overview of the prevalence of groundwater As 
contamination. ..............................................................................................4 
Figure 1.2:  As contamination of municipal groundwater supplies in the 
United States. ...............................................................................................5 
Figure 1.3:  Schematic representations of the oxidative and reductive 
pathways for As biomethylation. ...............................................................10 
Figure 1.4:  A schematic representation of the semi-automated HG-CT-
AAS method...............................................................................................23 
Figure 2.1:  HG-CT-AAS analysis of DIW and 10% liver homogenate 
spiked with As
III
 and As
V
 standards ...........................................................34 
Figure 2.2:  Recovery of total speciated As during the direct analyses of 
fresh (undigested) homogenates prepared from four 
sections of the liver of a mouse exposed to iAs
III
 (50 ppm 
As) for 9 days .............................................................................................38 
Figure 3.1:  The optimized HG-CT-AAS system for slurry sampling. .........................49 
Figure 3.2:  Peak areas recorded for iAs
III+V
, MAs
III+V
, and DMAs
III+V
 
during the direct HG-CT-AAS analysis of aliquots of a 
mouse liver homogenate pre-treated with 0.5, 2, or 4% 
cysteine for up to 80 minutes. ....................................................................50 
Figure 3.3:  HG-CT-AAS analysis of pooled mouse liver homogenates 
pre-treated with 2% cysteine for 1 hour: effect of Tris 
buffer concentration ...................................................................................51 
Figure 3.4:  HG-CT-AAS analysis of pooled mouse liver homogenates 
pre-treated with 2% cysteine for 1 hour: effect of NaBH4 
concentration ..............................................................................................52 
Figure 3.5:  Stability of trivalent arsenicals in a liver homogenate from 
a mouse exposed to iAs
III
 in drinking water (50 ppm As) 
for 9 days....................................................................................................54 
Figure 3.6:  Generation of DMAs
III
 in UROtsa/F35 culture exposed to 
0.1 mM MAs
III
 for up to 18 hours..............................................................56 
Figure 3.7:  Stability of DMAs
III
 in medium and cell lysates from 
UROtsa/F35 culture exposed to 0.1 µM MAs
III
 for 18 hours ....................57 
Figure 3.8:  Effect of Triton X100 on DMAs
III
 stability in cell lysates ........................58 
xv 
 
Figure 3.9:  The oxidation of DMAs
III
 in UROtsa/F35 culture medium 
and cell lysates placed in shipping containers packed with 
dry ice or with pre-frozen ice packs ...........................................................60 
Figure 3.10:  The oxidation of DMAs
III
 in UROtsa/F35 culture medium 
and cell lysates shipped to Prague, Czech Republic ..................................61 
Figure 4.1:  The separation and detection of six oxoarsenicals and 
DMTA by optimized HPLC-ICP-MS ........................................................74 
Figure 4.2:  The HPLC-ICP-MS profiles of As standards in DIW, 
including AsC, AsB, TMAO and iAs
III
 .....................................................75 
Figure 4.3:  Analyses of the complete in vitro methylation mixtures 
containing recombinant AS3MT incubated with 1 μM iAsIII 
for 2 hours at 37°C .....................................................................................79 
Figure 4.4:  Analyses of the complete in vitro methylation mixtures 
containing recombinant AS3MT incubated with 1 μM 
MAs
III
 for 40 min at 37°C ..........................................................................81 
Figure 4.5:  The HPLC-ICP-MS profiles for trivalent arsenical 
standards spiked into the complete in vitro methylation 
mixture in absence or presence of recombinant AS3MT  ..........................83 
Figure 4.6:  Comparison of the HPLC-ICP-MS profiles for As 
standards prepared in solutions containing the components 
of the in vitro methylation mixture ............................................................84 
Figure 4.7:  The amounts of trivalent arsenical standards in the 
complete reaction mixture before and after ultrafiltration .........................86 
Figure 4.8:  The HPLC-ICP-MS profiles for 0.5 µM DMAs
III
 standard 
spiked into 100 mM TRIS-HCl buffer (pH 7.4) or into 
human urine from an unexposed subject. ..................................................88 
Figure 5.1:  Average daily water consumption and estimated daily iAs 
intake for As3mt-KO and WT mice ...........................................................99 
Figure 5.2:  Change in body weights of As3mt-KO mice exposed to 0, 
15, 20, 25, or 30
 
ppm As and WT mice exposed to 50 ppm 
As .............................................................................................................100 
Figure 5.3:  Oxidation state specific analysis of As in tissues critical for 
glucose homeostasis .................................................................................102 
xvi 
 
Figure 5.4:  Oxidation state specific analysis of circulating As in As3mt-
KO mice exposed to 0, 15, 20, 25, and 30 ppm As and WT 
mice exposed to 50 ppm As as iAs
III
. ......................................................104 
Figure 5.5:  Oxidation state specific analysis of As in tissues from 
As3mt-KO mice exposed to 0, 15, 20, 25, and 30 ppm As 
and WT mice exposed to 50 ppm As as iAs
III
 .........................................107 
Figure 6.1:  Differences in composition of As species in BECs and 
urine .........................................................................................................127 
Figure 6.2:  The correlations between logarithmically transformed 
concentrations of iAs, MAs, DMAs and sum of As species 
in urine and BECs ....................................................................................129 
Figure 6.3:  The correlations between logarithmically transformed 
concentrations of iAs in water and iAs, MAs, DMAs and 
sum of As species in BECs ......................................................................130 
Figure 6.4:  The correlations between logarithmically transformed 
concentrations of iAs in drinking water and As metabolites 
in urine .....................................................................................................131 
Figure 6.5:  Gender differences in cells counts and As retention in 
BECs ........................................................................................................133 
Figure 6.6:  The associations of cell counts with sum of As species 
retained in BECs for samples obtained from males and 
females .....................................................................................................134 
Figure 6.7:  Gender differences in percent composition of As 
metabolites retained in BECs and excreted in urine ................................135 
Figure 6.8:  Association of diabetes with exposure to iAs in drinking 
water adjusted for age, sex, and BMI ......................................................138 
 
  
xvii 
 
LIST OF ABBREVIATIONS 
2HBG  2-hour blood glucose 
2HPG  2-hour plasma glucose 
AAS  Atomic absorption spectrometry 
AFS  Atomic fluorescence spectrometry 
ANOVA Analysis of variance 
APL  Acute promyelocytic leukemia 
AQP  Aquaglyceroporin 
As  Arsenic 
As
III
  Trivalent arsenic 
As
V
  Pentavalent arsenic 
AS3MT Arsenic (3+ oxidation state) methyltransferase 
AsB  Arsenobetaine 
AsC  Arsenocholine 
AT  Autotransformer 
BECs  Bladder exfoliated cells 
BSO  Buthionine sulfoximine 
CCA  Chromated copper arsenate 
CI  Confidence interval 
CT  Cryotrapping 
DIW  Deionized water 
DMAs  Dimethylated arsenic 
DMAs
III
 Dimethylarsinite (dimethylarsinous acid) 
xviii 
 
DMAs
III
I Iododimethylarsine 
DMAs
V
 Dimethylarsinate (dimethyarsinic acid) 
DMTA Dimethylthioarsinic acid 
DWF  Dewar flask 
FBG  Fasting blood glucose 
FDA  Food and Drug Administration 
FIAS  Flow injection for atomic spectroscopy 
GF  Glass flask 
GLS  Gas-liquid phase separator 
GLUT  Glucose transporter 
GSH  Glutathione 
GSTO  Glutathione S-transferase omega 
GSIS  Glucose-stimulated insulin secretion 
HbA1c  Glycosylated hemoglobin 
HG  Hydride generation 
HPLC  High performance liquid chromatography 
iAs  Inorganic arsenic 
iAs
III
  Arsenite 
iAs
V
  Arsenate 
ICP-MS Inductively coupled plasma mass spectrometry 
INJ  Injection valve 
KO  Knockout 
LOD  Limits of detection 
xix 
 
MAs  Methylated arsenic 
MAs
III
  Methylarsonite (methylarsonous acid) 
MAs
III
O Oxomethlarsine 
MAs
V
  Methylarsonate (methylarsonic acid) 
MC  Mixing coil 
MCL  Maximum contaminant level 
MRP  Multidrug resistance protein 
m/z  Mass-to-charge ratio 
NHANES National Health and Nutrition Examination Survey 
NTP  National Toxicology Program 
OAT   Organic anion transporting polypeptide 
ODS  Octadecylsilane 
OGTT  Oral glucose tolerance test 
OR  Odds ratio 
PBS  Phosphate-buffered saline 
PEEK  Polyether ether ketone 
PP  Peristaltic pump 
R  Remote 
RBC  Red blood cell 
RC  Reaction coil 
ROS  Reactive oxygen species 
RT  Rotamer tube 
SAM  S-adenosylmethionine 
xx 
 
SD  Standard deviation 
SNP  Single nucleotide polymorphism 
ST  Separating transformer 
SV  Solenoid valve 
SW  Relay switch 
T1D  Type 1 diabetes 
T2D  Type 2 diabetes 
TBAH  Tetrabutylammonium hydroxide 
TI  Thermal insulation 
TMAs
V
O Trimethylarsine oxide 
TRIS  Tris(hydroxymethyl)aminomethane 
US EPA United States Environmental Protection Agency 
V  Voltmeter 
WHO  World Health Organization 
WT  Wild-type 
 
   
 
 
CHAPTER I  
Introduction 
1.1 Biomarkers of Arsenic exposure and disease susceptibility 
Environmental and occupational exposures to inorganic arsenic (iAs) have been 
linked to several adverse health effects, including cancer of the skin, lungs, liver, and 
urinary bladder (1). Other effects of iAs exposure include vascular disease, hypertension, 
skin lesions, and diabetes (1-4). The presence of arsenic (As) in the earth’s crust and 
certain industrial activities contribute to its contamination of aquifers used for drinking 
water across the globe. Recently, exposure to high levels of iAs through the ingestion of 
contaminated drinking water has been implicated in an As-induced form of diabetes 
characterized by impaired glucose tolerance in the absence of fasting hyperinsulinemia 
and insulin resistance (5).  
Exposure to iAs and susceptibility to disease have commonly been assessed 
through analysis of total As and biological speciated metabolites of As in urine and other 
easily attainable and minimally invasive samples, including blood, hair, and nails. The 
United States Environmental Protection Agency (US EPA) and World Health 
Organization (WHO) recently lowered the safe levels for As in drinking water from 50 to 
10 ppb in response to evidence of increased risk of cancer associated with chronic 
ingestion of As, even at low levels (6, 7). Current evidence suggest that the toxic 
methylated trivalent metabolites of iAs, methylarsonite (MAs
III
) and dimethylarsinite 
(DMAs
III
) produced in the course of As metabolism, play a key role in the etiology of As-
induced diseases (8-11). While MAs
III
 and DMAs
III
 have been detected in urine of 
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subjects exposed to iAs (12, 13), the rapid oxidation of DMAs
III
 and, to a lesser extent, 
MAs
III
 to their pentavalent counterparts, methylarsonic acid (MAs
V
) and dimethylarsinic 
acid (DMAs
V
), complicates their analysis in samples of urine collected in field studies 
(13, 14). Furthermore, comparatively little work has been conducted toward the direct 
analysis of trivalent arsenicals in more complex biological matrices. 
This project was designed to develop methods for assessing trivalent arsenicals as 
biomarkers of iAs exposure and susceptibility to As-induced diabetes. Establishing 
methods for the determination of As metabolites in target human tissues and linking As 
concentrations in tissues to adverse health effects will help inform the risk assessment of 
As-induced diabetes and other chronic diseases in exposed populations worldwide. 
1.2 Human As exposure 
As is ubiquitous in the environment and has been detected in nearly every 
medium imaginable; it exists in water sources, soil, plants, and animal and human tissues. 
As is the 20
th
 most abundant element present in earth’s crust at an average concentration 
of approximately 0.5 mg/kg and is highly concentrated in sulfide ores (15). Arsenopyrite, 
a mineral containing As, sulfur, and iron, is the main form of As in the environment. Due 
to the presence of iAs in geological formations, As accumulates in aquifers naturally or 
due to anthropogenic activities depending upon several factors, including temperature, 
pressure, pH, redox state, and mineral content (16). Volcanic activity largely contributes 
to the natural emission of As into the atmosphere (17). 
A variety of anthropogenic activities and substances contribute to As 
accumulation in the environment. Notably, As is currently at the top of the Superfund 
Substance Priority List published by the Agency for Toxic Substances and Disease 
3 
 
Registry (18). During mining, sulfide minerals, which can include arsenopyrite, are 
exposed to air and often acidic water, resulting in favorable conditions for As leaching 
and potential As contamination of mine drainage (19). Additionally, the combustion of 
coal containing As generates fly ash, the disposal of which can contaminate nearby soil 
and water sources (20). Moreover, the use of geothermal waters, often containing high 
levels of iAs, during geothermal power production can inadvertently increase the 
concentration of As in nearby waterways (21). Manmade sources of As, including As-
based pesticides, herbicides, animal-feed additives, and wood treatments contribute to the 
persistence of As in the environment. Lead arsenate, a widely used pesticide until the 
1960’s, may persist in soils where it was employed. Monosodium methyl arsonate 
(CH4AsNaO3), an organic arsenical, is commonly used to for weed management on golf 
courses and cotton crops. Although, the chicken-feed additive, 4-hydroxy-3-
nitrobenzenearsonic acid (Roxarsone), is an organic arsenical, iAs accumulation has been 
detected in the tissues and litter from treated animals. Additionally, chromated copper 
arsenate (CCA) has been used as a wood preservative since the 1930’s; however, the US 
EPA limited the residential use of CCA-treated wood in 2004 because of potential 
leaching and exposure concerns (22). While the most common route of iAs exposure is 
through the ingestion of contaminated drinking water, other exposures include eating As-
rich foods, certain occupational settings, and medical treatments with As containing 
drugs.  
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1.2.1 Ingestion of As in drinking water 
Worldwide, tens of millions of people are chronically exposed to hazardous levels 
of As. Sources of drinking water with high levels of iAs occur across the globe (Figure 
1.1) (16). 
 
Figure 1.1: An overview of the prevalence of groundwater As contamination according 
to the 2002 British Geological Survey (16). 
 
In affected areas, including regions of Mexico, China, India, and Bangladesh, 
contaminated water can reach upwards of 1000 ppb (16). In the United States, levels of 
As can exceed 50 ppb (Figure 1.2), but municipal sources are generally below the EPA’s 
Maximum Contaminant Level (MCL) of 10 ppb (19). However, domestic well water in 
the US is only partially regulated and may not meet federal standards for safe drinking 
water. Speciation analysis of As in water reveals that arsenite (iAs
III
) and arsenate (iAs
V
) 
are the major species present, although MAs and DMAs have been reported in some 
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samples (23). Remediation techniques involving reverse osmosis, anion exchange, or 
adsorption are efficient, but often unattainable or difficult to maintain in regions that are 
plagued with water containing high levels of iAs (24). 
 
Figure 1.2: As contamination of municipal groundwater supplies in the United States 
(25). 
 
1.2.2 As exposure through food  
There are numerous reports of As in food items, including rice, seafood, seaweed 
and fruit juices. The use of water containing high iAs levels in agriculture can increase 
As in plants and animals used for consumption. Additionally, plants can bioaccumulate 
iAs through uptake from contaminated soils. Cooking with water high in iAs can also 
increase exposure. Seafood often contains organic arsenicals, including arsenobetaine 
(AsB), arsenocholine (AsC), and arsenosugars that can be detected in urine and increase 
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urinary excretion of dimethylated As (DMAs) (26). Additionally, unsafe levels of iAs 
ranging from 67–96 mg/kg have been found in samples of hijiki seaweed native to Japan, 
Korea, and China (27). Until recently, chickens for consumption were routinely fed 
Roxarsone, an antiparasitic agent used to prevent disease and stimulate growth. While 
Roxarsone, an organoarsenical, was not thought to breakdown into toxic iAs species, the 
Food and Drug Administration (FDA) recently published evidence of iAs accumulation 
in livers and muscle tissue from chickens even after the mandatory 5-day wash-out period 
(28). These findings prompted Pfizer, the drug’s manufacturer, to voluntarily halt sales in 
June 2011. 
1.2.3 Occupational and other exposures 
As exposure from coal fly ash, cigarette smoking, and certain occupational 
settings primarily result in the inhalation of As-containing particles. Non-ferrous metal 
smelting, including copper and lead, creates As laden dust and particles that can be 
inhaled and even emitted as air pollution. A rising industry with potential for As exposure 
is semiconductor chip manufacturing, where gallium arsenide is used to make electronic 
wafers (29). Furthermore, As has been measured in cigarette tobacco (30) leading to 
increased levels of As in hair (31) and urine (32) collected from smokers. Other 
industries with risk for As exposure include battery assembly, coal-fired power plants and 
the manufacture CCA-treated wood and glass. Additionally, activities that include 
handling of CCA-treated wood or As-based pesticides may lead to As exposure through 
dermal absorption or ingestion.    
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1.2.4 Current medical uses for As 
As containing compounds have been used for centuries to treat a variety of 
ailments, including several cancers and infectious diseases. Notably, iAs and Salvarsan, 
an As-containing drug, were routinely used to treat syphilis until after the mass 
production of effective antibiotics during WWII (33). As trioxide (Trisenox) and other 
arsenicals are currently being used or investigated for the treatment of certain cancers, 
including leukemias, lymphoid malignancies, and solid tumors (34). Trisenox used for 
the treatment of acute promyelocytic leukemia (APL) is the only As-based drug approved 
by the FDA (35).   
1.3 As Metabolism 
As is ubiquitous in the environment, and thus, human exposure is inevitable. Its 
toxicity and individual susceptibility to disease are largely dependent on the chemical 
form and oxidation state of As. Additionally, bioavailability, the ability to be absorbed by 
the body and enter circulation, influences As toxicity. From soils and As-containing 
foods, including rice, gastrointestinal uptake after oral exposure is largely dependent on 
speciation and matrix, with soluble As compounds being more bioavailable (36, 37); 
unabsorbed As is largely eliminated in the feces, while absorbed As is primarily 
eliminated in urine. This section will focus on the fate of As after oral exposure in 
humans and other mammals and factors affecting uptake, metabolism, retention, and 
excretion.   
1.3.1 As uptake and transport  
The mechanism of transport of As across membranes is dependent on its form and 
oxidation state along with the varied expression of transporters between organs. Several 
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protein families are thought to mediate the transport of As across cell membranes, 
including organic anion transporting polypeptides (OATs), aquaglyceroporins (AQPs), 
glucose transporters (GLUTs), phosphate transporters and multidrug resistance proteins 
(MRPs) from the ATP-binding cassette transporter peptide family. A recent study in the 
human intestinal epithelial cell line, Caco-2 indicates that iAs
III
 is largely transported by 
OATPB, AQP10 and GLUT5; conversely, iAs
V
, which competes with phosphate for 
uptake, is dependent on the phosphate transporter, NaPiIIb (38). GLUT1, which is 
expressed in the neonatal heart and epithelial cells of blood brain barrier, transports As
III
 
species using a different mechanism than for glucose transport (39). In primary human 
hepatocytes, the expression of MRP2 may mediate the efflux of DMAs, while GLUT2 
expression is associated with increased cellular accumulation of iAs and MAs (40). 
Moreover, AQP9, a membrane water channel expressed in the liver, preferentially 
transports trivalent arsenicals, mediates the accumulation of iAs
III
 and MAs
III
 in 
hepatocytes, and likely contributes to the efflux of pentavalent arsenicals into the blood 
stream (41). APQ9 null mice were shown to have reduced clearance and increased 
susceptibility to iAs toxicity (42). Furthermore, MRPs largely mediate the efflux of GSH 
conjugates, which are critical for detoxification of xenobiotics, and are thought to aid in 
the clearance of As species in the bile (43). GSH conjugates of iAs
III
 and MAs
III
 have 
been measured in rat bile after exposure to iAs species (44, 45).   
1.3.2 Biotransformation 
Methylated As species were discovered in human urine in 1973 (46) and further 
experiments confirmed that inhaled or ingested iAs was converted to methyl- and 
dimethylated As species (47, 48). Humans and many common laboratory animals 
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methylate As with the exception of guinea pigs (49), chimpanzees (50) and marmoset and 
tamarin monkeys (51). As (+3 oxidation state) methyltransferase (AS3MT) catalyzes the 
S-adenosylmethionine (SAM) dependent methylation of trivalent As species (52). This 
42 kDa protein was first purified from the liver of male Fischer 344 rats, and AS3MT 
mRNA has been found in several other tissues, including, kidney, urinary bladder, heart, 
lung, testes, and adrenal gland (53). Notably, the SV-40 transformed urothelial cell line, 
UROtsa, does not methylate As; however, cultured HepG2 cells and UROtsa cells 
expressing rat As3mt produce tri- and pentavalent arsenicals when exposed to iAs (54). 
Disruption of the As3mt gene in mice leads to a greater accumulation of whole-body As, 
almost exclusively as iAs, and an increased susceptibility to iAs toxicity (55, 56). These 
data indicate that As3mt genotype affects As methylation phenotype, a potential factor in 
the development of iAs-induced diseases.  
Current evidence supports two distinct mechanisms for the AS3MT-mediated 
biomethylation of As (Figure 1.3). The first pathway, characterized by the reduction of 
As
V
 species followed by an oxidative methylation of the As
III
 species, was proposed by 
Challenger in 1945 and later revised by Cullen in 1984 (57, 58). It is hypothesized that 
pentavalent arsenicals are first reduced to As
III
 species by a reducing equivalent, 
including glutathione (GSH) or the enzyme itself before the addition of a methyl group 
from SAM by AS3MT (59). After methylation, the pentavalent arsenicals, MAs
V
 and 
DMAs
V
 are available for reduction to their trivalent counterparts, MAs
III
 and DMAs
III
 for 
storage, transportation or excretion (60). While DMAs is the predominant end product of 
iAs metabolism in humans and laboratory animals, the major end product in some 
organisms is trimethylarsine oxide (TMAs
V
O) (61).  
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An additional proposed pathway for the biotransformation of iAs includes a 
reductive methylation where As
III
 species are bound to GSH or AS3MT during 
methylation, resulting in the formation of methylated pentavalent arsenicals as end 
products due to oxidation as opposed to intermediates (62). While some evidence has 
suggested As-GSH complexes at substrates for AS3MT (63), in vitro evidence indicates 
that GSH is not necessary for enzymatic function, and GSH alone in the absence of other 
endogenous dithiol reductants, including thioredoxin, only exhibits limited catalytic 
activity (59). The structure of CmArsM, a human AS3MT orthologue, has recently been 
published, and homology modeling of the human enzyme suggests that AS3MT lacks a 
reductase domain (64). Moreover, catalytic studies of CmArsM reveal that iAs- and 
MAs-GSH conjugates bind faster than iAs or MAs (65).  
 
Figure 1.3: Schematic representations of the oxidative (A) and reductive (B) pathways 
for As biomethylation (66).  
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1.3.2.1 Genetic factors affecting As biotransformation 
Genetic differences altering the As methylation phenotype in humans have been 
described for several enzymes, including AS3MT. Single nucleotide polymorphisms 
(SNPs) of the human AS3MT gene have been reported in both intronic and exonic 
locations, potentially altering As biomethylation and contributing to inter individual 
differences in As metabolite excretion. In primary human hepatocytes, a single allele 
missense mutation at position 14458 in AS3MT resulting in the Met287Thr (TC) amino 
acid substitution produced an altered methylation phenotype (67). While altered 
methylation phenotypes linked to several AS3MT SNPs of have been inconsistent across 
populations, results associated with the variants at positions 12390, in intronic site, and 
14458 have been consistent regardless of the populations examined (68). For example, 
increased urinary %MAs suggesting reduced overall methylation capacity has been 
linked to the Met287Thr AS3MT variant in regions of Mexico (69, 70), Europe (71), and 
Vietnam (72). Other genetic associations to the methylation of iAs in human populations 
include SNPs in glutathione S-transferase omega 1 (GSTO) (73), critical for 
detoxification of xenobiotics and enzymes associated with SAM biosynthesis, 
methylenetetrahydrofolate reductase (71) and cystathionine ß synthase (74). 
1.3.2.2 Dietary factors affecting As biotransformation 
Dietary factors that affect one-carbon metabolism are likely to influence As 
methylation profiles. SAM, the methyl donor required in the biomethylation of iAs, is 
generated by a set of cyclic reactions requiring several dietary constituents, including 
folate, amino acids, and vitamins B12 and B6. In a U.S. population, lower protein, iron, 
zinc, and niacin intakes were associated with increased %MAs and decreased %DMAs 
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composition in urine (75). In Bangladesh, increased intake of protein, methionine and 
cysteine were associated with a 10-15% increase in total As excretion (76). Moreover, in 
a double-blind study in folate-deficient individuals, folate supplementation led to 
increased %DMA and decreased %MAs and %iAs in urine compared to individuals 
given placebo (77).  
1.3.3 As retention, and excretion 
In humans and laboratory animals, ingested As is primarily excreted through the 
kidneys into urine as DMAs; however, urinary As levels reflects only recent As 
exposures and may not present an accurate picture of As species retained in target tissues. 
In a controlled human study, approximately 60% of ingested iAs was excreted in the 
urine, with DMAs representing 42-73% of total As (78). Individuals with higher urinary 
MAs/DMAs concentrations exhibit an increased risk for several adverse effects 
associated with As exposure, including skin lesions (79), cancer (80, 81), and 
cardiovascular disease (82), and. In human tissues analyzed at autopsy from individuals 
exposed to low levels of As, primarily through their diets, iAs and DMAs predominated 
with the highest total As present in the aorta (83). Studies of gestational exposure indicate 
that in humans, As crosses the placenta and is measured in maternal and cord blood 
primarily as DMAs (84). Because of the logistical complications involved in collecting 
human tissues, little research has focused on the speciation of As in target tissues of 
individuals exposed to iAs. However, a recent analysis of As speciation in bladder 
exfoliated cells (BECs) and urine from residents living in an As endemic area of 
Zimapan, Mexico indicates that As retention in this target tissue may not correlate with 
urinary excretion (85). 
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The retention of As species in laboratory animal tissues varies based on length of 
exposure and dosing protocol. Several recent in vivo studies in mice have examined tissue 
distribution after exposure to iAs
III
 or iAs
V
 through drinking water; however, oxidation 
state specific analysis was not performed. In mice subchronically exposed to 25 or 50 
ppm As as iAs
III
, DMAs predominated in tissues critical for glucose homeostasis, 
including adipose, skeletal muscle, pancreas, and liver (86, 87). Similarly, 12-week 
exposure to 50 ppm As as iAs
V
 revealed the predominant accumulation of DMAs in lung, 
but MAs in kidney, with the highest total As levels in kidney, lung and bladder (88). 
Gestational studies of exposures to iAs
III
 in pregnant mice indicate that As readily crosses 
the placenta and accumulates as DMAs in fetal lung, liver, and blood (89).   
Recently developed, As3mt-knockout (KO) mice lacking the ability to methylate 
iAs (55) have been shown to retain significantly higher total levels of As (55, 90, 91). 
These mice are more sensitive to iAs-induced toxicity compared to wild-type (WT) mice 
(56, 92). As speciation in tissues from As3mt-KO mice exposed to iAs primarily retain 
iAs; however, methylated metabolites have been detected in liver and plasma, suggesting 
As methylation mediated by additional methyltransferases or intestinal microbiota (55, 
93). Because As3mt genotype produces significantly different As methylation 
phenotypes, the As3mt-KO mouse model provides a unique model to study the toxic 
effects of methylated metabolites or individual arsenicals.  
1.4 As and Diabetes 
Worldwide, over 280 million people are estimated to be living with diabetes (94), 
and in the United States, the prevalence of diabetes in adults is 11.3% (95). Current 
classifications of diabetes includes insulin-dependent (type 1), non insulin-dependent 
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(type 2), and gestational (type 3), depending on etiology and disease presentation. Type 1 
diabetes (T1D) is characterized by a deficiency in insulin secretion (hypoinsulinemia) 
that leads to high levels of circulating glucose (hyperglycemia) due to a loss of pancreatic 
ß-cells within the islets of Langerhans, which are responsible for insulin production and 
secretion. This process is mediated by an auto-immune response that usually occurs in 
early childhood. Ketoacidosis, a characteristic of T1D, is a condition triggered by the β-
oxidation of fatty acids which replace glucose as the major source of energy, resulting in 
the accumulation of ketone bodies and harmful reduction of blood pH. In contrast, type 2 
diabetes (T2D) is characterized by insulin resistance in the liver and peripheral tissues, 
including skeletal muscle and adipose tissue that results in hyperglycemia. Thus, more 
insulin is needed to achieve insulin-stimulated glucose uptake in these tissues, resulting 
in hyperinsulinemia, and eventually pancreatic ß-cell function is diminished due to 
apoptosis (96). Type 3 diabetes occurs in women during pregnancy and generally 
resolves after childbirth. Current WHO diagnostic criteria for diabetes include individuals 
presenting with fasting plasma glucose levels ≥ 126 mg/dL or a two-hour plasma glucose 
level (2HPG) ≥ 200 mg/dL after an oral glucose tolerance test (OGTT) (97). Moreover, 
glycosylated hemoglobin (HbA1c) can be measured to estimated average plasma glucose 
levels over a 2 to 3 month period with levels ≥ 6.5% sufficient for a diagnosis of diabetes 
(98). 
While obesity and metabolic syndrome are implicated in 70% of T2D cases, 
environmental chemicals, including iAs, may contribute to its development (4). A recent 
National Toxicology Program (NTP) workshop on the effects of environmental chemicals 
on the development of diabetes and obesity discussed several suspected diabetogenic and 
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obesogenic environmental factors or chemicals, including maternal smoking, nicotine, 
As, bisphenol A, pesticides, organochlorine-based persistent organic pollutants, and 
peroxisome proliferator-activated receptor activators (e.g., organotins and phthalates). 
The As breakout panel concluded that there was “limited to sufficient” evidence to link 
iAs exposures to an increased prevalence of diabetes in populations exposed to levels of 
iAs in drinking water greater than 150 ppb (5). This section will discuss the current in 
vivo and in vitro data assessing the associations between As exposure and diabetes. 
1.4.1 Epidemiological evidence for associations between As and diabetes 
Early epidemiological evidence of an association between As and diabetes were 
published in the 1990’s from areas of Taiwan (99) and Bangladesh (100) with very high 
As levels in drinking water. The strongest associations are found in areas of Taiwan (99, 
101-103) and Bangladesh (100, 104) with drinking water As levels above 500 ppb. Many 
concerns regarding diabetes diagnosis, exposure assessment, the “healthy worker” effect 
and study power have been brought up for earlier epidemiological studies examining the 
associations between As and diabetes (5, 105). For example, some studies have used 
death certificates, glucose measurements in urine, or glycosylated hemoglobin for 
diagnosis, which may not accurately reflect diabetic status. A recent study of individuals 
in Bangladesh primarily exposed to < 300 ppb As in drinking water showed no 
associations between time weighted As exposure or urinary As and self-reported diabetes 
or glycosuria (106). However, FPG or 2HPG levels after an OGTT are preferred 
measurements for diagnosing diabetes; FPG and 2HPG levels greater than 126 and 200 
mg/dL, respectively are indicative of diabetes (97).  
16 
 
In U.S. residents participating in the 2003-2004 National Health and Nutrition 
Examination Survey (NHANES), a population exposed to low levels of iAs, data on the 
association between As exposure and T2D yield conflicting reports depending on 
exposure assessment used for the statistical model. Navas-Acien and associates found 
significantly increased odds of T2D correlated to total urinary As measurements; 
however, the total urinary As measurement included in the model contains AsB, a 
metabolite of seafood intake not considered to be toxic (107). While the authors excluded 
participants who reported seafood consumption within the past 24 hours and included 
urinary AsB in their statistical model, some criticisms have been made concerning the 
contribution of AsB metabolism to urinary DMAs levels. A reanalysis of the 2003-2004 
NHANES data by Steinmaus and associates included a model where AsB and AsC were 
subtracted from the total urinary As measurement, but seafood intake was not included as 
an independent variable in the statistical model, resulting in no increase in the odds of 
T2D (108). This method for estimated urinary As resulting from exposure to iAs does not 
account for other organoarsenicals from seafood consumption. Notably, consumption of 
arsenosugars increases urinary DMAs excretion (109). A more recent analysis of 
expanded NHANES data (2003-2006) further supporting the association between iAs 
exposure and diabetes using only participants with undetectable AsB levels eliminates the 
concerns regarding contribution of DMAs from seafood consumption (110). 
Despite this controversy, recent data provide consistent associations between As 
and diabetes (70, 111, 112) or gestational diabetes (113) in populations exposed to less 
than 150 ppb As diagnosed by preferred methods, including FPG, OGTT, or HbA1c 
levels. In As-endemic regions of Mexico, Del Razo and associates found associations 
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between urinary DMAs
III
 concentration and diabetes (70). Moreover, the AS3MT M287T 
genotype in this population was found to be associated with increased levels of FPG, 
2HPG, HbA1c, and urinary DMAs
III
 (114). Additional improvements in study design, 
including increasing population size, performing prospective studies, conducting more 
accurate exposure assessment, and using consistent diagnostic criteria for diabetes are 
likely to strengthen the body of evidence for an As-induced diabetes.  
Exposure assessment varies widely among studies examining the relationship 
between As and diabetes. Measurements of As concentration in drinking water does not 
reflect individual exposures through drinking water ingestion because water sources and 
consumption pattern may vary; however, some studies have combined historical water As 
data with self-reported use of drinking water. Other options include measuring 
biomarkers of the exposure, e.g., As in biological samples, including blood, hair, nails or 
urine, which may not be accurate indices of exposure. Hair and nail matrices are 
sulfhydryl rich leading to As accumulation and are not recommended for As exposure 
analysis (115). Moreover, the half-life of As in blood and urine are approximately 1 hour 
and a few days, respectively, reflecting only recent As exposures. In urine, As 
concentration can be affected by hydration status and normalization techniques have 
limitations. Urinary creatinine has been associated with total urinary As (116) and 
increased urinary DMAs excretion (117). Furthermore, the condition of diabetes was 
shown to result in an over-estimation of urinary As levels adjusted using creatinine 
measurements (118). It has been suggested that specific gravity could be used to adjust 
urinary As levels for hydration status; however, certain disease states, including diabetes 
can lead to abnormal urinary glucose and albumin excretion, which would overestimate 
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urine density (119, 120). Internal retention of As in human tissues has not been widely 
researched, on the other hand, exposure assessments in bladder exfoliated cells (BECs) 
(85) and saliva (121, 122) have been performed. In BECs from 21 individuals living in an 
As-endemic region of Mexico, the retention of speciated As did not correlate with urinary 
excretion (85); however, As species in saliva samples from individuals exposed to As in 
China did correlate with drinking water As concentrations (121).   
1.4.2 Effects of As on glucose metabolism and homeostasis: laboratory evidence   
Several laboratory-based in vitro and in vivo investigations link As exposure to 
altered glucose homeostasis and negative effects on mechanisms associated with glucose 
metabolism. In mice, impaired glucose tolerance has been observed after exposure to 
iAs
III
 in drinking water (86, 87, 123) and iAs
V
 (124). Notably, chronic iAs
III
 exposure 
combined with high fat diet produced a unique diabetic phenotype in mice which was 
characterized by impaired glucose tolerance in the absence of pronounced obesity, fasting 
hyperinsulinemia, or insulin resistance (87). While additional studies have shown As-
induced impaired glucose homeostasis in rats (125-128), DMAs, an iAs metabolite, forms 
hemoglobin adducts and accumulates in the red blood cells (RBCs) of this species unlike 
humans and other laboratory animal models (129). Therefore, rats are not an appropriate 
model for As toxicity studies relating to human health. 
In vitro studies have revealed several pathways for the pathogenesis of As-
induced diabetes, including pancreatic β-cell function and glucose uptake in peripheral 
tissues. A reduction in glucose-stimulated insulin secretion (GSIS) has been observed in a 
variety of β-cell cultures exposed to As (130). These studies noted several mechanisms 
for the diminished GSIS, including reduced insulin mRNA levels (131), alterations in 
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free Ca
2+
 oscillations (132), and a suppression of reactive oxygen species (ROS) due to 
an Nrf2-mediated antioxidant response (133, 134). It is suggested that ROS produced in 
the course of glucose metabolism may act as homeostatic regulators of insulin secretion, 
and thus, an Nrf2-mediated antioxidant response would hinder ROS signaling (135). In 
murine pancreatic islets, exposure to subtoxic concentrations of As
III
 species inhibited 
GSIS; however, basal insulin secretion or insulin content and expression were not 
affected, suggesting that trivalent arsenicals inhibit insulin transport vesicle packaging or 
translocation to the plasma membrane (136).  
Mechanisms for peripheral tissue alterations in glucose homeostasis include 
inhibition of cellular differentiation and inhibited insulin-stimulated glucose uptake. iAs
III
 
has been shown to inhibit differentiation of adipocytes (137, 138) and myoblasts (139). 
Moreover, trivalent arsenicals inhibit insulin-stimulated glucose uptake by adipocytes 
through reducing GLUT 4 translocation to the plasma membrane (140, 141). Subtoxic 
concentrations of iAs
III
 and MAs
III
 were shown to inhibit the phosphorylation of protein 
kinase B (Akt) by 3-phosphoinositide-dependent kinase-1,2 (PI3K) in cultured murine 
adipocytes (141). 
1.5 As Speciation Analysis 
As analysis became widespread with the development of the Marsh test in 1836, 
which sought to detect As in suspected poisoning cases (142). Quantitative determination 
of As has been conducted using a variety of techniques, including thin-layer 
chromatography with autoradiography using radiolabeled As and hydride generation 
(HG) or liquid chromatography coupled to various spectrometric detention techniques. 
After the discovery of methylated As species and the toxic MAs
III
 and DMAs
III
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metabolites, speciation analysis became critical to assess exposure and potential disease 
mechanisms. However, due the instability of trivalent arsenicals, oxidation state specific 
analysis has not been widely explored until the last two decades. Currently, two main 
techniques, HG with cryotrapping (CT) and high performance liquid chromatography 
(HPLC), are used to separate As species for oxidation state analysis. These separation 
methods are coupled to a variety of detection devices, including the atomic absorption 
spectrometer (AAS), atomic fluorescence spectrometer (AFS), or inductively coupled 
plasma-mass spectrometer (ICP-MS). With these methods, the retention and excretion of 
As species can be assessed in a variety of biological samples to better characterize the 
metabolism and adverse effects of chronic As exposure. This section will focus on 
separation and detection techniques used for oxidation state specific analysis of As 
species in a variety of biologically relevant samples. 
1.5.2 Separation of As species 
The formation of arsine gas using HG has a distinct history in the analysis of As. 
In the Marsh test, zinc and sulfuric acid are mixed with the sample to generate arsine that 
was then oxidized with a flame to form pure As, generating a black stain that could be 
compared to known standards for quantification purposes. Modern HG techniques use a 
strong reducing agent, e.g., sodium borohydride, to generate arsine and methyl 
substituted arsines from seven As species, included tri- and pentavalent iAs, MAs and 
DMAs, and TMAs
V
O using sample volumes up to 1 mL. The generation of arsine gases 
from different oxidation states of As can be manipulated by measuring two aliquots of 
each sample and altering the reagents used for HG. Early optimization of the HG 
technique for detecting As
III
 species and As
III+V
 involved performing the HG reaction at 
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pH 6 and 2, respectively (143, 144). The acidic environment allows for the generation of 
arsines and methyl substituted arsines from both trivalent and pentavalent species in one 
analysis, while the reaction mixture buffered at pH 6 selectively generates arsines from 
trivalent As species only. Further development paired the direct analysis at pH 6 to detect 
As
III
 species with the pretreatment of an additional samples aliquot with L-cysteine to 
detect As
III+V
 species. The L-cysteine forms a conjugation with As
V
 species reducing 
them to trivalency and likely forming As-sulfhydryl conjugates, resulting in arsine and 
methyl-substituted arsine generation from both As
III
 and As
V
 species. Pentavalent 
arsenicals can then be quantified by taking the difference of the results from the L-
cysteine pretreated and directly analyzed aliquots. The online prereduction of As
V
 species 
using thioglycolic acid has been explored, but is not widely used (145).  
Because arsine and methyl-substituted arsines are generated simultaneously from 
the sample, HG used as the primary separation technique is combined with a CT step for 
separation based on boiling points of individual arsines. Current techniques use a glass 
capillary U-tube wrapped with Ni-Cr wire and filled with Chromosorb, a diatomaceous 
earth filling often used for gas chromatography, which is submerged in liquid N2. After 
sufficient reaction time for the generation of hydrides, the U-tube is removed from the 
liquid N2 either manually or automatically using a doubled walled flask connected to a 
remotely activated solenoid valve. A power source then heats the wire wrapped U-tube 
allowing for separation of arsine and the methyl-substituted arsines based on boiling 
point. The boiling points of arsine and methyl-, dimethyl- and trimethylarsine are -62.5, 
1.2, 35.6, and 53.8°C, respectively and can be fully resolved in less than one minute 
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(146). A schematic of the HG-CT system coupled to an atomic absorption spectrometer 
(AAS) is presented in Figure 1.4. 
An additional method widely used for the separation of As species is HPLC, most 
commonly ion exchange and reversed-phase. The high pressures generated during HPLC 
provide for improved resolution and greatly reduced separation times over conventional 
liquid chromatography; however, sample volumes are generally limited to a few hundred 
microliters. Separation of sample components is based on interactions with the stationary 
phase of the column and mobile phase used for elution and can be optimized for the 
oxidation state separation of As species. 
Reversed-phase HPLC is characterized by a hydrophobic column packing 
combined with a hydrophilic mobile phase. The most common stationary phase for As 
speciation is octadecylsilane (ODS), which consists of C18 chains bonded to silicone. To 
enhance separation of ionic species, an ion-pairing reagent can be used to interact with 
the column matrix and alter analyte retention times. Reversed-phase ion pairing HPLC 
was first used for the oxidation state speciation of the more toxic MAs
III
 and DMAs
III
 
species in 2000 (12). Here, a mobile phase of tetrabutylammonium hydroxide (TBAH), 
malonic acid, and methanol was used with an ODS-3 C18 column to separate six As 
species. Rabieh and associates further optimized the concentrations of mobile phase 
components for improved separation of six As species in less than seven minutes (147).  
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Figure 1.4: A schematic representation of the semi-automated HG-CT-AAS method. The 
following abbreviations are used: Flow injection for atomic spectroscopy (FIAS) 
peristaltic pump (PP1 and PP2); injection valve (INJ, 500 μl loop); mixing coil (MC); 
reaction coil (RC); gas-liquid phase separator (GLS); Dewar flask (DWF); glass flask 
(GF); thermal insulation (TI); FIAS remotes (R4 and R5); relay switches (SW1 and 
SW2); autotransformer (AT); separating transformer (ST); voltmeter (V); solenoid valve 
(SV); and rotameter tube for gas outlet monitoring (RT) (146).  
 
Another common HPLC technique used to separate tri- and pentavalent As 
species is ion-exchange chromatography, commonly referred to as either cation or anion 
exchange chromatography depending on the composition of the stationary phase. In this 
method, a charged stationary phase attracts and retains ionic analytes of the opposite 
charge. Hence, cation exchange involves negatively charged functional groups attached 
to the stationary phase, which increases the retention time of positively charged analytes. 
Conversely, in anion-exchange HPLC, positively charged functional groups are attached 
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to the stationary phase, which interacts and increases the retention time of negatively 
charged analytes. A combination of anion- and cation-exchange HPLC has been used to 
separate 6 tri- and pentavalent As species and AsB in urine; however, two separate 
columns with nearly 10 minutes of separation each are needed (148).  
1.5.3 Analytical detectors 
Systems for the separation of As species are generally coupled to AAS, AFS, or 
ICP-MS for the detection of As species. These methods measure elemental As, but 
several factors affect their use for As speciation analysis. AAS is often coupled with HG-
CT and the gaseous hydrides are atomized at high temperatures. As detection is 
facilitated by an electrodeless discharge lamp which emits light at a wavelength that 
elemental As absorbs, 193.7 nm, through the atomizer where the unabsorbed light is 
detected. AAS offers low detection limits and is relatively inexpensive to purchase and 
operate. Current HG-CT-AAS methodologies have produced detection limits from 16 to 
40 ppt in biological matrices (149). AFS, has been widely used to speciate As both with 
HG-CT and HPLC-HG separations. It offers greater sensitivity than AAS (150) and is 
less expensive to operate than ICP-MS (151), but may be complicated by quenching and 
spectral interferences (152). In ICP-MS, nebulized samples are ionized in an argon-
generated plasma flame prior to detection of the charged particles based on the mass-to-
charge ratio (m/z), approximately 75 for As. Despite the expenses involved with ICP-MS 
analyses, this method offers several advantages, including very low detection limits, a 
wide dynamic range, and multielemental capabilities. In addition to the increased cost, 
polyatomic inferences, specifically by atoms of 
40
Ar
35
Cl, must also be considered.  
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1.5.4 Biological matrices 
The quantification of As metabolites in laboratory- and population-based samples 
can provide critical information on the toxicity of individual As species and explore 
mechanisms of action for the development of iAs-induced diseases. Recent developments 
for the speciation of As in biological samples have focused on HG-CT-AAS and HPLC-
ICP-MS. However, HG steps have been used after HPLC separation in conjunction with 
AFS and ICP-MS to minimize interferences. Here, biologically relevant samples 
available for As speciation will be discussed. 
Laboratory-based samples used for As speciation are an excellent tool to assess 
methylation and even tissue retention under experimental conditions. Simple in vitro 
assays using cytosolic liver fractions (153) or recombinant AS3MT (154) have been used 
to measure enzymatic activity and the effects of relevant SNPs. The HG-CT-AAS 
technique has been recently optimized for the oxidation state specific analysis of As 
species. Here, As
III
 and As
V
 species have been quantified in reaction mixtures containing 
recombinant AS3MT and in HepG2 cells and primary rat hepatocytes after in vitro 
exposure to iAs
III
 (143, 149). While the speciation of As in animal tissues after exposure 
to a variety of arsenicals has been extensively studied, no data on the oxidation state of 
these As metabolites has been available because acid digestion or extractions were 
performed prior to analysis converting As
III
 to As
V
 species.   
Urine is often used for the speciation of As in population studies because it is 
minimally invasive to collect and provides robust information on exposure to iAs. Other 
biological samples routinely collected in population studies for the speciation of As 
species include blood, hair, nails, saliva. However, these specimens might not reflect 
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internal As exposures in target tissues critical for disease development. Recent research 
has focused on target tissues and the analysis of As metabolites in BECs has been 
performed (85). Despite the developments in As speciation analysis, little work has 
focused on the quantification of the more toxic trivalent As species, MAs
III
 and DMAs
III
 
in target human tissues. 
1.6 Conclusions 
In conclusion, increasing evidence indicates an increased prevalence of diabetes 
in populations exposed to high levels of iAs in drinking water. The trivalent methylated 
metabolites of iAs, MAs
III
 and DMAs
III
, likely contribute to its adverse effects. However, 
internal exposures to these toxic metabolites in humans are not well characterized. The 
following chapters will present an optimized method for analyzing these toxic iAs 
metabolites in biological samples and its application to laboratory- and population-based 
studies examining the associations between the more toxic, trivalent As metabolites and 
development of iAs-induced diabetes. These results will ultimately aid in the risk 
assessment of exposure to iAs through contaminated drinking water.  
   
 
 
 
 
CHAPTER II  
Direct Analysis of Methylated Trivalent Arsenicals in Mouse Liver by Hydride 
Generation-Cryotrapping-Atomic Absorption Spectrometry
1
 
2.1 Overview 
Growing evidence suggest that the methylated trivalent metabolites of inorganic 
arsenic (iAs), methylarsonite (MAs
III
) and dimethylarsinite (DMAs
III
), contribute to 
adverse effects of iAs exposure. However, the lack of suitable methods has hindered the 
quantitative analysis of MAs
III
 and DMAs
III
 in complex biological matrices. Here, we 
show that hydride generation-cryotrapping-atomic absorption spectrometry can quantify 
both MAs
III
 and DMAs
III
 in livers of mice exposed to iAs. No sample extraction is 
required, thus limiting MAs
III
 or DMAs
III
 oxidation prior to analysis. The limits of 
detection are below 6 ng As/g of tissue, making this method suitable even for studies 
examining low exposures to iAs.  
2.2 Introduction 
Inorganic arsenic (iAs), a carcinogenic metalloid found in the earth’s crust, can 
accumulate in aquifers naturally or due to industrial activities (16). Chronic iAs exposure 
through contaminated drinking water has been linked to risks of various diseases, 
including cancer, hypertension, and diabetes (1, 3, 155). The individual susceptibility to 
                                                 
1
 Adapted with permission from Jenna M. Currier, Milan Svoboda, Diogo P. de Moraes, Tomas Matousek, 
Jirí Dedina, and Miroslav Stýblo (2011) Chem. Res. Toxicol. 24, 478-480. Copyright 2011 American 
Chemical Society. 
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these diseases varies considerably, even at similar exposure levels, complicating the risk 
assessment. Current evidence suggests that the trivalent methylated metabolites of iAs, 
methylarsonite (MAs
III
) and dimethylarsinite (DMAs
III
), are more toxic than pentavalent 
methylarsonate (MAs
V
) and dimethylarsinate (DMAs
V
), or iAs species, arsenite (iAs
III
) 
and arsenate (iAs
V
) (8). Both MAs
III
 and DMAs
III
 are products of iAs methylation by 
arsenic (+3 oxidation state) methyltransferase (149) and by cultured human hepatocytes 
(144). Both MAs
III
 and DMAs
III
 are present in urine of individuals exposed to iAs in 
drinking water (156). However, results of recent studies indicate that the concentrations 
and proportion of iAs metabolites in urine do not necessarily reflect the concentrations 
and speciation of As in tissues targeted by iAs exposure (85, 157, 158). Other studies 
demonstrate an organ specific accumulation of iAs and methylated arsenicals after 
exposure to iAs (88). Thus, the quantitative analysis of iAs metabolites in target tissues is 
crucial for elucidating the mechanisms of the adverse effects of iAs exposure and for 
understanding the inter-individual variations in manifestation and severity of the diseases 
associated with this exposure.  
Several methods have been developed for the speciation analysis of As in aqueous 
samples, including human urine (14, 159, 160). However, only hydride generation-
cryotrapping-atomic absorption spectroscopy (HG-CT-AAS) is uniquely suited for the 
oxidation state specific analysis of As in complex biological matrices (143, 146, 149). 
Unlike HPLC techniques, HG-CT-AAS does not require digestion or extraction of 
biological samples and, therefore, limits the artifacts associated with the oxidation or with 
on-column binding of the reactive, but unstable methylated trivalent metabolites (161). 
We have previously used HG-CT-AAS for quantitative analysis of iAs metabolites, 
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including MAs
III
 and DMAs
III
 in cultured mammalian cells capable of methylating iAs 
(149). Here, speciation analysis of As is carried out in two sample aliquots. In the first 
aliquot, hydrides (arsine and methyl-substituted arsines) from the trivalent As species 
(iAs
III
, MAs
III
 and DMAs
III
) are selectively generated at pH 6 and measured directly 
without sample pretreatment. The second aliquot is treated with 2% L-cysteine to reduce 
the pentavalent As species (iAs
V
, MAs
V
 and DMAs
V
) to trivalency; thus, arsines 
generated from this sample aliquot represent both tri- and pentavalent As species 
(iAs
III+V
, MAs
III+V
 and DMAs
III+V
) present in the sample. The concentrations of the 
pentavalent As species are then determined by subtracting the results of analysis in the 
1st sample aliquot from results of the analysis in the 2nd aliquot. The goal of the present 
study was to examine whether this HG-CT-AAS technique is also suitable for 
quantitative, oxidation state specific analysis of As species in tissues. 
2.3 Materials and Methods  
2.3.1 Arsenicals 
Sodium arsenite (iAs
III
) and sodium arsenate (iAs
V
), (>99% pure) were purchased 
from Sigma-Aldrich (St. Louis, MO). A 1000 μg/L As AAS standard solution was 
purchased from Merck (Darmstadt, Germany). Because sodium arsenite is commonly 
contaminated with arsenate, arsenic trioxide (As2O3; >99.9% pure from Sigma-Aldrich) 
was used as the trivalent inorganic As specie for validation of the oxidation state specific 
analyses. Methylarsonic acid (MAs
V
), disodium salt (CH3As
V
O(ONa)2) and 
dimethylarsinic acid (DMAs
V
) both better than 98% pure were purchased from Chem 
Service (West Chester, PA). The methylated trivalent arsenicals, oxomethylarsine 
(MAs
III
O) and iododimethylarsine (DMAs
III
I), were custom synthesized by Dr. William 
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Cullen (University of British Columbia, Vancouver, Canada). In aqueous solutions, 
MAs
III
O and DMAs
III
I hydrolyze to form the methylarsonous (MAs
III
) and 
dimethylarsinous (DMAs
III
) anions, respectively.  
2.3.2 Speciation Analysis of As  
We used a semi-automated HG-CT-AAS system similar to that described in our 
previous reports (146, 149). AAnalyst 800 spectrometer (Perkin-Elmer, Norwalk, CT, 
USA) equipped with a multiple microflame quartz tube atomizer (multiatomizer) and 
coupled to a cryotrap was controlled by FIAS 400 flow injection accessory (Perkin-
Elmer). As compared to the previously described HG-CT-AAS setup (146), the injection 
port of the FIAS 400 was bypassed to avoid plugging with homogenate slurries. Using 
this system, iAs and the methylated arsenicals in samples are reduced to the 
corresponding arsines (arsine, methylarsine, and dimethylarsine) in a reaction mixture 
containing sodium borohydride (NaBH4; Sigma-Aldrich, St. Louis, MO) and a 0.75M 
Tris(hydroxymethyl)aminomethane (TRIS)-HCl buffer (pH 6; Sigma-Aldrich). The 
arsines are cryotrapped and then separated by their boiling points prior to detection by the 
AA spectrometer. Here, two aliquots of each sample are analyzed to determine As
III
 
species and As
III+V
 species. Trivalent arsenicals (iAs
III
, MAs
III
 and DMAs
III
) are analyzed 
directly without sample extraction or pretreatment. For analysis of total, tri- and 
pentavalent arsenicals (iAs
III+V
, MAs
III+V
 and DMAs
III+V
), the 2nd sample aliquot is 
pretreated with 2% L-cysteine (biochemistry grade, EMD Chemicals, Inc., Gibbstown, 
NJ) for 1 hour at room temperature. L-cysteine reduces the pentavalent arsenicals to 
trivalency, allowing arsine generation from both As
III
 and As
V
 species. The 
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concentrations of iAs
V
, MAs
V
, and DMAs
V
 are then determined by subtracting the results 
of analysis in the 1st sample aliquot from results of the analysis in the 2nd aliquot.  
Calibration curves for quantification of As species were generated using aqueous 
solutions of the pentavalent standards, iAs
V
, MAs
V
, and DMAs
V
 treated with L-cysteine. 
To account for contamination, the As content in each of the standards was determined by 
graphite furnace-AAS (146). We have shown that the slopes of these curves are identical 
with slopes of curves generated from solutions of the trivalent arsenicals in the absence of 
cysteine (149). There are no standard reference materials available with certified levels of 
MAs
III
 and DMAs
III
. We have routinely used custom synthesized MAs
III
 and DMAs
III
 
standards (MAs
III
O and DMAs
III
I) for quality control, including calibration (when 
needed) or the standard addition techniques with relevant biological matrices.  
2.3.3 Animals 
Twelve week-old C57BL/6 mice were obtained from Jackson Laboratory (Bar 
Harbor, ME, USA) and housed in polycarbonate cages (2/cage) with corn cob bedding at 
the University of North Carolina Animal Facility (12 h light/dark cycle, 22 ± 1 °C and 
humidity of 50 ± 10%), accredited by the American Association for Accreditation of 
Laboratory Animal Care. Mice were allowed free access to food (Lab Diet 5058, 
Nutrition International, Brentwood, MO) and pure deionized water (DIW) or DIW 
containing iAs
III
 (50 mg As/L). 
2.3.4 Tissues 
Freshly dissected mouse livers were collected from unexposed (control) mice and 
from mice exposed to iAs
III
 in drinking water for 9 days. Liver homogenates were 
prepared in ice cold DIW (10% w/v). Liver homogenates from control mice were used 
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for calibration and to prepare homogenates spiked with As standards. Liver homogenates 
from mice exposed to iAs
III
 were used for the method validation. Here, the As
III
 species 
were analyzed directly in freshly prepared homogenates; As
III+V
 species were analyzed in 
homogenates pretreated with 2% L-cysteine. To determine % recovery of As during these 
analyses, aliquots of the homogenates were digested using a MARS Microwave Reaction 
System equipped with MarsXpress Temperature Control (CAM, Matthews, NC). Briefly, 
100 μL of 10% homogenate was digested in 3 mL of 2 M ultrapure phosphoric acid 
(EMD Chemicals, Inc.) for 10 hours at 90 ± 4°C. After digestion, 1 mL of each digestate 
was neutralized with 0.25 mL of 10 N NaOH to a final pH between 6 and 7. Since this 
digestion oxidizes all trivalent arsenicals to their pentavalent counterparts, the neutralized 
digestates were treated with 2% L-cysteine by the addition of 20% L-cysteine and 
incubated at room temperature for 1 hour prior to analysis.  
2.3.5 Statistical Analyses 
All statistical analyses were performed using GraphPad Instat software package 
(GraphPad Software Inc., San Diego, CA). Linear regression and correlation analyses 
were employed to determine characteristic of calibration curves of As
V
 species in liver 
homogenates and DIW. ANOVA followed by Bonferroni’s multiple comparison posttest 
was employed to determine differences in As recovery between DIW and homogenate 
solutions spiked with As standards. Statistical significance was considered at the level of 
p < 0.05. 
2.4 Results and Discussion 
In the first step, we compared the efficiency of generation of As species in 
aqueous solutions and in mouse livers. Here, we used liver from an untreated mouse fed a 
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regular diet and drinking deionized water (DIW). Ten percent liver homogenates (w/v) 
were prepared in DIW on ice and spiked with iAs
V
, MAs
V
, and DMAs
V
 standards to 
generate calibration curves. In parallel, calibration curves were generated for solutions of 
these standards in DIW. Both, the aqueous standard solutions and the spiked 
homogenates were treated with 2% L-cysteine and analyzed by HG-CT-AAS (143, 146, 
149) using AAnalyst800 atomic absorption spectrometer equipped with FIAS400 flow 
injection accessory (PerkinElmer Norwalk, CT, USA). We found that the slopes of the 
calibration curves generated for the aqueous standards and spiked homogenates are very 
similar (Table 2.1), suggesting that the complex matrix of the liver homogenate does not 
interfere with the analysis. 
Table 2.1: Characteristics of the calibration curves for As
V
 standards spiked into DIW or 
10% liver homogenate (a) 
Matrices As Standard Linear Regression (b) Correlation Coefficient 
DIW iAs
V
 0.821x - 0.019 0.999 
 
MAs
V
 0.825x - 0.024 0.999 
 
DMAs
V
 0.835x - 0.024 0.999 
Homogenate iAs
V
 0.873x + 0.00004 0.999 
 
MAs
V
 0.880x - 0.005 0.998 
 DMAsV 0.941x - 0.027 0.997 
(a) Arsines and methyl substituted arsines were generated after 1-hour pretreatment with 
2% L-cysteine. 
(b) The linear regression for each As
V
 standard was determined over the range of 0.125 to 
4 ng As/mL. 
 
In the second step, we compared the recovery of As standards from a liver 
homogenate and aqueous solutions. Here, a mixture of pentavalent iAs
V
, MAs
V
, and 
DMAs
V
 standards (10 ng As each) and individual trivalent iAs
III
, MAs
III
, and DMAs
III
 
standards (10 ng As each) were prepared in DIW or in a 10% liver homogenate from an 
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untreated mouse and analyzed with or without L-cysteine pretreatment. Figure 2.1 shows 
that, regardless of the matrix, the trivalent arsenicals can be quantitatively analyzed in the 
absence or presence of L-cysteine with As recoveries of ~92 - 105%. Lower As 
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Figure 2.1: HG-CT-AAS analysis of DIW and 10% liver homogenate spiked with As
III
 
(A) and As
V
 (B) standards. DIW and aliquots of the homogenate were spiked with a 
mixture of As
V
 standards (10 ng each) or with individual As
III
 standards (10 ng each) and 
analyzed before and after pretreatment with 2% L-cysteine (Cys) (mean with SD, n = 3). 
*Statistically significant differences (p < 0.05) between the amounts of an As species 
detected in DIW and in the homogenate as determined by ANOVA with a Bonferroni 
multiple comparison post-test. 
 
recoveries were found only for homogenates spiked with iAs
III
 (~80%) or DMAs
III
 
(~72%) that were not treated with L-cysteine. In contrast, the pentavalent arsenicals were 
detected only after the pre-reduction with L-cysteine. Consistent with our previous 
findings (146), only DMAs
V
 generated a small amount of dimethylarsine (~6-7% of total 
As) in the absence of L-cysteine. The recoveries of As for DIW and homogenates spiked 
with pentavalent standards ranged from ~90 to 102%. Detection limits calculated for a 
35 
 
blank liver homogenate with and without L-cysteine pretreatment ranged from 9 to 14 pg 
As, which translate to ≤ 6 ng As/g of the tissue (Table 2.2).  
Table 2.2: The instrumental and tissue detection limits for analysis of As
III
 and As
III+V
 
species in mouse liver homogenate. 
Detection Limit iAs
III
 MAs
III
 DMAs
III
 iAs
III+V
 MAs
III+V
 DMAs
III+V
 
Instrumental (pg As) (a) 14 13 9 10 10 12 
Tissue (ng As/g tissue) (b) 6 5 4 4 4 5 
(a) The instrumental detection limits were calculated from the AAS spectra generated for 
blanks (control liver homogenates, n=8) as 3(SD/slope) for the absorbance areas with the 
retention times corresponding to arsine, methylarsine, and dimethylarsine signals. 
(b) Tissue detection limits were calculated from the instrumental detection limits and 
reflect the concentration and dilution of the liver homogenates used for the analysis. 
 
Finally, we used HG-CT-AAS to determine concentrations of As species in the 
liver of a mouse exposed to iAs
III
 in drinking water (50 mg As/L) for 9 days. Here, the 
freshly dissected liver was divided into 4 sections. Each section was homogenized in ice-
cold DIW. Aliquots of the 10% homogenates were immediately analyzed for As
III
 species 
(without L-cysteine pretreatment) and for As
III+V
 species (after pretreatment with L-
cysteine). Additional aliquots from each liver section were digested in phosphoric acid 
for 10 hours at 90°C using the MARS5 Microwave system (90). This digestion eliminates 
the biological matrix and oxidizes all trivalent As species to pentavalency (162). Thus, 
only the total iAs (iAs
III+V
), MAs (MAs
III+V
) and DMAs (DMAs
III+V
) can be measured in 
the digested samples. Table 2.3 compares results of the direct speciation analysis and 
analysis of the digested homogenate from one of the liver sections. Based on the direct 
analysis, MAs
III
 and DMAs
III
 represented respectively 12% and 45% of the total 
speciated As, while their pentavalent counterparts, MAs
V
 and DMAs
V
, accounted for 8% 
and 18%. Notably, the sums of tri- and pentavalent MAs and DMAs determined by the 
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direct analysis were in a good agreement with the concentrations of MAs
III+V
 and 
DMAs
III+V
 determined in the digested homogenates. However, the amount of iAs 
recovered during the direct analysis represented only ~79% of iAs recovered after the 
digestion. Figure 2.2 shows the recoveries of iAs, MAs and DMAs in directly analyzed 
homogenates from all four sections of the liver as compared to the analyses in digested 
homogenates. Here, the direct analysis recovered approximately 99% of total As, with 
individual recoveries of 83±5% for iAs
III+V
, 100±6% for MAs
III+V
, and 107±1% for 
DMAs
III+V
. Together with data in Table 2.3, these results suggest high As recoveries and 
a good reproducibility of the speciation analysis in liver homogenates. 
In conclusion, this work shows that HG-CT-AAS is suitable for the quantitative, 
oxidation state specific analysis of As species, including the unstable MAs
III
 and 
DMAs
III
, in mammalian tissues. Our data show that approximately 66% of As in the liver 
of a mouse exposed to iAs is represented by trivalent species; ~12% by MAs
III
 and ~45% 
by DMAs
III
. These results further strengthen the hypothesis that methylated trivalent 
arsenicals contribute to the adverse effects in tissues targeted by iAs exposure. Additional 
optimization may be needed to improve recoveries of iAs which is likely bound to high-
affinity binding sites in tissue homogenates and to prevent the oxidation of DMAs
III
 
which contributes to lower recoveries of this unstable As species. 
 
 
Table 2.3: The concentration of As species in one section of the liver (ng As/g of tissue) 
from a mouse exposed to iAs
III
 in drinking water (50 ppm As) for 9 days. Results of the 
direct analysis of fresh liver homogenate and the homogenate digested in phosphoric 
acid. 
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As species 
 
Analysis of digested liver 
homogenate (a) 
ng As/g of tissue 
Direct analysis of fresh 
liver homogenate (b) 
     ng As/g of tissue              % Recovery (c) 
iAs
III
 
 
151 ± 15 
 
iAs
V
 
 
158 ±16 
 
iAs
III+V
 392 ± 12 309 ± 7 79 ± 3 
MAs
III
 
 
220 ± 5 
 
MAs
V
 
 
143 ± 6 
 
MAs
III+V
 390 ± 1 363 ± 4 93 ± 1 
DMAs
III
 
 
828 ± 11 
 
DMAs
V
 
 
324 ± 16 
 
DMAs
III+V
 1069 ± 10 1152 ± 11 108 ± 2 
Total As
III+V
 1851 ± 16 1824  ± 14 99 ± 1 
A total of 9 aliquots of the homogenate prepared from 1 section of the liver were 
analyzed by HG-CT-AAS: 
(a) 3 aliquots were microwave digested in phosphoric acid at 90
o
C for 10 hours and 
analyzed for As
III+V
 species. (Mean ± SD are shown for n = 3) 
(b) 6 aliquots were analyzed directly: 3 aliquots were analyzed for As
III
 species (without 
pretreatment) and 3 aliquots were analyzed for As
III+V
 species after pretreatment with 2% 
L-cysteine. The concentrations of As
V
 species were calculated as the difference between 
the two measurements. (Mean ± SD are shown for n = 3 replicate measurements of 
homogenate from 1 liver section) 
(c) % recovery = (ng As
III+V
 determined by the direct analysis / ng As
III+V
 determined in 
the digested homogenate) x 100 
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Figure 2.2: Recovery of total speciated As during the direct analyses of fresh 
(undigested) homogenates prepared from four sections of the liver of a mouse exposed to 
iAs
III
 (50 ppm As) for 9 days (mean ± SD, n = 4). The homogenates were analyzed by 
HG-CT-AAS as described for Figure 2.1. The % recovery was calculated as (As
III+V
 
analyzed directly/ As
III+V
 after digestion) x 100. 
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CHAPTER III  
Direct Analysis and Stability of Methylated Trivalent Arsenic 
Metabolites in Cells and Tissues
2
 
3.1 Overview 
Chronic ingestion of water containing inorganic arsenic (iAs) has been linked to a 
variety of adverse health effects, including cancer, hypertension and diabetes. Current 
evidence suggests that the toxic methylated trivalent metabolites of iAs, methylarsonous 
acid (MAs
III
) and dimethylarsinous acid (DMAs
III
) play a key role in the etiology of these 
diseases. Both MAs
III
 and DMAs
III
 have been detected in urine of subjects exposed to 
iAs. However, the rapid oxidation of DMAs
III
 and, to a lesser extent, MAs
III
 in oxygen-
rich environments leads to difficulties in the analysis of these metabolites in samples of 
urine collected in population studies. Results of our previous work indicate that MAs
III
 
and DMAs
III
 are relatively stable in a reducing cellular environment and can be 
quantified in cells and tissues. In the present study, we used the oxidation state-specific 
hydride generation-cryotrapping-atomic absorption spectroscopy (HG-CT-AAS) to 
examine the presence and stability of these trivalent metabolites in the liver of mice and 
in UROtsa/F35 cells exposed to iAs. Tri- and pentavalent metabolites of iAs were 
analyzed directly (without chemical extraction or digestion). Liver homogenates prepared 
in cold deionized water and cell culture medium and lysates were stored at either 0°C or  
-80°C for up to 22 days. Both MAs
III
 and DMAs
III
 were stable in homogenates stored at   
                                                 
2
 Currier, J.M., Svoboda, M., Matousek, T., Dedina, J., and Stýblo, M. (2011) Metallomics 3, 1347-1354. 
Reproduced by permission of The Royal Society of Chemistry. http://pubs.rsc.org/en/content/ 
articlelanding/2011/mt/c1mt00095k 
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-80°C. In contrast, DMAs
III
 in homogenates stored at 0°C began to oxidize to its 
pentavalent counterpart after 1 day; MAs
III
 remained stable for at least 3 weeks under 
these conditions. MAs
III
 and DMAs
III
 generated in UROtsa/F35 cultures were stable for 3 
weeks when culture media and cell lysates were stored at 80°C. These results suggest that 
samples of cells and tissues represent suitable material for the quantitative, oxidation 
state-specific analysis of As in laboratory and population studies examining the 
metabolism or toxic effects of this metalloid. 
3.2 Introduction 
Inorganic arsenic (iAs) is a natural, carcinogenic metalloid found in water sources 
worldwide, most commonly as arsenite (iAs
III
) and arsenate (iAs
V
) (16). The ingestion of 
drinking water containing high levels of iAs is associated with an array of adverse health 
effects, including cancer of the skin, lungs, liver and urinary bladder (1). Non-neoplastic 
effects of iAs exposure include vascular disease, hypertension, skin lesions and diabetes 
(3, 155, 163). Chronic toxicity due to drinking water with high levels of iAs can lead to a 
collection of these symptoms, known as arsenicosis (164). The United States 
Environmental Protection Agency and World Health Organization lowered the safe level 
for As in drinking water from 50 to 10 ppb in response to evidence of iAs toxicity even at 
low exposure levels (6, 7). For the tens of millions of people chronically exposed to iAs, 
outcomes vary widely and depend not only on the level of exposure but also on the inter-
individual differences in As metabolism. Exposure levels and the pattern of iAs 
metabolism are commonly assessed through analysis of iAs metabolites in urine; 
however, concentrations of these metabolites in human tissues are not well researched.  
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The metabolism of iAs in humans is mediated by arsenic (+3 oxidation state) 
methyltransferase (AS3MT) (53). The AS3MT-catalyzed and S-adenosylmethionine-
dependent methylation of iAs yields both trivalent and pentavalent methylated arsenicals, 
including methylarsonic acid (MAs
V
), methylarsonous acid (MAs
III
), dimethylarsinic acid 
(DMAs
V
) and dimethylarsinous acid (DMAs
III
) (59, 60). Several intronic and exonic 
polymorphisms have been described for the human AS3MT gene, including Met287The 
(T - C), potentially altering the rates and yields of iAs methylation and contributing to the 
inter-individual differences in susceptibility to iAs toxicity (67, 72). 
While the methylation of iAs is critical for its detoxification, recent evidence 
suggests that methylated trivalent As metabolites (MAs
III
 and DMAs
III
) generated in the 
course of iAs metabolism in human cells and tissues are more cytotoxic and genotoxic 
than their pentavalent counterparts or iAs species (8). MAs
III
 and DMAs
III
 are also potent 
enzyme inhibitors, alter cell signaling pathways, and induce oxidative damage (9-11). 
Moreover, these As metabolites have been shown to inhibit insulin signaling and insulin-
stimulated glucose uptake in cultured murine adipocytes, providing a potential 
mechanism for the diabetogenic effects of iAs exposure (86, 140).  
The analysis of iAs metabolites in human population studies has been typically 
limited to urine. The half life of iAs in the human body measures in days. Thus, although 
urine is an important source of information about exposure to iAs, the urinary metabolites 
reflect only recent exposures (165). Furthermore, analysis of As species in urine of 
chronically exposed individuals produces a wide range of responses, making it difficult to 
elucidate the mechanisms responsible for iAs toxicity and the direct effects on target 
human tissues, such as, skin, urinary bladder, lungs, and liver. Interestingly, in vivo 
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studies indicate that urinary excretion of iAs and its metabolites does not correspond to 
tissue distribution of these As species (157, 158). For example, in mice exposed to iAs
V
 
in drinking water the predominant accumulation of MAs in the kidney and DMAs in the 
lungs has been reported (157, 158). Furthermore, a study comparing human urinary 
metabolites of iAs to As species retained in bladder exfoliated cells found no correlation, 
suggesting that monitoring urine may not give a clear idea of As species stored in specific 
tissues (85). Thus, identification and quantification of iAs metabolites in human tissues, 
including the target organs, or in cells originating from these tissues could provide 
important information about the risk associated with iAs exposure and about the 
mechanism underlying the adverse effects of this exposure.  
The oxidation state-specific speciation analysis of As in urine is complicated 
mainly by the low stability of methylated trivalent arsenicals, particularly DMAs
III
. 
DMAs
III
 can be completely converted to DMAs
V
 in several hours even in frozen urine; 
MAs
III
 can oxidize in several months (14). However, the rate of oxidation varies and 
depends, in part, on individual urine composition, further confusing the interpretation of 
the analytical data. To date, no attempt has been made to characterize the stability of the 
methylated trivalent As species in tissues and cells. Mammalian cells contain millimolar 
concentrations of a potent low-molecular weight reductant, glutathione (GSH), which is 
known to bind trivalent arsenicals, producing As
III–thiol complexes (166). Thus, the 
binding to GSH or to protein thiols is likely to protect the methylated trivalent arsenicals 
from oxidation and extend their lifetime inside the cells. The main objective of this study 
was to optimize the hydride generation-cryotrapping-atomic absorption spectroscopy 
(HG-CT-AAS) system for analysis of tissues and cells and to characterize the stability of 
43 
 
trivalent arsenicals, particularly DMAs
III
 in these complex biological matrices. Here we 
report, for the first time, that DMAs
III
 is relatively stable in tissue homogenates and cell 
lysates under conditions that are typically used for storage and transport of biological 
samples collected in laboratory and population studies. We, therefore, suggest that 
samples of the tissues targeted by iAs exposure or cells originated from these tissues are 
used to obtain more complete information about the metabolism of iAs or about the 
mechanisms of iAs toxicity in animals and humans. 
3.3 Methods 
3.3.1 Arsenicals 
The following arsenicals were used for calibration and in cell culture experiments: 
sodium arsenite (NaAs
III
O2) and sodium arsenate (Na2HAs
V
O4, 99% pure) were 
purchased from Sigma-Aldrich (St. Louis, MO). Methylarsonic acid, disodium salt 
(CH3As
V
O(ONa)2), and dimethylarsinic acid ((CH3)2As
V
O(OH)) both better than 98% 
pure were purchased from Chem Service (West Chester, PA). Oxomethylarsine 
(CH3AsO)4 which forms MAs
III
 in aqueous solution was provided by Dr William Cullen 
(University of British Columbia, Vancouver, Canada). The As content in each of the 
standards was determined by graphite furnace-AAS (146). 
3.3.2 Mice and treatments 
Twelve week-old C57BL/6 mice were obtained from Jackson Laboratory (Bar 
Harbor, ME, USA) and housed in polycarbonate cages (2 per cage) with corn cob 
bedding at the University of North Carolina Animal Facility (12 h light/dark cycle, 22 ± 
1°C and humidity 50 ± 10%), accredited by the American Association for Accreditation 
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of Laboratory Animal Care. Mice were allowed free access to food (Lab Diet 5058, 
Nutrition International, Brentwood, MO) and pure deionized water (DIW) or DIW 
containing iAs
III
 (50 mg As per L, i.e. 50 ppm). Mice were euthanized by cervical 
dislocation. Freshly dissected mice livers were processed as previously described (167). 
Liver homogenates were prepared in ice cold DIW (10% w/v). All procedures involving 
mice were approved by the UNC Institutional Animal Care and Use Committee.  
3.3.3 Cultured cells and treatments  
The SV-40 transformed human urothelial cell line, UROtsa, was obtained from Dr 
Unimye (Department of Urology, West Virginia University). The UROtsa/F35 clonal cell 
line expressing rat As3mt and capable of As methylation was previously generated from 
the parental UROtsa cell line using a retroviral pLEGFP-N1 gene delivery system (54). In 
the present study, UROtsa/F35 cells were cultured in MEM (Mediatech, Manassas, VA) 
supplemented with 10% heat inactivated FBS (Gemini Bio-Products, Sacramento, CA), 
50 U penicillin (Sigma) per mL and 50 mg streptomycin (Sigma) per mL. Cells were 
cultured in 6-well plates (Corning, Inc., Corning, NY) at 37°C in a humidified incubator 
with a 95% air/5% CO2 atmosphere.  
To generate DMAs
III
, near confluent cells in 6-well plates were incubated with 
MAs
III
 in 2 mL of MEM/well for varying lengths of time. After incubation, media were 
aspirated into capped tubes, cells were lysed on ice in pre-chilled DIW for 20 minutes 
and harvested by scraping with a pipette tip to reduce transfer losses. In some 
experiments, cells were lysed in 0.5% Triton X-100. Control, unexposed UROtsa/F35 
cells were used to establish the background levels of As species in the cell culture. 
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3.3.4 Depletion of intracellular GSH 
In some experiments, the cultured UROtsa/F35 cells were treated with butathione 
sulfoximine (BSO), the inhibitor of GSH synthesis. BSO was added to the culture 
medium at a final concentration of 250 mM BSO for 24 hours. The GSH concentrations 
were measured before and after BSO treatment in cell lysates prepared in 2% 
sulfosalicylic acid, using a previously described enzymatic recycling assay (168). 
3.3.5 Speciation analysis of As by HG-CT-AAS 
Arsenic species were analyzed by a semi-automated HG-CT-AAS using a 
AAnalyst 800 spectrometer (Perkin-Elmer, Norwalk, CT, USA) equipped with a multiple 
microflame quartz tube atomizer (multiatomizer) and coupled to a cryotrap. The HG and 
CT steps were controlled by a FIAS 400 flow injection accessory (Perkin-Elmer) (146, 
149). Using this system, arsines from trivalent arsenicals (iAs
III
, MAs
III
 and DMAs
III
) are 
generated directly at pH 6; to generate arsines from both tri- and pentavalent arsenicals 
(iAs
III+V
, MAs
III+V
 and DMAs
III+V
), the As
V
-standards and samples are pre-reduced with 
L-cysteine (EMD Chemicals Inc., Gibbstown, NJ) (146, 149). The concentrations of 
iAs
V
, MAs
V
, and DMAs
V
 are then determined as a difference between AAS signals 
obtained for cysteine-treated and untreated sample aliquots.  
We have previously shown that the slopes of the calibration curves for the 
cysteine-treated As
V
-standards prepared in DIW are identical with the slopes of curves 
generated for the trivalent arsenicals in the absence of cysteine (149). We have also 
shown that the slopes of the calibration curves for the cysteine-treated aqueous solutions 
of As standards do not significantly differ from the slopes of curves prepared for liver 
homogenates spiked with these standards and treated with cysteine (167). Therefore, 
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calibration curves for quantification of tri- and pentavalent As species in this study were 
generated using aqueous solutions of the pentavalent standards (iAs
V
, MAs
V
, and 
DMAs
V
) treated with cysteine. 
3.3.6 Acid digestion 
To determine the recovery of As species during the direct analyses of mouse liver 
homogenates, aliquots of the homogenates were acid digested using a MARS Microwave 
Reaction System equipped with MarsXpress Temperature Control (CAM, Matthews, 
NC). Here, 100 mL of 10% homogenate was mixed with 3 mL of 2M ultrapure 
phosphoric acid (EMD Chemicals, Inc.) and microwaved for 10 hours at 90°C. One 
milliliter of the digestate was neutralized with 0.25 mL of 10 N NaOH to a final pH of 
~6. Because this digestion oxidizes all trivalent arsenicals to their pentavalent 
counterparts, the neutralized digestates were treated with 2% cysteine for 1 hour prior to 
analysis (167). 
3.3.7 Statistical analysis 
All statistical analyses were performed using GraphPad Instat software package 
(GraphPad Software Inc., San Diego, CA). Linear regression and correlation analyses 
were employed to characterize the calibration curves. ANOVA followed by Bonferroni’s 
multiple comparison posttest was used to determine significant differences in As 
concentration between fresh, immediately analyzed samples and each time point during 
the storage of samples at either 0°C or -80°C. This test was also used to determine 
differences in DMAs
III
 present in cell lysates after lysis with either DIW or 0.5% Triton 
X-100. Statistical significance was considered at the level of p < 0.01. 
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3.4 Results and discussion 
3.4.1 Speciation analysis of As in biological matrices  
The growing number of reports on widespread exposures to iAs in drinking water 
has triggered an intensive search for biomarkers that could serve as indicators of these 
exposures or could predict the susceptibility of individuals to diseases associated with 
chronic toxicity of iAs. For many years, the urinary concentrations of As species that 
originate from iAs metabolism in human tissues have been used as the exposure 
indicators. In addition, the composition of iAs metabolites in human urine (e.g., 
DMAs/MAs ratio) is believed to provide information about the capacity of individuals to 
methylate and thus to detoxify iAs (169, 170). The attempts to determine concentrations 
of iAs metabolites, especially the toxic MAs
III
 and DMAs
III
 in tissues, have been rare and 
suffered problems associated with the lack of suitable analytical techniques and with low 
stability of these methylated trivalent arsenicals.  
We have shown that in rat liver cytosol large portions of iAs and its methylated 
metabolites are bound to proteins (153). The binding of As species to proteins that has 
also been reported by others (62, 171) makes it necessary to perform digestions or 
extraction when chromatographic methods are used for speciation analysis of As in cells, 
tissues, or tissue fractions. However, both digestion and extraction can lead to oxidation 
or losses of the unstable and highly reactive methylated As
III
 species (148). Our previous 
work has provided strong evidence that, in spite of their limited specificity, HG-based 
techniques coupled with a sensitive detector may provide a unique tool for the detection 
and quantification of MAs
III
 and DMAs
III
 in the biological matrices as complex as 
cultured cells or tissue (144, 146, 149, 167). The present study continues this work by 
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examining stability of the methylated trivalent arsenicals in liver homogenates and cell 
lysates using a HG-CT-AAS technique developed by our laboratories.  
3.4.2 Optimization of HG-CT-AAS for analysis of slurries 
The previously described HG-CT-AAS system was developed for analysis of 
solutions and relatively simple liquid biological matrices (146, 149). This system was 
optimized in the present study for analysis of complex biological slurries, including tissue 
homogenates and crude cell lysates (Figure 3.1). To avoid plugging of the FIAS 400 
injection port with tissue and cell fragments, the homogenates and cell lysates were 
introduced directly to the manifold. The sample (typically 500 mL) was pipetted into a 1 
mL pipette tip connected to the FIAS 400 peristaltic pump. From the pipette tip, the 
sample was pumped into the system followed by 500 mL of DIW. The sample was then 
mixed with equal flows (2 mL min
-1
) of Tris-HCl buffer (pH 6) and NaBH4 solutions 
prior to entering the reaction coil and the gas–liquid separator. For drying of the gaseous 
phase prior to the cryotrapping stage, a cartridge filled with NaOH pellets was included 
(172). The cryotrapping step and AAS detection were performed without modifications 
as previously described (146).  
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Figure 3.1: The optimized HG-CT-AAS system for slurry sampling. 
 
Further optimization focused on the pre-reduction with cysteine and on the 
components of the HG mixture. Here, liver homogenate from a single mouse exposed to 
iAs
III
 (50 ppm As) in drinking water was aliquoted, pre-treated with cysteine (0.5, 2 or 
4%) for up to 80 minutes and analyzed directly by HG-CT-AAS. Results of the direct 
analysis suggest that treatment with 0.5–2% cysteine for at least 20 minutes is optimal for 
generation of arsines from all As species present in the homogenate (Figure 3.2). It is 
unclear why the AAS signals were lower for homogenate aliquots treated with 4% 
cysteine. It is possible that portions of arsenicals in homogenates were reduced by high 
cysteine concentration to form volatile arsines, thus decreasing the amounts of arsines 
generated during the HG step. 
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Figure 3.2: Peak areas recorded for iAs
III+V
 (A), MAs
III+V
 (B), and DMAs
III+V
 (C) during 
the direct HG-CT-AAS analysis of aliquots of a mouse liver homogenate pre-treated with 
0.5, 2, or 4% cysteine for up to 80 minutes. Time 0 minutes shows results of the direct 
analysis of liver homogenates prior to the cysteine treatment. Each point represents a 
single measurement. 
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In the next step, AAS signals were tested in the reaction mixtures containing liver 
homogenates treated for 1 hour with 2% cysteine and varied concentrations of Tris-HCl 
(pH 6) or NaBH4. For this test we pooled liver homogenates from several mice exposed 
to 50 ppm As in drinking water. No significant differences in AAS signals were 
measured in mixtures containing 1% NaBH4 and 0.2 M to 1 M Tris, even though the pH 
measured after the HG reaction decreased from 8.3 to 6.9 (Figure 3.3). Similarly, 
changing NaBH4 concentration (0.5% to 2.5%) in a reaction mixture containing 0.75 M 
Tris had little effect on the HG efficiency (Fig. 3.4).  
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Figure 3.3: HG-CT-AAS analysis of pooled mouse liver homogenates pre-treated with 
2% cysteine for 1 hour: effect of Tris buffer concentration in the HG reaction mixture on 
AAS signals for iAs
III+V
, MAs
III+V
, and DMAs
III+V
. Each point represents mean ± SD for 
n = 3. 
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Figure 3.4: HG-CT-AAS analysis of pooled mouse liver homogenates pre-treated with 
2% cysteine for 1 hour: effect of NaBH4 concentration in the HG reaction mixture on 
AAS signals for iAs
III+V
, MAs
III+V
, and DMAs
III+V
. Each point represents mean ± SD for 
n = 3. 
Thus, each of the experimental parameters we examined exhibits a relatively 
broad optimum, which is important for achieving robust and reliable analytical 
conditions. Based on these results, we concluded that the 1 hour treatment with 2% 
cysteine and the HG mixture containing 0.75 M Tris and 1% NaBH4 is optimal for 
analysis of liver homogenates. Notably, the same reaction conditions were previously 
used in our laboratories for analyses of liquid samples (146, 149). To examine As 
recoveries under these conditions, additional aliquots of the homogenates were analyzed 
after digestion in phosphoric acid. The analysis of acid-digested homogenates showed 
that the direct analysis of the homogenates treated with 2% cysteine recovered ~100% of 
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MAs
III+V
 and DMAs
III+V
. Consistent with our previous report, (167) the average recovery 
of iAs
III+V
 was lower, reaching only about 85%.  
The 1 hour treatment with 2% cysteine and the HG mixture containing 0.75 M 
Tris and 1% NaBH4 was used in all following experiments examining the stability of 
trivalent arsenicals in mouse liver homogenates and cell lysates. 
3.4.3 Stability of trivalent arsenicals in mouse liver homogenates 
The stability of As
III
 species was examined in a 10% homogenate prepared from a 
liver of a single mouse exposed to iAs
III
 in drinking water (50 ppm As) for 9 days. The 
homogenate was prepared in ice-cold DIW and immediately aliquoted. Three freshly 
prepared aliquots were analyzed directly for As
III
 species; another 3 aliquots were 
pretreated with 2% cysteine and analyzed for As
III+V
 species. The As
III+V
 species were 
also analyzed in acid digested aliquots of the homogenate. To determine the stability of 
trivalent arsenicals, remaining aliquots were stored at 0°C (on ice) or -80°C and analyzed 
for As
III
 and As
III+V
 species after 1, 6, 13, and 22 days (Figure 3.5).  
In the fresh homogenate, trivalent arsenicals accounted for 65% of the sum of As 
species: iAs
III
 (8%), MAs
III
 (12%), and DMAs
III
 (45%). However, the recovery of iAs
III+V
 
was only about 82% (Figure 3.5A,B), suggesting that a part of iAs, possibly protein-
bound iAs
III
, is not available for the HG reaction under these conditions. The recoveries 
of iAs remained low for up to 13 days, but increased at day 22 for aliquots of the 
homogenate stored either at 0°C (105%) or at -80°C (113%) due to increased levels of 
iAs
V
. These data suggest that a prolonged storage may result in the release of iAs
III
 from 
high-affinity binding sites, followed by oxidation of iAs
III
 to iAs
V
. Notably, both MAs
III
 
and DMAs
III
 were relatively stable in aliquots of the homogenate stored at -80°C for up  
54 
 
0 2 4 6 8 10 12 14 16 18 20 22 24
0
200
400
600
800
1000
1200
1400
1600
1800
DMAs III
DMAsV
DMAs III+V acid digestion
DMAs III+V
* *
Storage at -80°C (days)
D
M
A
s
 (
n
g
 A
s
 /
 g
 t
is
s
u
e
)
0 2 4 6 8 10 12 14 16 18 20 22 24
0
200
400
600
800
1000
1200
1400
1600
1800
DMAs III
DMAsV
DMAs III+V acid digestion
DMAs III+V
*
*
*
*
Storage at 0°C (days)
D
M
A
s
 (
n
g
 A
s
 /
 g
 t
is
s
u
e
)
0 2 4 6 8 10 12 14 16 18 20 22 24
0
100
200
300
400
500
600
MAsIII
MAsV
MAsIII+V acid digestion
MAsIII+V
* * *
Storage at -80°C (days)
M
A
s
 (
n
g
 A
s
 /
 g
 t
is
s
u
e
)
0 2 4 6 8 10 12 14 16 18 20 22 24
0
100
200
300
400
500
600
MAsIII
MAsV
MAsIII+V acid digestion
MAsIII+V
*
*
Storage at 0°C (days)
M
A
s
 (
n
g
 A
s
 /
 g
 t
is
s
u
e
)
0 2 4 6 8 10 12 14 16 18 20 22 24
0
100
200
300
400
500
600
iAsIII
iAsV
iAsIII+V acid digestion
iAsIII+V
* *
Storage at -80°C (days)
iA
s
 (
n
g
 A
s
 /
 g
 t
is
s
u
e
)
0 2 4 6 8 10 12 14 16 18 20 22 24
0
100
200
300
400
500
600
iAsIII
iAsV
iAsIII+V acid digestion
iAsIII+V
Storage at 0°C (days)
iA
s
 (
n
g
 A
s
 /
 g
 t
is
s
u
e
)
A
C
E
B
D
F
 
Figure 3.5: Stability of trivalent arsenicals in a liver homogenate from a mouse exposed 
to iAs
III
 in drinking water (50 ppm As) for 9 days: liver homogenate was prepared in 
DIW. The direct HG-CT-AAS analysis was used to determine the concentrations of iAs 
(A, B), MAs (C, D) and DMAs (E, F) species in aliquots of the fresh homogenate and in 
aliquots stored at –80°C (A, C, E) or 0°C (B, D, F) for up to 22 days (mean ± SD, n = 3). 
To control for As recoveries during the direct analyses, iAs
III+V
, MAs
III+V
, and DMAs
III+V
 
were determined in aliquots of the fresh homogenate digested in phosphoric acid (mean, 
n = 3). *The concentration is significantly different from that found in the fresh 
homogenate (p < 0.01). 
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to 22 days. Only about 18% of MAs
III
 and 9% of DMAs
III
 oxidized under these 
conditions (Figure 3.5C,E). In contrast, 42% of MAs
III
 and 88% of DMAs
III
 oxidized in 
aliquots of the homogenate stored at 0°C (Figure 3.5 D,F).  
3.4.4 Generation and stability of DMAs
III
 in UROtsa/F35 cells 
We have previously shown that cultured UROtsa/F35 cells treated with MAs
III
 
produce DMAs
III
 and DMAs
V
 (54). In the present study, DMAs
III
 was generated in 
UROtsa/F35 culture exposed to 0.1 mM MAs
III
 (15 ng As per well) for 18 hours. 
DMAs
III
 levels were monitored in the culture medium and in cell lysates that were 
prepared in ice-cold DIW. Figure 3.6 shows that DMAs
III
 was the major product of 
MAs
III
 methylation and that a substantial portion of DMAs
III
 was retained by cells. 
DMAs
III
 represented almost 50% and 90% of all As species associated with the culture 
medium and cells, respectively. The stability of DMAs
III
 was examined in both the 
medium and cell lysates prepared in DIW and stored at either 0°C or -80°C for up to 23 
days. DMAs
III
 in cell lysates was stable regardless of the storage temperature; DMAs
III
 in 
culture medium was stable only at -80°C (Figure 3.7). In contrast, almost 50% of 
DMAs
III
 oxidized in the medium stored at 0°C. 
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Figure 3.6: Generation of DMAs
III
 in UROtsa/F35 culture exposed to 0.1 mM MAs
III
 (15 
ng As per well) for up to 18 hours. Tri- and pentavalent As species were measured by 
HG-CT-AAS in culture medium (A) and cell lysates (B) before and after pretreatment 
with 2% cysteine (mean ± SD, n = 3). 
 
We also tested the stability of DMAs
III
 in cell lysates prepared in an ice-cold 
solution of 0.5% Triton X-100, a non-ionic laboratory detergent that is commonly used in 
biomedical studies for sample processing. We found that fresh cell lysates prepared in 
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Triton X-100 contained significantly less DMAs
III
 than the lysates prepared in DIW. The 
oxidation state specific analysis showed that 54% of DMAs
III
 in these lysates oxidized to 
DMAs
V
 (Figure 3.8).  
 
Figure 3.7: Stability of DMAs
III
 in medium and cell lysates from UROtsa/F35 culture 
exposed to 0.1 µM MAs
III
 (15 ng As per well) for 18 hours: DMAs
III
 and DMAs
V
 were 
analyzed in culture medium (A, B) and cell lysates (C, D) immediately after the exposure 
and after storage at -80°C or 0°C for up to 23 days (mean ± SD, n = 3). *The 
concentration is significantly different from that found in fresh medium or cell lysate (p < 
0.01). 
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To assess the role of GSH in the stability of DMAs
III
, UROtsa/F35 cells were 
incubated with BSO for 24 hours and then exposed for 18 hours to MAs
III
. The treatment 
with BSO decreased the intracellular GSH concentration to 15% of the original level, but 
had no effect on the stability of DMAs
III
 in cell lysates prepared in DIW and stored at 
either -80°C or 0°C (data not shown). Thus, it is possible that the remaining GSH 
provided sufficient protection for DMAs
III
 in cell lysates or that DMAs
III
 was primarily 
bound to protein thiols and could not be affected by BSO treatment. 
 
Figure 3.8: Effect of Triton X100 on DMAs
III
 stability in cell lysates: UROtsa/F35 cells 
were exposed to 0.1 μM iAsIII (15 ng As/well) for 24 hours. Cells were then lysed in 
either DIW or 0.5% Triton X-100. DMAs
III
 and DMAs
V
 were analyzed in fresh cell 
lysates by HG-CT-AAS. Values represent the percentage of total As in lysate (mean ± 
SD, n=3). * The percentage of DMAs
III
 in lysates prepared in Triton X100 is significantly 
different from that in lysates prepared in DIW (p < 0.01). 
 
Finally, we examined the stability of DMAs
III
 under conditions that are consistent 
with a shipment of samples from field studies to analytical laboratories. Here, 
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UROtsa/F35 cells were exposed to 0.5 mM MAs
III
 (75 ng As per well) for 18 hours; 
aliquots of cell lysates prepared in DIW and aliquots of culture medium were placed in 
two polystyrene shipping containers filled with dry ice and two additional containers 
filled with ice packs that were pre-frozen at -80°C. One of the containers with dry ice and 
one with ice packs were stored at UNC Chapel Hill and DMAs
III
 was analyzed in aliquots 
of the stored samples for up to 7 days. The other containers were shipped by an express 
postal service to Prague, Czech Republic for analysis in the Institute of Analytical 
Chemistry. The HG-CT-AAS analysis at UNC found that DMAs
III
 is stable in both cell 
lysates and media stored in dry ice for 2 days; however, significant loses of DMAs
III
 
occurred at day 5 and 7 (Figure 3.9). DMAs
III
 oxidized faster in samples stored with ice 
packs. The shipment to Prague was delayed in customs for 4 days, resulting in a 
significant oxidation of DMAs
III
 in culture medium and cell lysates shipped in either dry 
ice or ice packs (Figure 3.10). 
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Figure 3.9: The oxidation of DMAs
III
 in UROtsa/F35 culture medium (A) and cell 
lysates (B) placed in shipping containers packed with dry ice or with pre-frozen ice packs 
(mean ± SD, n = 3). Cells were exposed to 0.5 μM MAsIII (75 ng As/well) for 18 hours, 
lysed in cold DIW and then aliquoted for storage and analysis by HG-CT-AAS. * The 
concentration of DMAs
III
 is significantly different from that in fresh cell lysates or 
culture medium (p < 0.01). 
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Figure 3.10: The oxidation of DMAs
III
 in UROtsa/F35 culture medium (A) and cell 
lysates (B) shipped to Prague, Czech Republic: DMAs
III
 concentrations cell lysates and 
medium were measured immediately after exposure to 0.5 μM MAsIII (75 ng As/well) for 
18 hours and after shipment to Prague (mean ± SD, n = 4). The samples were shipped in 
containers filled with either dry ice or pre-frozen ice packs. The samples were analyzed 
in Prague 8 days after shipment due to a 4 day customs delay. * The concentration of 
DMAs
III
 is significantly different from the concentration determined in fresh cell lysates 
or culture medium (p < 0.01). 
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3.5 Conclusions 
Previous work has shown that methylated trivalent metabolites of iAs, MAs
III
 and 
DMAs
III
 are unstable in human urine (14). We have recently reported that up to 50% of 
DMAs
III
 can oxidize during 24 hours even in urine stored in dry ice, (70) making it 
difficult to detect and quantify this metabolite in urine samples collected in population 
studies. The work presented here confirms that the trivalent metabolites of iAs, iAs
III
, 
MAs
III
, and DMAs
III
 can be detected and quantified in fresh cell lysates and tissue 
homogenates by direct HG-CT-AAS analysis. The optimum conditions for analysis of the 
pentavalent arsenicals include the pre-treatment with 2% cysteine for 60 minutes and 
generation of arsines in the reaction mixture containing 1% NaBH4 and 0.75M Tris buffer 
(pH 6). Notably, the methylated trivalent metabolites of iAs, including DMAs
III
, are 
stable for at least 3 weeks in cell lysates and tissue homogenates prepared in cold DIW 
and stored at -80°C. When packed in dry ice, these types of samples can be shipped 
without major losses of DMAs
III
, as long as the shipping time does not exceed 2 days and 
dry ice is not depleted during the shipment. 
In summary, results of the present study suggest that, unlike urine, samples of 
tissues or cells collected in human population studies provide suitable material for the 
quantitative, oxidation state specific analysis of As species, assuming that these samples 
are properly handled and stored prior to the analysis. Thus, while urine analysis helps to 
estimate the levels of exposure to iAs and to evaluate the efficiency of iAs methylation, 
the analysis of tissues or cells may provide important information about the internal dose 
and chemical species of As, including highly toxic but unstable MAs
III
 and DMAs
III
, in 
target tissues. 
   
 
 
CHAPTER IV  
Comparative Oxidation State Specific Analysis of Arsenic by High-Performance Liquid 
Chromatography-Inductively Coupled Plasma-Mass Spectrometry and Hydride 
Generation-Cryotrapping-Atomic Absorption Spectrometry
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4.1 Overview 
The formation of methylarsonous acid (MAs
III
) and dimethylarsinous acid 
(DMAs
III
) in the course of inorganic arsenic (iAs) metabolism play an important role in 
the adverse effects of chronic exposure to iAs. High-performance liquid chromatography-
inductively coupled plasma-mass spectrometry (HPLC-ICP-MS) and hydride generation-
cryotrapping-atomic absorption spectrometry (HG-CT-AAS) have been frequently used 
for the analysis of MAs
III 
and DMAs
III
 in biological samples. While HG-CT-AAS has 
consistently detected MAs
III
 and DMAs
III
, HPLC-ICP-MS analyses have provided 
inconsistent and contradictory results. This study compares the capacities of both 
methods to detect and quantify MAs
III
 and DMAs
III
 in an in vitro methylation system 
consisting of recombinant human arsenic (+3 oxidation state) methyltransferase 
(AS3MT), S-adenosylmethionine as a methyl donor, a non-thiol reductant tris(2-
carboxyethyl)phosphine, and arsenite (iAs
III
) or MAs
III 
as substrate. The results show that 
reversed-phase HPLC-ICP-MS can identify and quantify MAs
III
 and DMAs
III
 in aqueous 
mixtures of biologically relevant arsenical standards. However, HPLC separation of the 
in vitro methylation mixture resulted in significant losses of MAs
III
, and particularly 
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DMAs
III
 with total arsenic recoveries below 25%. Further analyses showed that MAs
III
 
and DMAs
III
 bind to AS3MT or interact with other components of the methylation 
mixture, forming complexes that do not elute from the column. Oxidation of the mixture 
with H2O2, which converted trivalent arsenicals to their pentavalent analogs prior to 
HPLC separation, increased total arsenic (As) recoveries to ~95%. In contrast, HG-CT-
AAS analysis found large quantities of methylated trivalent arsenicals in mixtures 
incubated with either iAs
III
 or MAs
III
 and provided high (>72%) As recoveries. These 
data suggest that an HPLC-based analysis of biological samples can underestimate MAs
III
 
and DMAs
III
 concentrations and that controlling for As species recovery is essential to 
avoid artifacts.  
4.2 Introduction 
Arsenic (As) is one of the most prevalent elements in the Earth’s crust. Inorganic 
As (iAs) species, arsenite (iAs
III
) and arsenate (iAs
V
) are common ground and surface 
water contaminants (16). Millions of people worldwide who drink iAs-contaminated 
water are at risk of developing cancer and non-cancerous diseases, including 
hypertension, peripheral neuropathy, or diabetes (1-4). However, the susceptibility to 
chronic iAs toxicity varies among individuals and depends, in part, on the efficiency and 
pattern of iAs metabolism. Thus, the analysis of iAs metabolites in biological matrices 
has become an essential tool for population studies examining the inter-individual 
differences in responses to iAs exposure, as well as for laboratory studies using animal or 
in vitro models for iAs toxicity and metabolism. 
Once ingested, iAs is enzymatically methylated by As (+3 oxidation state) 
methyltransferase (AS3MT) in a sequence of S-adenosylmethionine-dependent reactions 
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(53). Both tri- and pentavalent methylated oxoarsenicals are generated in this pathway, 
including methylarsonic acid (MAs
V
), methylarsonous acid (MAs
III
), dimethylarsinic acid 
(DMAs
V
), and dimethylarsinous acid (DMAs
III
) with trimethylarsine oxide (TMAs
V
O) 
being the final metabolite in some mammalian species (59, 60). All these tri- and 
pentavalent oxoarsenicals have been detected in human urine and in biological samples 
collected in laboratory experiments (70, 148, 156, 167, 173-177). Recent studies have 
suggested that in addition to oxoarsenicals, a variety of sulfur-containing As species 
(thioarsenicals) can be produced in the course of iAs metabolism, possibly by intestinal 
bacteria or by reactions of oxoarsenicals with hydrogen sulfide in tissues (178-180). To 
date, only one of these thioarsenicals, dimethylthioarsinic acid (DMTA), has been 
detected in urine of people exposed to iAs in drinking water (181, 182). A growing body 
of evidence suggests that among all known metabolites of iAs, the methylated trivalent 
oxoarsenicals (MAs
III
 and DMAs
III
) are the most biologically active and toxic species (8-
11). 
The methods used for speciation analysis of As in biological samples have been 
discussed in detail in several recent reviews (23, 151, 175, 183, 184). Most of these 
methods use high-performance liquid chromatography (HPLC) for separation of As 
species and various spectrometric techniques, including inductively coupled plasma-mass 
spectrometry (ICP-MS) for quantification of As in the chromatographic fractions. An 
alternative approach uses hydride generation (HG) to convert iAs and methylated As 
species in analyzed samples to gaseous arsine (AsH3) with boiling point (b.p.) of -55°C 
and methyl-substituted arsines: methylarsine (CH3AsH2, b.p. 2 °C), dimethylarsine 
((CH3)2AsH, b.p. 36 °C) and trimethylarsine ((CH3)3As, b.p. 52 °C). The generation of 
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arsines by reaction with sodium borohydride is then followed by a cryotrapping (CT) step 
and separation of arsines by their boiling points. The HG-CT techniques typically use 
atomic absorption spectrometry (AAS), AFS or ICP-MS for the detection and 
quantification of As in the separated arsines (151, 175). In general, the HPLC-based 
methods are highly specific and can identify a wide spectrum of As species, including 
species that originate in foods and are not products of iAs metabolism in human tissues, 
e.g., arsenobetaine (AsB), arsenocholine (AsC), or arsenosugars (184). The HG-based 
techniques are characterized by low detection limits, but have only limited specificity. A 
thorough method development and validation using appropriate standards and HG 
conditions are required for these methods to reliably identify and quantify As species and 
to avoid artifacts associated with generation of a single form of arsine from two or more 
As species present in the analyzed samples. 
A variety of HPLC-ICP-MS techniques have been used for separation of iAs 
metabolites and other As species in aqueous solutions and biological samples, mainly 
urine. Anion-exchange HPLC has been shown in some studies to separate tri- and 
pentavalent metabolites of iAs and As species originating in seafood, including AsB and 
AsC (159, 173, 184-186). Other studies used a combination of anion- and cation-
exchange chromatography to achieve the same goal (148). On the other hand, reversed-
phase HPLC has successfully separated AsC and the tri- and pentavalent metabolites of 
iAs, including MAs
III
 and DMAs
III
 with the use of a single column (12, 14, 147, 187, 
188), but could not fully resolve AsB (189). Notably, while some researchers using 
HPLC for As speciation analysis found MAs
III
 and/or DMAs
III
 in biological samples, 
including human urine (12, 13, 44, 147, 148, 173, 186-188, 190, 191), others failed to 
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detect these metabolites (183, 192). What causes these inconsistent results is unclear but 
the oxidation of MAs
III
 and DMAs
III
 in aqueous solutions and in human urine (14, 70, 
193) could play a major role. In addition, HPLC-based analysis typically involves sample 
preparation (extraction, filtration, etc.) which could produce oxidation state specific 
conversions and/or provide opportunities for unwanted analyte interaction with the 
matrix, chemicals, or surfaces inherent within the analysis procedure (143). Because 
surprisingly many of the published studies did not employ oxidation state specific 
procedural spikes or control for As-based mass balance to assess the impact of these 
undesirable artifacts, it is difficult to determine whether a procedure element was 
responsible for the analyte loss or conversion.  
Unlike HPLC, the HG-CT-based methods, specifically HG-CT-AAS and HG-CT-
ICP-MS, have consistently detected MAs
III
 and DMAs
III
 in biological samples, including 
urine of individuals exposed to iAs in drinking water (69, 70, 143, 156), tissues from 
mice exposed chronically to iAs (167, 193), mammalian cells or tissue cultures treated in 
vitro with iAs (136, 143, 149), and in vitro systems in which iAs was methylated by 
recombinant rat As3mt or human AS3MT (149, 154). However, because of a limited 
specificity of the HG-based techniques, results of these analyses have often been 
questioned, and the detection of DMAs
III
 has been viewed by some as an artifact (183, 
194). The present study was designed to address these concerns. This study compares the 
capacities of previously described reversed-phase HPLC-ICP-MS (14, 147, 147, 187, 
188) and HG-CT-AAS (136, 195) techniques to detect and quantify MAs
III
 and DMAs
III
 
in an in vitro system in which the methylated As metabolites are produced in reactions 
catalyzed by recombinant human AS3MT and which, because of its simplicity, limits 
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possible artifacts. Results of this study suggest that analysis of biological samples by 
HPLC-based techniques can underestimate MAs
III
 or DMAs
III
 content due formation of 
stable complexes between these arsenicals and proteins or other endogenous substances 
and due to retention of these complexes on the chromatographic column. 
4.3 Experimental 
4.3.1 Arsenicals 
The following arsenicals were used for method optimization and calibration: iAs
III
 
(NaAs
III
O2) and iAs
V
 (Na2HAs
V
O4), both >99% pure from Sigma-Aldrich (St. Louis, 
MO, USA); MAs
V
 (CH3As
V
O(ONa)2) and DMAs
V
 ((CH3)2As
V
O(OH)), both >98% pure 
from Chem Service (West Chester, PA); oxomethylarsine (CH3AsO, MAs
III
O4) and 
iododimethylarsine ((CH3)2AsI, DMAs
III
I) provided by Dr. William Cullen (University of 
British Columbia, Vancouver, Canada). In aqueous solutions, MAs
III
O and DMAs
III
I 
form the corresponding MAs
III
 and DMAs
III
 oxoanions (196). TMAs
V
O, AsC and AsB 
were also provided by Dr. William Cullen. DMTA was synthesized in Dr. Creed’s 
laboratory as previously described (195). Stock solutions of the pentavalent arsenicals, 
DMTA, AsC and AsB were prepared in deionized water (DIW) and stored at -80
o
C. 
Stock solutions of the methylated trivalent arsenicals were prepared in ice-cold DIW 
immediately before each experiment to limit oxidation. 
4.3.2 Instrumentation 
4.3.2.1 HG-CT-AAS 
The speciation analysis of As by HG-CT-AAS was performed as previously 
described (146, 149). The instrumentation, reagents, and operating conditions are 
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summarized in Table 4.1. Briefly, the HG-CT-AAS system consisted of custom made 
HG and CT units controlled by FIAS 400 flow injection accessory (Perkin-Elmer, 
Norwalk, CT) and coupled with AAnalyst 800 spectrometer (Perkin-Elmer) that was 
equipped with a multiple microflame quartz tube atomizer (multiatomizer) (146, 149).
 
Arsine and the methyl-substituted arsines from trivalent arsenicals (iAs
III
, MAs
III
, and 
DMAs
III
) and from TMAs
V
O were generated directly in a buffered reaction mixture 
containing 0.75 M Tris (pH 6) and 1% NaBH4 in 0.1 % KOH (all from Sigma-Aldrich). 
To generate arsines from both tri- and pentavalent arsenicals (iAs
III+V
, MAs
III+V
 and 
DMAs
III+V
) at pH 6, standards or samples were pre-reduced with 2% L-cysteine 
hydrochloride (EMD Chemicals Inc., Gibbstown, NJ) for 1 hour prior to the HG step. 
Arsines were cryotrapped in a capillary U-tube filled with Chromosorb WAW-DCMS 
45/60 (15% OV-3) (Sigma-Aldrich) and submerged in liquid N2, and then separated by 
their boiling points prior to detection by the AA spectrometer. Concentrations of iAs
V
, 
MAs
V
, and DMAs
V
 were calculated as the differences between species concentrations 
obtained for the cysteine-treated and untreated sample aliquots.  
4.3.2.2 HPLC-ICP-MS 
The HPLC-ICP-MS analysis followed a previously described isocratic reversed-
phase HPLC protocol (147). The operating conditions are summarized in Table 4.1. The 
Prodigy ODS(3) C18 column (150 x 4.6 mm, Phenomenex, Torrance, CA) was heated to 
30°C and eluted with a mobile phase containing tetrabutylammonium hydroxide (TBAH) 
(Acros Organic, Morris Plains, NJ), malonic acid (Sigma-Aldrich), and methanol (JT 
Baker Chemical Co., Phillipsburg, NJ). Ultrapure nitric acid (Fisher Scientific Co., Fair 
Lawn, NJ) was used to adjust pH of the mobile phase for optimal arsenical separation. 
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The HPLC column was connected with PTFE tubing to the nebulizer of a 7500cx ICP-
MS (Agilent Technologies, Palo Alto, CA). 
4.3.3 In vitro methylation mixture  
Recombinant human wild-type AS3MT which has methionine in position 287 was 
expressed and purified as previously described (154). Methylated arsenicals were 
generated enzymatically in a reaction mixture containing 100 mM TRIS-HCl buffer (pH 
7.4, Mediatech, Inc., Manassas, VA), recombinant AS3MT (60 or 80 μg/mL), 1 mM 
tris(2-carboxyethyl)phosphine (TCEP, Sigma), 1 mM S-adenosylmethionine (SAM, 
Sigma), and 1 µM iAs
III
 or 1 µM MAs
III
 as substrates. The final volume of the mixture 
was 150 μL. The in vitro methylation mixtures were incubated at 37°C for up to 2 hours. 
The mixture was then chilled on ice and split into aliquots that were analyzed 
concurrently by HG-CT-AAS and HPLC-ICP-MS. Some of these aliquots were treated 
with 2% L-cysteine (for 1 hour) or 3% H2O2 (for 4 hours) prior to analysis as described in 
Results and Discussion. Sums of As species detected by HG-CT-AAS or HPLC-ICP-MS 
analyses were used to calculate As recovery as percentage of the known amount of As 
added into the in vitro methylation mixture. Spikes of arsenical standards into complete 
or incomplete reaction mixtures were used to assess interactions between the components 
of the mixture and the metabolites of iAs
III
 or MAs
III
 and effects of these interactions on 
results of the HG-CT-AAS and HPLC-ICP-MS analyses. 
Table 4.1: HG-CT-AAS and HPLC-ICP-MS operating conditions 
HG-CT Perkin-Elmer FIAS 400 
Sample volume 500 µL 
Buffer 0.75 M TRIS-HCl (pH 6.0) 
Reducing agent 1% NaBH4 in 0.1% KOH 
Carrier gases He (75 ml/min); H2 (15 ml/min) 
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Column packing Chromosorb WAW-DCMS 45/60 (15% OV-3)  
Column heating Ni80/Cr20 wire, 20 Ω 
AAS Perkin-Elmer AAnalyst 800 
Lamp As electrodeless discharge (390 mA) 
Wavelength 193.7 nm 
Slit width 0.7 nm 
Atomizer Multiatomizer (900°C) 
Outer gas Air (35 ml/min) 
HPLC  Agilent 1260 Infinity Series 
Column Phenomenex Prodigy 3μ ODS(3) 100A, 150x4.60 mm 
Temperature 30 °C 
Mobile phase 
4.7 mM tetrabutylammonium hydroxide + 2 mM malonic 
acid +  
4% methanol (pH 5.85) 
Flow rate 1.5 mL/min 
Injection volume 20 µL 
ICP-MS  Agilent 7500cx Series 
Masses 75 (As), 77 (ArCl) 
Integration time 0.1 s 
RF power 1550 W 
Skimmer cone Ni 
Spray chamber Double-pass Scott-type 
Sample depth 8 mm 
S/C temperature 2 °C 
Plasma gas (Ar) 15 L/min 
Carrier gas (Ar) 0.95 L/min 
Make-up gas (Ar) 0.25 L/min 
Cell gas (He) 4.0 L/min 
Nebulizer Micromist 
 
4.3.4 Ultrafiltration 
To examine binding of As species to AS3MT, the reaction mixtures with or 
without recombinant AS3MT were spiked with iAs
III
, MAs
III
, or DMAs
III
 (1 µM each) 
and incubated on ice for 5 minutes. After incubation, the reaction mixtures were filtered 
using Nanosep Omega spin columns with 3 kDa cut-off (Pall Life Sciences, Ann Arbor, 
MI) at 4°C and 14,000 x g for 15 minutes. To ensure maximum As recovery, the columns 
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were washed with 100 μL of 100 mM TRIS-HCl buffer (pH 7.4) and centrifuged for an 
additional 15 minutes at 4°C. The filtrate and wash containing unbound arsenicals were 
analyzed by HG-CT-AAS after cysteine pre-treatment.  
4.3.5 Statistical Analysis 
All statistical analyses were performed using the GraphPad Instat software 
package (GraphPad Software Inc., San Diego, CA). Linear regression and correlation 
analyses were employed to characterize the calibration curves. ANOVA followed by 
Bonferroni’s multiple comparison posttest was used to determine significant differences 
in As concentration between the analytical methods and the effects of protein binding on 
As recovery. The differences with p < 0.05 were considered statistically significant.  
4.4 Results and discussion 
4.4.1 Method optimization 
The method optimization focused on tri- and pentavalent As species that are 
known to be produced in the course of iAs methylation by human AS3MT, including 
iAs
III
, iAs
V
, MAs
III
, MAs
V
, DMAs
III
, DMAs
V
 (59, 60). The following As species that are 
not products of AS3MT-catalyzed methylation of iAs but are commonly found in human 
urine were also included: TMAs
V
O, DMTA, AsC and AsB.  
4.4.1.1 HG-CT-AAS 
The HG-CT-AAS technique has been previously optimized and used for analysis 
of As species in biological systems as complex as tissue homogenates (167, 193) or as 
simple as in vitro methylation systems in which iAs was methylated by recombinant rat 
As3mt or human AS3MT (149, 154). The oxidation state specific generation of arsine 
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and methyl-substituted arsines from tri- and pentavalent iAs and methylated arsenicals in 
a buffered system at pH 6 has been described in details in our previous reports (146, 149). 
In absence of cysteine pretreatment, arsines were generated almost exclusively from 
trivalent arsenicals (iAs
III
, MAs
III
, and DMAs
III
) and from TMAs
V
O. Only small portions 
of DMAs
V
 (up to 3.5%) and DMTA (up to 11.7%) were converted to dimethylarsine 
under these conditions (149). However, DMTA cannot be present in the in vitro 
methylation system used in this study because the reaction mixture does not contain H2S 
or other donors of sulfur needed for DMTA formation. Thus, arsine and methyl-
substituted arsines generated from the in vitro methylation mixture can only represent 
iAs
III
, iAs
V
, MAs
III
, MAs
V
, DMAs
III
, DMAs
V
, or TMAs
V
O. Notably, neither AsC nor 
AsB produced arsines in the reaction with 1% NaBH4 at pH 6 regardless of cysteine 
treatment (data not shown).  
4.4.1.2 HPLC-ICP-MS 
The reversed-phase C18 column and mobile phases consisting of TBAH, malonic 
acid, and methanol have been used by other laboratories for the HPLC-ICP-MS analysis 
of As species in aqueous solutions, human urine, saliva or cells (147, 187, 188, 197). This 
method was tested in the present study using a 150 x 4.6 mm C18 column heated to 30°C. 
A base-line separation of six oxoarsenicals (iAs
III
, iAs
V
, MAs
III
, MAs
V
, DMAs
III
, and 
DMAs
V
) and DMTA was achieved with the mobile phase consisting of 4.7 mM TBAH, 2 
mM malonic acid, and 4% methanol at pH 5.85 and with a flow rate of 1.5 mL/min 
(Figure 4.1). In this study, pH lower or higher than 5.85 resulted in an incomplete 
separation of iAs
V
, DMAs
III
, and DMTA (data not shown). The optimized mobile phase 
was also used to examine elution profiles of TMAs
V
O, AsC and AsB. The retention time  
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Figure 4.1: The separation and detection of six oxoarsenicals and DMTA by optimized 
HPLC-ICP-MS. The operating conditions are described in Table 4.1. The standards (250 
pg As each) were injected in 20 μL of DIW. 
 
for AsC was shorter than those for all the other As species; however, TMAs
V
O, and AsB 
co-eluted with iAs
III
 (Figure 4.2). The co-elution of TMAs
V
O and AsB with iAs
III
 did not 
represent a problem for the current study because neither TMAs
V
O nor AsB are products 
of the AS3MT-catalyzed methylation of iAs. However, without further optimization, this 
HPLC technique could produce artifacts if used for analysis of biological samples that 
contain all three As species, e.g., human urine.  
4.4.2 Calibration  
Calibration curves were prepared only for the tri- and pentavalent oxoarsenicals 
that are products of As methylation by human AS3MT. 
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Figure 4.2: The HPLC-ICP-MS profiles of As standards in DIW, including AsC, AsB, 
TMAO (A, 2,000 pg each) and iAs
III
 (B, 280 pg). Detailed operating conditions are 
described in Table 4.1. 
4.4.2.1 HG-CT-AAS 
Aqueous solutions of the pentavalent As standards (iAs
V
, MAs
V
, and DMAs
V
) 
pre-reduced with L-cysteine were used to generate 5-point calibration curves. The 
calibration procedure, including validation using the trivalent As standards has been 
described in our previous reports (146, 149). Slopes of the calibration curves are provided 
in (Table 4.2). We have previously shown that the slopes of calibration curves for As 
standards prepared in DIW and for As standards prepared in complex biological matrices 
(e.g., cell lysates or tissue homogenates) do not significantly differ (143, 149, 167). Thus, 
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the calibration curves for As standards prepared in DIW were used in the present study 
for quantification of As metabolites in the in vitro methylation mixtures analyzed by HG-
CT-AAS.  
Table 4.2: The slopes of calibration curves generated by HG-CT-AAS (10-3s/ng) and 
HPLC-ICP-MS (cps*s/pg) for As standards 
  HG-CT-AAS 
a
 
Solvents iAs
III+V
 MAs
III+V
 DMAs
III+V
 
DIW 814 808 788 
  HPLC-ICP-MS  
b
 
  iAs
III
 iAs
V
 MAs
III
 MAs
V
 DMAs
III
 DMAs
V
 
DIW 1503 1461 1152 1543 632 1425 
Reaction Mixture 1550 707 1145 1643 811 1486 
a
 Standards were prepared in DIW and were reduced with 2% cysteine prior to HG-CT-
AAS analysis. 
b
 Standards were prepared in DIW or in the in vitro reaction mixture containing Tris-HCl 
buffer, SAM and TCEP, but not AS3MT. 
4.4.2.2 HPLC-ICP-MS 
Six-point calibration curves were prepared using solutions of tri- and pentavalent 
As standards in DIW or in the in vitro methylation mixture containing Tris-HCl buffer, 
SAM and TCEP, but not AS3MT. Consistent with previously published data (14, 188), 
slopes of the calibration curves for individual As standards varied (Table 4.2). 
Specifically, the calibration slopes for MAs
III
 and DMAs
III
 in either solvent were lower 
than those for the other As standards, suggesting that these methylated trivalent arsenicals 
are partially retained on the column. A lower calibration slope was also found for iAs
V
 
standard prepared in the in vitro methylation mixture lacking AS3MT. Thus, the 
calibration curves for As standards prepared in this mixture were used in the present 
study to quantify As metabolites detected by HPLC-ICP-MS.  
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4.4.3 Limits of detection (LODs)  
Standard deviations (SDs) of the integrated peak areas corresponding to the 
retention times of As standards were determined for 10 injections of 500 μL of 2% L-
cysteine in DIW into the HG-CT-AAS system or 20 μl of DIW into the HPLC-ICP-MS 
system. These injection volumes are consistent with the volumes of samples analyzed by 
HG-CT-AAS and HPLC-ICP-MS in this study. The LOD value was calculated for each 
As species as 3*SD/slope*injection volume. LOD values for HG-CT-AAS ranged from 
24 to 57 pg As mL
-1
; LODs for HPLC-ICP-MS were generally higher, ranging from 31 
pg As mL
-1 
for MAs
III
 to 295 pg As mL-1 for iAs
V
 (Table 4.3).  
Table 4.3: Limits of detection (LOD) for the analysis of As species by HPLC-ICP-MS 
and HG-CT-AAS 
 
LOD (pg/mL) 
 
Method iAs
III
 iAs
V
 iAs
III+V
 MAs
III
 MAs
V
 MAs
III+V
 DMAs
III
 DMAs
V
 DMAs
III+V
 
HPLC-ICP-MS
 a
 32 295 
 
31 57 
 
88 98 
 HG-CT-AAS 
b 
36 54 40 32 57 46 24 44 38 
a LODs were calculated as 3*SD/slope for 10 injections of DIW (20 μl each).  
b 
LODs were calculated as 3*SD/slope for 10 injections of DIW or 2% cysteine in DIW 
(0.5 ml each).  
4.4.4 Speciation analysis of As in the in vitro methylation mixture 
The in vitro methylation was carried out in reaction mixtures containing either 1 
μM iAsIII or 1 μM MAsIII as substrate (i.e., 11.25 ng As in 150 μl of the mixture). The 
reaction mixtures with iAs
III
 contained 80 μg/mL of recombinant AS3MT and were 
incubated for 2 hours at 37
o
C. MAs
III
 is methylated by AS3MT more efficiently than 
iAs
III
 (154). Therefore, the mixtures containing MAs
III were incubated with 60 μg/mL of 
AS3MT for only 40 minutes. Two aliquots from each reaction mixture were immediately 
and simultaneously analyzed by HG-CT-AAS and HPLC-ICP-MS. Here, one aliquot (20 
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μL of the mixture) was diluted to 500 mL with ice-cold DIW and analyzed by HG-CT-
AAS. The other 20-μl aliquot was injected directly into the HPLC-ICP-MS system. Two 
additional aliquots (20 μL each) were treated either with L-cysteine for determination of 
As
III+V
 species by HG-CT-AAS or with H2O2 for analysis of As
III+V
 species by HPLC-
ICP-MS.  
4.4.4.1 Analysis of the reaction mixture incubated with iAs
III 
Representative chromatograms and amounts of As species detected in the mixture 
after incubation with iAs
III
 are shown in Figure 4.3. HG-CT-AAS identified two 
methylated metabolites, DMAs
III 
and DMAs
V
 (Figure 4.3A), which accounted for 43% 
and 16% of As added as iAs
III
 into the mixture prior to incubation; 13% of iAs
III
 
remained unmethylated (Figure 4.3C). The average sum of As species detected by HG-
CT-AAS in the mixtures treated with cysteine was 7.5 ng, i.e., 72.1% of the added As 
(Figure 4.3D). In contrast, two major peaks recorded by the direct HPLC-ICP-MS 
analysis represented DMAs
V
 and iAs
III 
(Figure 4.3B) and accounted for only 12.3% and 
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9.4% of the added As, respectively (Figure 4.3C). DMAs
III
 was a minor metabolite 
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Figure 4.3: Analyses of the complete in vitro methylation mixtures containing 
recombinant AS3MT (80 μg/mL) incubated with 1 μM iAsIII (11.25 ng) for 2 hours at 
37°C. Representative HG-CT-AAS (A) and HPLC-ICP-MS (B) chromatograms and 
amounts of As species detected (C) are shown. The recovery of As by either method is 
expressed in ng As and as percentage of the amount of As added into the reaction mixture 
prior to incubation (D). The mixtures were analyzed by HPLC-ICP-MS directly (HPLC 
direct) or after oxidation with 3% H2O2 (HPLC oxidized). HG-CT-AAS analysis was 
performed directly and after 2% L-cysteine pretreatment to measure As
III
 and As
III+V
 
species, respectively. Pentavalent As species were calculated as the difference between 
these two analyses. Values are expressed as mean ± SD for four separate reaction 
mixtures. 
 
(2.5% of the added As). Only 25% of the added As was recovered by the direct HPLC-
ICP-MS analysis (Figure 4.3D). However, As recovery by HPLC-ICP-MS increased 
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dramatically after oxidation of the reaction mixture with H2O2, reaching on average 95%. 
Here, DMAs
V
 was the major As species detected, representing on average 7.1 ng As, i.e., 
68% of the added As. Notably, the amount of DMAs
V
 detected in the oxidized mixtures 
exceeded by 5.4 folds sums of DMAs
III
 + DMAs
V
 found by the direct HPLC-ICP-MS 
analysis but was in a good agreement with the sum of DMAs
III
 + DMAs
V
 detected by 
HG-CT-AAS. 
4.4.4.2 Analysis of the reaction mixture incubated with MAs
III 
Results of this analysis are summarized in Figure 4.4. The HG-CT-AAS analysis 
found DMAs
III
 to be the major product of MAs
III
 methylation, accounting on average for 
52% of the added As; DMAs
V
 represented 10% of the added As. About 21.5% of the 
substrate remained unmethylated and was partially oxidized during the incubation to 
MAs
V
 (Figure 4.4A,C). The recovery of As in the L-cysteine-treated mixtures was 
83.4% (Figure 4.4D). In comparison, DMAs
V
 was the only major species detected by the 
direct HPLC-ICP-MS analysis, representing 17% of added As. No DMAs
III
 and only 
traces of the unmethylated MAs
III
 were found. In the reaction mixtures oxidized with 
H2O2, DMAs
V
 and MAs
V
 were the major species, accounting for 74% and 23% of added 
As. Here again, the total amounts of MAs
V
 and DMAs
V
 in the oxidized mixtures 
analyzed by HPLC-ICP-MS compared well with the sums of MAs
III
 + MAs
V 
and 
DMAs
III
 + DMAs
V
 detected by HG-CT-AAS. The average As recovery by HPLC-ICP-
MS was 19.3% and 99% for the reaction mixtures before and after oxidation with H2O2.  
Taken together, these results suggest that DMAs
III
 is the major product of iAs
III
 
and MAs
III
 methylation by recombinant AS3MT. However, HPLC-ICP-MS analysis 
underestimates DMAs
III
 yields because a major portion of this metabolite either alone or 
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in complexes with AS3MT protein or other components of the reaction mixture is lost on 
the chromatographic column. The interactions of DMAs
III
 with the components of the 
reaction mixture may also be responsible for the incomplete As recoveries during the 
HG-CT-AAS analysis.  
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Figure 4.4: Analyses of the complete in vitro methylation mixtures containing 
recombinant AS3MT (60 μg/mL) incubated with 1 μM MAsIII (11.25 ng) for 40 min at 
37°C. Representative HG-CT-AAS (A) and HPLC-ICP-MS (B) chromatograms and 
amounts of As species detected (C) are shown. The recovery of As by either method is 
expressed in ng As and as percentage of the amount of As added into the reaction mixture 
prior to incubation (D). The mixtures were analyzed by HPLC-ICP-MS directly (HPLC 
direct) or after oxidation with 3% H2O2 (HPLC oxidized). HG-CT-AAS analysis was 
performed directly and after 2% L-cysteine pretreatment to measure As
III
 and As
III+V
 
species, respectively. Pentavalent As species were calculated as the difference between 
these two analyses. Values are expressed as mean ± SD for four separate reaction 
mixtures. 
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4.4.5 Interactions of As
III
 species with the components of the methylation mixture 
To investigate the interactions of DMAs
III
 and other trivalent oxoarsenicals with 
AS3MT, we compared HPLC profiles for the iAs
III
, MAs
III
 and DMAs
III
 standards (0.5 
µM each) that were incubated for 5 minutes in the complete reaction mixture (1 mM 
TCEP and 1 mM SAM in 100 mM Tris-HCl buffer) or in the Tris-HCl buffer in the 
presence or absence of recombinant AS3MT (60 μg/mL). The incubation was carried out 
at 0
o
C to suppress the enzymatic activity of AS3MT. The presence of the recombinant 
protein in the complete reaction mixture dramatically changed the HPLC profiles and 
recoveries for all three arsenicals (Figure 4.5). Only 47% of iAs
III
 and 6% of MAs
III
 were 
recovered from the mixtures containing AS3MT as compared to the mixtures that lacked 
the protein (Figure 4.5B,C). However, presence of AS3MT had no significant effects on 
HPLC profiles and recoveries of the iAs
III
 or MAs
III
 standards that were incubated in the 
Tris-HCl buffer (Figure 4.6A,B), suggesting that the presence of SAM or TCEP 
facilitates the interactions of these arsenicals with the enzyme. In contrast, DMAs
III
 was 
detected only in the mixture with Tris-HCl buffer, but not in the complete reaction 
mixtures incubated either in the presence or absence of AS3MT (Figure 4.5D). 
Incubation of DMAs
III
 with AS3MT in the Tris-HCl buffer in absence of SAM and TCEP 
decreased the area of DMAs
III
 to 21% (Figure 4.6C). Incubation of DMAs
III
 in the Tris-
HCl buffer with either 1 mM SAM or 1 mM TCEP in the absence of AS3MT also 
decreased the DMAs
III
 signal, and thus recovery during the HPLC separation (Figure 
4.6C). These results suggest that, unlike iAs
III
 or MAs
III
, DMAs
III
 interacts not only with 
AS3MT, but also with SAM and TCEP, making a quantitative HPLC-ICP-MS analysis of 
this metabolite in the complete reaction mixture practically impossible.  
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Figure 4.5: The HPLC-ICP-MS profiles for trivalent arsenical standards spiked into the 
complete in vitro methylation mixture (1 mM TCEP, 1 mM SAM in 100 mM TRIS-HCl 
buffer, pH 7.4) in absence (full line) or presence (dashed line) of recombinant AS3MT 
(60 µg/mL). Representative chromatograms for the methylation mixtures without As 
standards (A) and for the mixtures incubated at 0°C for 5 minutes with 0.5 μM iAsIII (B), 
MAs
III
 (C), or DMAs
III
 (D) are shown. The dotted line in panel D represents 0.5 μM 
DMAs
III
 incubated in the TRIS-HCl buffer alone. 
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Figure 4.6: Comparison of the HPLC-ICP-MS profiles for As standards prepared in 
solutions containing the components of the in vitro methylation mixture: 0.5 µM iAs
III
 
(A) and 0.5 μM MAsIII (B) in the 100 mM TRIS-HCl buffer (pH 7.4) in absence (―) and 
presence (---) of AS3MT (60 µg/mL). 0.5 μM DMAsIII (C) in a mixture with TRIS-HCl 
buffer (―), 1 mM TCEP (―), AS3MT (60 µg/mL; ---) or 1 mM SAM (---). 
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4.4.6 Binding of As
III
 species to AS3MT 
The interactions of As species with AS3MT were further examined using 
ultrafiltration. Here, iAs
III
, MAs
III
, or DMAs
III
 (1 µM each) were incubated in the 
complete in vitro reaction mixture in presence or absence of recombinant AS3MT (60 
µg/mL) at 0
o
C for 5 minutes. After incubation, an aliquot of each reaction mixture was 
treated with L-cysteine and analyzed by HG-CT-AAS for As
III+V
 species. A second 
aliquot was ultrafiltered using a Pall Omega 3k spin column with a 3 kDa cut-off filter 
membrane. The filtrate and wash (i.e., the low-molecular weight fraction) were analyzed 
by HG-CT-AAS for As
III+V
 species. Figure 4.7 summarizes results of the analyses of the 
unfiltered aliquots and the ultrafiltrates. The amounts of arsenicals detected by HG-CT-
AAS in the unfiltered aliquots of the mixtures containing AS3MT were lower as 
compared to the unfiltered aliquots of mixtures that did not contain the recombinant 
protein. However, this difference was statistically significant only for mixtures incubated 
with MAs
III
 or DMAs
III
 (Figure 4.7B,C), suggesting that interactions of these arsenicals 
with the recombinant protein limit the efficiency of hydride generation. The HG-CT-AAS 
analysis of ultrafiltrates confirmed that significant amounts of MAs
III
 or DMAs
III
 are 
bound to AS3MT. Specifically, the amounts of MAs
III
 or DMAs
III
 were significantly 
lower (by 38 and 40%, respectively) in ultrafiltrates from the AS3MT-containing 
mixtures as compared to the unfiltered AS3MT-containing mixtures. In contrast, 
ultrafiltration had no significant effects on the amount of iAs
III
 suggesting that iAs
III
 
binds to AS3MT with lower affinity than the methylated trivalent species (Figure 4.7A). 
These findings are consistent with results of a recent study by Marapakala and associates  
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Figure 4.7: The amounts of trivalent arsenical standards in the complete reaction mixture 
before and after ultrafiltration. The mixture (1 mM TCEP, 1 mM SAM in 100 mM TRIS-
HCl buffer, pH 7.4) was incubated at 0°C for 5 minutes with 1 μM iAsIII (A), MAsIII (B), 
or DMAs
III
 (C) in presence or absence of recombinant AS3MT (60 µg/mL). The As
III+V
 
species were analyzed by HG-CT-AAS in the mixtures before and after ultrafiltration 
using a 3 kDa cutoff membrane. Values are expressed as mean ± SD for 3 separate 
mixtures. The effect of AS3MT protein (a,b) and of ultrafiltration (#) on the recovery of 
As were examined. Values labeled with the same letter or symbol are significantly 
different (p < 0.05). 
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who showed that MAs
III
 binds faster than iAs
III
 to CmArsM, a bacterial orthologue of 
AS3MT (binding of DMAs
III
 was not examined) (65). Notably, the losses of MAs
III
 or 
DMAs
III
 after ultrafiltration were not as high as those observed during the separation of 
the in vitro methylation mixtures by reversed-phase HPLC (Figure 4.3 and 4.4), 
suggesting that that the AS3MT-bound MAs
III
 or DMAs
III
 partially oxidized and detach 
from the recombinant protein during the ultrafiltration or that small complexes of 
arsenicals with TCEP and SAM which are not eluted from the HPLC column can pass 
through the filter. 
AS3MT is a cysteine-rich protein (60). Some of its cysteine residues have been 
shown to play the catalytic role in the process of iAs methylation (198-200), possibly 
providing binding sites for the substrate or reaction intermediates. However, other 
cysteine-containing proteins and endogenous low-molecular weight thiols, like 
glutathione have been shown to bind As (45, 201-205). Results of the present study 
suggest that by binding trivalent arsenicals, these proteins and thiols can interfere with 
quantitative speciation analysis of As by HPLC-based techniques. These results also 
show that DMAs
III
 interacts not only with AS3MT, but also with other components of the 
in vitro methylation mixture – SAM and TCEP. Thus, it is possible that interactions with 
these or other compounds may interfere with DMAs
III
 analysis in biological samples, 
including urine. To test this hypothesis, we compared HPLC-ICP-MS profiles for 
DMAs
III
 spiked into an ice-cold TRIS-HCl buffer or human urine at final concentration 
of 0.5 µM (Figure 4.8). Notably, the peak area for DMAs
III
 in urine represented only 
27% of the peak area in the buffer, suggesting that the urine matrix significantly impairs 
the ability of HPLC-ICP-MS to detect DMAs
III
 and that calibrating for aqueous standards 
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when analyzing As species in urine could result in a substantial underestimation of 
DMAs
III
 content.   
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Figure 4.8: The HPLC-ICP-MS profiles for 0.5 µM DMAs
III
 standard spiked into 100 
mM TRIS-HCl buffer (pH 7.4) or into human urine from an unexposed subject. 
 
4.5 Conclusions 
Results of this study suggest that reversed phase HPLC-ICP-MS and HG-CT-
AAS are almost equally effective when used for analysis of tri- and pentavalent iAs, MAs 
and DMAs in standard solutions prepared in DIW or TRIS-HCl buffer. However, when 
these techniques are utilized for analysis of a simple biological system in which the 
methylated arsenicals are generated in enzymatic reactions, HG-CT-AAS produces much 
better As recoveries (mass balances) than does HPLC-ICP-MS. This difference in 
performance is not detector based but rather is associated with losses of the methylated 
trivalent arsenicals during chromatographic separation. Spiking of the reaction mixture 
with standards provides evidence that MAs
III
 and DMAs
III
 interact with AS3MT and/or 
other components of the mixture to produce complexes that do not elute from the 
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chromatographic column. These findings are consistent with results of Šlejkovec and 
associates who reported an on-column binding and losses of As species during analyses 
using an ion-exchange HPLC-ICP-MS (192). The higher recoveries associated with HG-
CT-AAS indicate that either the MAs
III
-  and DMAs
III
-complexes are unstable in the 
chemical environment associated with the HG step or the complexes produce the same 
hydrides as do free MAs
III
 and DMAs
III
.
 
In either case, if quantifying MAs
III
 and/or 
DMAs
III
 as a biomarker is an essential part of the study objectives then the existing HG-
CT-AAS technique provides far less negative bias as compared to the existing HPLC-
ICP-MS approach. This negative bias is not only present in the in vitro system used here 
to illustrate the problem but it should also be expected in other biological matrices which 
provide binding sites for MAs
III
 and DMAs
III
, including human urine. The need to assess 
the losses of trivalent methylated arsenicals during HPLC-based analyses is clearly 
demonstrated in this study by almost complete recoveries of As from the reaction 
mixtures treated with H2O2. Thus, laboratories that do not attempt to quantify species 
specific recoveries or quantify the chromatographic mass balance within the matrix are 
choosing not to estimate a source of uncertainty that may undermine the reliability and 
utility of the data set.   
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CHAPTER V  
Oxidation State Specific Analysis of Arsenic Species in Tissues of Wild-type and Arsenic 
(+3 oxidation state) Methyltransferase (As3mt) Knockout Mice
4
 
5.1 Overview 
Arsenic (+3 oxidation state) methyltransferase (As3mt) catalyzes the conversion 
of inorganic arsenic (iAs) to methylated metabolites, including methylarsonite (MAs
III
) 
and dimethylarsinite (DMAs
III
). While this enzyme is critical for the detoxification of 
iAs, MAs
III
 and DMAs
III
 are more toxic than iAs. As3mt-knock out (KO) mice can be 
used to explore the role of MAs
III
 and DMAs
III
 in the adverse effects of iAs exposure. 
However, this mouse strain retains significantly more iAs than wild-type (WT) mice and 
are more susceptible to iAs-induced toxicity. Previously, WT C57BL/6 mice exposed to 
50 ppm As as arsenite (iAs
III
) in drinking water developed diabetes characterized by 
impaired glucose tolerance without insulin resistance. Methylated arsenicals were 
detected in tissues maintaining glucose homeostasis, including liver, pancreas, skeletal 
muscle and adipose tissue, but the oxidation state of As was not determined. In this study, 
a recently developed hydride generation-cryotrapping-atomic absorption spectrometry 
(HG-CT-AAS) method for the oxidation state specific speciation of As in complex 
biological matrices was used to compare retention of tri- and pentavalent As species in 
tissues of WT and As3mt-KO mice, and to determine doses in As3mt-KO mice that 
produce equivalent internal dose of total As in tissues critical for glucose homeostasis 
and in other tissues. WT mice were exposed to 50 ppm and As3mt-KO mice were 
                                                 
4
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exposed to 0, 15, 20, 25 or 30 ppm As as iAs
III
 in drinking water for 4 weeks. As3mt-KO 
mice retained almost exclusively iAs; iAs
III
 was the most prevalent species in liver, 
pancreas, adipose, lung, heart, and kidney, ranging from 53 to 74% of total As. 
Methylated arsenicals did not exceed 10% of total As in any tissue. Tissues of WT mice 
retained iAs and methylated arsenicals; iAs
III
, MAs
III
 and DMAs
III
 represented 55-68% of 
the total As in the liver, pancreas, and brain. High levels of MAs
III
 were found in the 
intestine and intestinal content of WT, but not As3mt-KO mice, suggesting that intestinal 
bacteria are not a major source of methylated As species. Significantly more total As was 
detected in plasma and blood cells of WT mice exposed to 50 ppm As as compared to all 
As3mt-KO treatment groups. These results indicate that internal total As doses in tissues 
critical to glucose homeostasis (liver, pancreas, skeletal muscle, adipose) equivalent to 
WT mice can be achieved in As3mt-KO mice after exposure to 25 and 30 ppm As. These 
results will help to design future studies comparing the diabetogenic and other adverse 
effects of iAs exposure in WT and As3mt-KO mice lacking the capacity to methylate iAs. 
5.2 Introduction 
Inorganic arsenic (iAs), a potent human carcinogen, is ubiquitous in the 
environment and accumulates in aquifers naturally and through anthropogenic activities. 
The ingestion of iAs through contaminated drinking water, most commonly as arsenite 
(iAs
III
) and arsenate (iAs
V
), has been associated with several adverse effects, including 
peripheral vascular disease, hypertension, and cancer of the lungs, liver, and bladder (1, 
3, 163). A recent National Toxicology Program workshop examining the effects of 
environmental chemicals on the development of diabetes and obesity concluded that there 
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was sufficient evidence to link iAs exposures to an increased prevalence of diabetes in 
populations exposed to levels of iAs in drinking water greater than 150 ppb (5).  
The enzyme, arsenic (3+ oxidation state) methyltransferase (AS3MT) mediates 
the S-adenosylmethionine (SAM) dependent biomethylation of As
III
 species to tri- and 
pentavalent methylated metabolites (52). AS3MT mRNA has been found in several 
human and rodent tissues, including, liver, kidney, urinary bladder, heart, lung, testes, 
and adrenal gland (53). Once ingested, iAs is sequentially methylated by AS3MT 
producing methylarsonite (MAs
III
), methylarsonate (MAs
V
), dimethylarsinite (DMAs
III
), 
and dimethylarsinate (DMAs
V
). Increasing evidence suggest that the methylated trivalent 
As (As
III
) species, MAs
III
 and DMAs
III
, produced in the course of iAs metabolism, are 
more toxic than iAs or their pentavalent counterparts (8-11, 136). 
Laboratory-based studies have shown that As exposure alters glucose homeostasis 
and several mechanisms responsible for glucose metabolism. In vitro studies implicate 
diminished pancreatic β-cell function and glucose uptake in peripheral tissues as targets 
for iAs-induced diabetes. Our laboratory has recently shown that in murine pancreatic 
islets exposure to subtoxic concentrations of iAs
III
, MAs
III
 or, DMAs
III
 inhibited glucose-
stimulated insulin secretion without affecting basal insulin secretion or insulin content 
and expression, suggesting that As
III
 species inhibit insulin transport vesicle packaging or 
translocation to the plasma membrane (136). In β-cell cultures, diminished glucose-
stimulated insulin secretion has been associated with reduced insulin mRNA levels (131), 
alterations in free Ca
2+
 oscillations (132), and the induction of a an Nrf2-mediated 
antioxidant response suppressing endogenous reactive oxygen species (ROS) (133, 134). 
Because ROS produced in the course of glucose metabolism may act as intracellular 
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regulators of insulin secretion, an Nrf2-mediated antioxidant response would hinder ROS 
signaling, and thus, the secretion of insulin (135). In cell culture models of peripheral 
tissues, iAs
III
 been shown to inhibit differentiation of adipocytes (137, 138) and 
myoblasts (139). Moreover, in adipocytes, As
III
 species have been shown to inhibit 
insulin-stimulated glucose uptake by interfering with GLUT4 translocation to the plasma 
membrane (140, 141).  
We have previously shown that in C57/BL6 mice exposure to 50 ppm As as iAs
III
 
in drinking water for as little as 8 weeks resulted in impaired glucose tolerance (86, 87, 
123). Moreover, mice chronically exposed to iAs
III
 in combination with high-fat diet 
produced a unique diabetic phenotype characterized by impaired glucose tolerance in the 
absence of significant obesity and fasting hyperinsulinemia, but not insulin resistance, 
suggesting an atypical As-induced diabetic phenotype (87).  
Genetically altered, As3mt-knockout (KO) mice lacking the ability to methylate 
iAs have been recently developed (55). These mice retain significantly higher total levels 
of As (55, 90, 91) and exhibit increased sensitivity to iAs-induced toxicity compared to 
WT mice (56, 92). In As3mt-KO mice, the toxic effects of iAs exposure have been 
observed at concentrations as low as 25 ppm As, with significant lethality at 
concentrations greater than 50 ppm (56, 92). While iAs was the predominant species in 
tissues from As3mt-KO mice exposed to iAs, methylated metabolites have been detected 
in liver and plasma, suggesting the methylation of As by other methyltransferases or 
intestinal microbiota (55, 93). Nonetheless, because the As3mt genotype produces 
significantly different As methylation phenotypes, As3mt-KO mice can be used as a 
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model to explore the role of iAs methylation, and specifically the formation of trivalent 
methylated arsenicals in the development of iAs-induced diseases. 
Hydride generation-cryotrapping-atomic absorption spectrometry (HG-CT-AAS) 
is uniquely suited for analysis of complex biological matrices because no sample 
pretreatments or extractions are required, thus preserving the methylation state of 
unstable MAs
III
 and DMAs
III
 (146, 149, 167, 193). This method has successfully detected 
the methylated trivalent arsenicals, MAs
III
 and DMAs
III
, after iAs exposure in human 
urine (69, 70, 143, 156), mouse tissues (167, 193), and in vitro cell cultures (136, 143, 
149) or in vitro mixtures for methylation of iAs by recombinant AS3MT (149, 154).   
In this study, we aimed to characterize the retention of tri- and pentavalent 
arsenicals in target organs of wild-type (WT) C57/BL6 and As3mt-KO mice after chronic 
iAs
III
 exposure and to determine exposure levels that produce equivalent internal doses of 
total As in tissues critical for regulating glucose homeostasis, as well as in other tissues. 
Our results indicate that 4-week exposure to 25 or 30 ppm As as iAs
III
 in As3mt-KO mice 
produces equivalent internal doses of As in liver, pancreas, skeletal muscle, and adipose 
tissue compared to WT mice treated with 50 ppm As. These doses will be used in follow 
up studies examining the effects of methylated As species in a mouse model of As-
induced diabetes.      
5.3 Methods  
5.3.1 Arsenicals 
The following pentavalent arsenicals were used for mouse exposure in drinking 
water and for determining calibration slopes by HG-CT-AAS: sodium arsenite 
(NaAs
III
O2) and sodium arsenate (Na2HAs
V
O4) (99% pure) were purchased from Sigma-
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Aldrich (St. Louis, MO). Methylarsonic acid, disodium salt (CH3As
V
O(ONa)2), and 
dimethylarsinic acid ((CH3)2As
V
O(OH)) both better than 98% pure were purchased from 
Chem Service (West Chester, PA). The As content in each of the standards was 
determined by graphite furnace-AAS (146). 
5.3.2 Mice and Treatments 
All procedures involving mice were approved by the University of North Carolina 
Institutional Animal and Use Committee. As3mt-KO mice were developed and 
maintained as previously described (55). In this study, 13- to 18-week old male As3mt-
KO mice were bred by brother-sister matings at the University of North Carolina Animal 
Facility. Male C57BL/6 mice (WT) between 13 and 17 weeks were obtained from 
Jackson Laboratory (Bar Harbor, ME, USA). All mice were housed in polycarbonate 
cages (5 per cage) with corn cob bedding at the University of North Carolina Animal 
Facility (12 h light/dark cycle, 22 ± 1°C and humidity 50 ± 10%). Mice were fed Lab 
Diet 5058 (Nutrition International, Brentwood, MO) and drank pure deionized water 
(DIW) or DIW containing iAs
III
 ad libitum for the 4-week study period. As3mt-KO mice 
were exposed to 0, 15, 20, 25, or 30 ppm As as iAs
III
 (5 mice per exposure group). WT 
mice were exposed to 50 ppm As (n = 10), the dose that previously produced a diabetic 
phenotype (86). The concentration of iAs in water in all treatment groups was verified by 
HG-CT-AAS analysis (data not shown). Mice were euthanized by cervical dislocation. 
Freshly dissected tissues were processed as previously described, and tissue homogenates 
were prepared in ice cold DIW (10% w/v) using an electrical overhead stirrer equipped 
with a Teflon pestle tissue homogenizer (Wheaton Industries, Inc., Millville, NJ) (167).  
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5.3.3 Speciation analysis of As by HG-CT-AAS 
As species were analyzed by an optimized method for oxidation state specific 
analysis of As species in biological matrices (146, 149, 167, 193). Briefly, HG-CT-AAS 
was performed using a FIAS 400 flow injection accessory (Perkin-Elmer, Norwalk, CT, 
USA) coupled to a cryotrapping unit and an AAnalyst 800 spectrometer (Perkin-Elmer) 
equipped with a multiple microflame quartz tube atomizer (multiatomizer) (146, 149). To 
measure the oxidation state of As species, two aliquots of each sample are analyzed; 
arsine gases from trivalent arsenicals (iAs
III
, MAs
III
 and DMAs
III
) are generated directly 
at pH 6, while arsines from both tri- and pentavalent arsenicals (iAs
III+V
, MAs
III+V
 and 
DMAs
III+V
) are measured after pre-reduction for 1 hour at room temperature with 2% L-
cysteine (EMD Chemicals Inc., Gibbstown, NJ) (146, 149). The concentrations of the 
pentavalent arsenicals, iAs
V
, MAs
V
, and DMAs
V
, are calculated by subtracting the AAS 
peak area signals obtained for L-cysteine-treated and directly analyzed, untreated sample 
aliquots.  
Calibration curves for quantification of tri- and pentavalent As species were 
generated using aqueous solutions of the pentavalent standards (iAs
V
, MAs
V
, and 
DMAs
V
) pre-treated with 2% L-cysteine. To determine the recovery of speciated As 
during the direct analyses, aliquots of tissue homogenates were acid digested in ultrapure 
phosphoric acid, using a MARS Microwave Reaction System equipped with MarsXpress 
Temperature Control (CAM, Matthew, NC), as previously described (167). This 
procedure oxidizes trivalent arsenicals to pentavalency, but does not convert methylated 
arsenicals to iAs. 
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5.3.5 Statistical Analysis 
All statistical analyses were performed using GraphPad Instat software package 
(GraphPad Software Inc., San Diego, CA). Linear regression and correlation analyses 
were employed to characterize the calibration curves of aqueous pentavalent As 
standards. ANOVA followed by Bonferroni’s multiple comparison posttest was used to 
determine significant differences between total speciated As in tissues from As3mt-KO 
and WT mice. Statistical significance was considered at the level of p < 0.05. 
5.4 Results and Discussion  
5.4.1 Water consumption and body weights 
The consumption of water for each exposure group and individual body weights 
were measured weekly throughout the study. Figure 5.1 depicts the estimated daily water 
consumption, calculated from group weekly consumption, and the corresponding iAs 
intake for mice in each exposure group over the 4-week study period. Water intake rose 
after the first week and then plateaued for the remaining study period except in As3mt-
KO mice exposed to 25 ppm As, which exhibited decreased water consumption in weeks 
3 and 4 (Figure 5.1A). Figure 5.1B depicts the average daily water intake for mice 
within each group; As3mt-KO mice exposed to pure DIW consumed an average of 3.9 
mL/day, which is significantly more water than all iAs-treated groups ranging from 1.4 to 
2.2 mL/day. The average daily iAs intake per mouse was estimated from the average 
daily water consumption. As3mt-KO mice exposed to 15, 20, 25, or 30 ppm As ingested 
approximately 27.1, 34.9, 43.4, and 42.7 µg of iAs/day, respectively, while WT mice 
exposed to 50 ppm As ingested approximately 107.6 µg of iAs/day (Figure 5.1C). There 
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was no significant difference in iAs/day ingestion among the As3mt-KO groups, but the 
WT group ingested significantly more iAs than all other groups.  
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Figure 5.1: Average daily water consumption and estimated daily iAs intake for As3mt-
KO and WT mice. (A) Variations in daily water consumption by week for As3mt-KO 
mice exposed to 0 (●), 15 (■), 20 (▲), 25 (♦), or 30 (▼) ppm As and WT mice exposed 
to 50 ppm As (○). (B) Average daily water consumption per mouse for each treatment 
group. (C) Estimated daily iAs intake per mouse for each treatment group. Mean and SD, 
n = 5 for each As3mt-KO group and n = 10 for WT group. 
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The body weight of each mouse was measured prior to iAs exposure and weekly 
throughout the study (Figure 5.2). On average, all mice gained weight except for As3mt-
KO mice exposed to 30 ppm As (Figure 5.2). Unexposed As3mt-KO mice gained an 
average of 3.2 g over the 4-week study period, while As3mt-KO mice exposed to 15, 20, 
or 25 ppm As gained an average of 1.2, 1.6, and 1.1 g, respectively. As3mt-KO mice 
exposed to 30 ppm As lost an average of 1.2 g over the study period. However, no signs 
of toxicity were observed for any treatment group during the study or tissue dissection. 
This is in contrast with previous studies reporting lethality and histopathological 
abnormalities in As3mt-KO mice exposed to 25 ppm for 4 weeks (91, 92).   
0 1 2 3 4
22
24
26
28
30
32
34
36
0 ppm As3mt-KO
15 ppm As3mt-KO
20 ppm As3mt-KO
25 ppm As3mt-KO
30 ppm As3mt-KO
50 ppm WT
Time (weeks)
B
o
d
y
  
W
e
ig
h
t 
(
g
)
 
Figure 5.2: Change in body weights of As3mt-KO mice exposed to 0 (●), 15 (■), 20 (▲), 
25 (♦), or 30 (▼) ppm As and WT mice exposed to 50 ppm As (○). Mean and SD, n = 5 
for each As3mt-KO group and n = 10 for the WT group. There were no significant 
differences in weekly average weights determined by two-way ANOVA.   
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5.4.2 Effect of genotype on As speciation in tissues  
The speciation of As in tissues of As3mt-KO mice has previously been examined.
 
However, the analysis was limited to plasma, red blood cells, liver, kidney, lung, and 
bladder and did not determine the oxidation state of As in the detected As species (55, 90, 
91). Only recent optimization of the HG-CT-AAS method has allowed for the analysis of 
tri-and pentavalent As species in tissue homogenates without sample extractions or 
digestions. This method was used in the present study to characterize retention of As
III
 
and As
V
 species retained in tissues of As3mt-KO mice at various levels of exposure and 
to compare the internal doses to that in WT mice exposed to 50 ppm As, the 
concentration previously used in this laboratory to examine the diabetogenic effects of 
iAs.  
As expected,
 
iAs
III
 and iAs
V
 were the main species retained in tissues of As3mt-
KO mice, while methylated As metabolites predominated in most tissues from WT mice. 
Figure 5.3 displays As retention in tissues involved in regulation of glucose homeostasis 
(i.e., liver, adipose tissue, pancreas, and skeletal muscle). As3mt-KO mice exposed to 0 
ppm As (pure DIW) retained only small amounts of iAs, likely due to the presence of iAs 
in standard rodent chow (86). In As3mt-KO mice, iAs
III
 was the predominate species 
retained in liver, adipose tissue, and pancreas, representing 57 to 74% of total speciated 
As (Figure 5.3A,B,C). In skeletal muscle, iAs
III
 and iAs
V
 ranged from 42 to 53% and 45 
to 57% of total speciated As, respectively (Figure 5.3D). The concentration of As species 
in As3mt-KO mice exposed to 15, 20, 25, or 30 ppm As increased in a dose-dependent 
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manner in liver, skeletal muscle and pancreas. In adipose tissue, the amount of iAs 
increased only between 15 and 25 ppm iAs, but decreased at 30 ppm.  
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Figure 5.3: Oxidation state specific analysis of As in tissues critical for glucose 
homeostasis. The concentration (ng As/g wet tissue) of seven As species in liver (A), 
adipose tissue (B), pancreas (C), and skeletal muscle (D) of As3mt-KO mice exposed to 
0, 15, 20, 25, and 30 ppm and WT mice exposed to 50 ppm As as iAs
III
. Homogenates 
(10% w/v) were prepared in ice-cold DIW. All tissues and homogenates were stored at -
80°C prior to analysis by HG-CT-AAS. One aliquot was measured directly to determine 
As
III
 species and another was measured after 2% L-cysteine pretreatment to determine 
As
III+V
 species. Pentavalent arsenicals were determined as the difference between the 
peak areas of each arsenical for the two aliquots. Data is represented as means with SD 
for each arsenical (As3mt-KO, n = 5; WT, n =10). (*) Statistically significant difference 
in total speciated As compared to 50 ppm WT group (p > 0.05). 
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This decrease was associated with the overall loss of body mass of the As3mt-KO mice 
exposed to 30 ppm As, implying toxicity of the exposure. DMAs
III
 predominated in the 
liver and pancreas of WT mice, accounting for 29% and 32% of total speciated As 
respectively. DMAs
V
 represented 45% and 47% of As in adipose and skeletal muscle, 
respectively. Notably, the sum of trivalent species (iAs
III
 + MAs
III
 + DMAs
III
) accounted 
for 55% and 68% of As in pancreas and liver of WT mice, respectively.  
In the previous report, methylated species accounted for 28 to 32% of total As in 
liver and 22 to 28% in urine of As3mt-KO mice exposed to a single dose of iAs
V
, 
suggesting the role of alternative As methylation mechanisms (55). However, a more 
recent study in As3mt-KO mice exposed to iAs
III
 through drinking water support our 
finding that iAs
III
 and iAs
V
 were exclusively retained in liver (91). Methylated 
metabolites generated in As3mt-KO mice may be quickly cleared, and the observed 
differences are likely explained by the dosing (single vs. subchronic) or by the fact that 
mice were exposed to iAs
III
 in one study and to iAs
V
 in the other. Notably, in the present 
study, the methylated arsenicals in tissues of As3mt-KO mice never exceeded 10% of the 
total speciated As and no methylated As species were detected in liver, pancreas, or 
adipose tissue.  
Figure 5.4 displays the oxidation state specific speciation of As in blood plasma 
and blood cells of WT and As3mt-KO mice. Significantly more total As was detected in 
plasma and blood cells of WT mice exposed to 50 ppm As as compared to all As3mt-KO 
treatment groups. In plasma and erythrocytes of As3mt-KO mice, iAs
III
 and iAs
V
 were 
present at approximately equal concentrations. An average of 348 ng As/mL was present 
in plasma of WT mice exposed to 50 ppm As compared with only 6, 17, 21,33, and 22 ng 
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As/mL in As3mt-KO mice exposed to 0, 15, 20, 25 and 30 ppm As, a greater than 10-fold 
difference (Figure 5.4A). In blood cells of As3mt-KO mice, a dose-dependent increase in  
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Figure 5.4: Oxidation state specific analysis of circulating As in As3mt-KO mice 
exposed to 0, 15, 20, 25, and 30 ppm As and WT mice exposed to 50 ppm As as iAs
III
. 
The concentration of seven As species in plasma (A, ng As/mL) and blood cells (B, ng 
As/g wet tissue). Analysis was performed as described in Figure 5.3. Data is represented 
as means with SD for each arsenical. (As3mt-KO, n = 5; WT, n =10). (*) Statistically 
significant difference in total speciated As compared to 50 ppm WT group (p > 0.05).  
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As from 15 to 317 ng As/g tissue was observed, while an average of 506 ng As/g tissue 
was retained in blood cells of WT mice (Figure 5.4B). Our finding that WT mice retain 
more total As in blood cells than As3mt-KO mice conflicts with a previous study where 
WT and As3mt-KO mice were exposed to 1, 10, and 25 ppm As as iAs
III
 in drinking 
water for 33 days (91). Here, the authors reported that greater levels of total As were 
retained by erythrocytes of As3mt-KO mice than WT mice. This difference could be 
associated with differences in sample preparation, analytical speciation technique, or with 
higher exposures in the present study for WT mice. Notably, the total As level in blood 
cells from As3mt-KO exposed to 25 ppm As in our study (245 ng As/g tissue) is in good 
agreement with the level reported by Chen and associates (~ 300 ppb As).  
The concentrations of As species in several other tissues from WT and As3mt-KO mice, 
including intestine with intestinal content, kidney, lung, heart, brain, and testes were also 
examined (Figure 5.5). Notably, MAs
III
 accounted for 62% of As in the intestine (with 
intestinal content included) of WT mice exposed to 50 ppm As, while iAs
III
 predominated 
in the intestine from As3mt-KO mice (Figure 5.5A). Additionally, total speciated As in 
the intestinal tissue averaged between 4,040 and 9,273 ng As/g tissue in As3mt-KO mice, 
but 24,879 ng As/g tissue in WT mice. It has been previously suggested that other 
methyltransferases or bacterial-mediated As methylation contribute to the formation of 
methylated As species in As3mt-KO mice (55); however, our results indicate that 
functional As3mt enzyme is necessary for the methylated As species to be found in the 
intestine and intestinal content. Moreover, the greater than 2-fold increase in total 
speciated As retained in the intestine of WT mice suggests that methylation increases 
excretion of ingested As in feces. In a previous study where WT C57/BL6 and As3mt-KO 
106 
 
mice were repeatedly dosed with 0.5 mg/kg iAs
V
, whole body As burden and daily 
excretion analysis revealed that WT mice excreted As greater than 10 to 20 times faster 
than As3mt-KO mice (90). Thus, it is possible that in addition to urine, excretion in feces 
contributes significantly to the clearance of methylated As species from the mouse body. 
In the kidney, lung, brain, and testes of As3mt-KO mice, iAs
III
 accounted for 49 to 
81% of total speciated As. In kidney, heart, lung of WT mice, DMAs
V
 accounted for 36, 
40, and 63% of speciated As, respectively, while DMAs
III
 predominated in brain (61%) 
and testes (67%). Notably, total speciated As in lung from WT mice exposed to 50 ppm 
As was significantly higher than in As3mt-KO mice in any treatment group. A recent 
report indicates significantly higher retention in lungs of As3mt-KO mice exposed to 1 
and 10 ppm iAs
III
 compared to WT mice at the same exposures, but not 25 ppm (91). Our 
results suggest that at higher exposures, methylated arsenicals are more preferentially 
retained in lung tissue. Overall, these data indicate that trivalent As species are highly 
retained in most tissues of WT and As3mt-KO mice exposed to As and likely play a 
significant role in the development of iAs-induced diseases. 
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Figure 5.5: Oxidation state specific analysis of As in tissues from As3mt-KO mice 
exposed to 0, 15, 20, 25, and 30 ppm As and WT mice exposed to 50 ppm As as iAs
III
. 
The concentration of seven As species (ng As/g wet tissue) in intestine with intestinal 
content (A), kidney (B), lung (C), heart (D), brain (E), and testes (F). Analysis was 
performed as described in Figure 5.3. Data is represented as means with SD for each 
arsenical. (As3mt-KO: n = 5; WT, n =10). 
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5.4.3 Recovery of speciated As during direct analysis 
The %recovery of As during was determined by comparing the amount of total 
speciated As found in tissue homogenates by direct analysis and the amount of total 
speciated As determined in tissue homogenates after digestion in phosphoric acid (Table 
5.1). Plasma was not acid digested due to sample volume constraints. This digestion 
oxidizes all trivalent As species to pentavalency, and thus, only the total iAs (iAs
III+V
), 
MAs (MAs
III+V
), and DMAs (DMAs
III+V
) can be measured. Our laboratory has previously 
shown that in liver homogenates from WT mice exposed to 50 ppm As as iAs
III
 for 9 
days, near 100% recovery of MAs and DMAs were achieved by direct HG-CT-AAS 
analysis; however, the recovery of iAs by direct analysis was only ~83% (167). A portion 
of iAs
III
 retained in this tissue is likely bound to high-affinity targets and is unavailable 
for hydride generation. A follow-up study revealed that the recovery of iAs in mouse 
liver increased to approximately 100% after 3 weeks of storage at 0°C or -80°C, 
indicating that prolonged storage may result in the release and subsequent oxidation of 
iAs
III
 from the high-affinity thiol binding sites (193).  
In the present study, As recovery during direct analysis of all treatment groups 
was greater than 80% for pancreas liver, lungs, intestine, brain, adipose tissue, and blood 
cells. As recoveries lower than 80% were observed for three tissues collected from 
As3mt-KO mice. In heart and skeletal muscle of As3mt-KO mice, the recovery of iAs 
ranged from 52 to 89%, while in testes of As3mt-KO mice treated with 30 ppm As, 66% 
of iAs was recovered during direct analysis. In WT mice, total As recoveries were low 
(63%-85%) in kidney and skeletal muscle. In adipose tissue of WT mice, 89% of iAs was 
recovered. Notably, only 25% of MAs in kidney and 85% of DMAs in lung in WT mice 
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was recovered by direct analysis. High levels of MAs in kidneys of C57/BL6 mice 
treated with iAs
V 
have been previously reported
 
(158). As accumulation has been 
observed in the renal cortex of rats treated with iAs, but As speciation and potential 
binding targets have not been identified (206).  
Table 5.1: Recovery of speciated As during direct analysis 
  %recovery of direct analysis
a
 
 
As3mt-KO
b
 WT
c
 
 15 ppm 20 ppm 25 ppm 30 ppm 50 ppm 
Pancreas 106 (19) 89 (1) 90 (7) 92 (7) 103 (11) 
Liver 119 (18) 112 (27) 106 (13) 108 (17) 119 (38) 
Skeletal Muscle 52 (10) 66 (20) 60 (6) 63 (12) 85 (15) 
Adipose Tissue 92 (50) 100 (45) 115 (96) 104 (14) 109 (47) 
Blood Cells 133 (10) 139 (19) 142 (18) 148 (22) 128 (23) 
Intestine 106 (21) 162 (31) 179 (121) 125 (27) 114 (49) 
Kidney 123 (23) 81 (4) 112 (59) 98 (50) 63 (17) 
Lung 95 (14) 121 (32) 128 (24) 131 (31) 102 (45) 
Heart  71 (8) 78 (6) 77 (7) 89 (7) 124 (23) 
Brain 83 (11) 80 (8) 83 (10) 101 (14) 120 (16) 
Testes 114 (49) 178 (43) 123 (55) 66 (9) 156 (66) 
a
 Mean (SD), As3mt-KO, n = 5 and WT, n = 10 
b
 For As3mt-KO treatment groups, %recovery is for iAs
III+V
 
c
 For WT mice treated with 50 ppm As, %recovery is for total speciated As 
 
5.4.4 Comparison of the internal of As 
Previous studies in our laboratory have shown the development of diabetes in WT 
mice exposed to 50 ppm As (86, 87). While methylated As metabolites and toxic trivalent 
species have been detected in tissues critical for glucose homeostasis, the effects of 
specific As species on disease development have yet to be examined. The As3mt-KO 
mouse model provides a unique platform to study the adverse effects of individual 
arsenicals because little internal methylation occurs. However, the As3mt genotype 
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affects As retention and susceptibility to As-induced toxicity; studies in As3mt-KO mice 
have reported lethality in 50 ppm As exposures and toxic effects at exposure as low as 25 
ppm, concentrations that are well tolerated in WT mice (56, 92). Thus, to determine 
which As exposures in As3mt-KO mice yield equivalent internal As doses compared to 
WT mice, As retention in tissues critical for glucose homeostasis (i.e., pancreas, liver, 
skeletal muscle, and adipose tissue) was examined (Figure 5.3). Here, statistical 
difference between the sum of iAs
III+V
, MAs
III+V
, DMAs
III+V
 and TMAs
V
O for each 
As3mt-KO group and the WT group exposed to 50 ppm As were determined by one-way 
ANOVA and Bonferroni's multiple comparison test (Table 5.2). Total As values for 
As3mt-KO exposure groups that were not significantly different from the 50 ppm WT 
group were considered to produce equivalent internal doses. In the pancreas, equivalent 
internal doses to WT mice were only achieved in As3mt-KO mice exposed to 30 ppm As. 
Equivalent internal As doses in the liver were seen in As3mt-KO mice exposed to 15, 20, 
and 25 ppm As and for all exposures in adipose tissue. In skeletal muscle, 25 and 30 ppm 
As exposure in As3mt-KO mice resulted in equivalent internal As doses compared to WT 
mice exposed to 50 ppm As. Because recoveries of the direct analysis method determined 
after acid digestion were low (50-75%) for skeletal muscle in all treatment groups, 
statistical analysis was repeated with the digested sums of iAs, MAs, and DMAs (data not 
shown). Reanalysis revealed that all As3mt-KO treatment groups (15, 20, 25, and 30 ppm 
As) produced equivalent internal As doses in skeletal muscle compared to the 50 ppm 
WT group. However, the equivalent internal As doses determined for pancreas, liver or 
adipose tissue of As3mt-KO mice did not change.  
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While exposure to 30 ppm in As3mt-KO mice for 4 weeks produced equivalent 
total As tissue retention in the pancreas, skeletal muscle and adipose, decreased body 
weights were observed in this treatment group after 4 weeks of exposure (Figure 5.2). 
However, in contrast to other studies, As-induced toxicity after 4 weeks of exposure was 
not observed in any of the As3mt-KO treatment groups (56, 92). Nonetheless, study 
duration and potential toxicity should be carefully considered when planning experiments 
with As3mt-KO mice. Therefore, exposure to both 25 and 30 ppm would produce 
equivalent internal As doses in tissues critical for glucose homeostasis and will be used in 
future studies examining the effects of As on the development of diabetes.  
Table 5.2: Determination of equivalent internal As doses in tissues critical for glucose 
homeostasis 
  Total speciated As
a
, ng As/g tissue 
Treatment Group Pancreas Liver Skeletal Muscle  Adipose 
0 ppm As3mt-KO 16 (7) 67 (10) 69 (102) 21 (14) 
15 ppm As3mt-KO 381 (38) 3,137 (476)# 386 (55) 181 (107)# 
20 ppm As3mt-KO 394 (86) 3,525 (787)# 479 (49) 304 (112)# 
25 ppm As3mt-KO 452 (26) 4,497 (300)# 677 (114)# 413 (329)# 
30 ppm As3mt-KO 576 (83)# 5,564 (1,024) 688 (147)# 277 (61)# 
50 ppm WT 693 (141) 3,511 (1,174) 658 (185) 239 (118) 
a
 Total speciated As includes the sum of
 
iAs
III+V
, MAs
III+V
, DMAs
III+V
 and TMAs
V
O 
determined by HG-CT-AAS. Mean (SD); As3mt-KO, n = 5 and WT, n = 10  
# Statistically non-significant difference in total speciated As compared to 50 ppm WT 
group (p > 0.05).  
 
5.5 Conclusions 
In As3mt-KO mice, iAs
III
 is the most prevalent species in liver, pancreas, and 
adipose exposed to 15, 20, 25, or 30 ppm As. Moreover, the majority of species retained 
in liver and pancreas of WT mice exposed to 50 ppm As are in the trivalent form. 
DMAs
V
 is the most prevalent species retained in skeletal muscle and adipose of WT 
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mice. For tissues critical to glucose homeostasis, doses of 25 and 30 ppm As as iAs
III
 in 
As3mt-KO mice will produce equivalent total As retention to that of WT mice. Ongoing 
studies will examine the effects of As methylation phenotype on the development of iAs-
induced diabetes. 
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CHAPTER VI   
Retention of Trivalent Arsenic Metabolites in Urothelial Cells is Associated with 
Markers of iAs Exposure and Diabetes
5
 
6.1 Overview 
Chronic exposure to inorganic arsenic (iAs) in drinking water has been linked to 
an increased prevalence of diabetes. Laboratory evidence suggests that trivalent 
arsenicals formed in the course of iAs metabolism contribute to the diabetogenic effects 
of iAs exposure. To date, risk assessment of iAs-associated diabetes has relied almost 
entirely on the measure of As in drinking water or urine. This study examined whether 
trivalent arsenical retained in tissues can provide better markers of the diabetogenic 
effects of iAs exposure. We determined the concentrations of iAs in urine and in urinary 
bladder exfoliated cells (BECs) isolated from urine of 378 residents of Chihuahua, 
Mexico who drink water contaminated with iAs (0.01 - 400 ppb). Diabetes was 
diagnosed using fasting plasma glucose (FPG), two-hour plasma glucose (2HPG) after 
oral glucose tolerance test (OGTT), self-reported doctor diagnosis, or use of anti-diabetic 
medications. As species in BEC and in urine were measured by hydride generation (HG)-
cryotrapping (CT)-inductively coupled plasma-mass spectrometry and HG-CT-atomic 
absorption spectrometry, respectively. Associations between diabetes and As species 
retained in BECs or found in urine were analyzed by logistic and linear regression with 
adjustment for age, sex, and body mass index. iAs was the major species retained in 
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BECs (~66% of total As). The log-transformed sum of As species and individual As 
metabolites retained in BECs were positively correlated with As metabolites in urine (ß = 
0.31 – 0.79, r2 = 0.06 – 0.55, p < 0.01) and iAs in drinking water (ß = 0.21 – 0.43, r2 = 
0.07 – 0.54, p < 0.01). There was significant positive correlation between FPG and 2HPG 
with iAs in drinking water, trivalent As species retained in BECs and urinary As species 
(ß = 0.041 – 0.078, r2 = 0.12 - 0.21, p < 0.01). Moreover, the risk of diabetes was 
positively associated with iAs
III
 and MAs
III
 in BECs (OR = 1.57 and 1.63, 95% CI 1.19 – 
2.07 and 1.24 – 2.15 per inter-quartile range, respectively, p < 0.01) and with the ratio of 
DMAs/MAs in urine (OR 1.37 per inter-quartile range, p = 0.03). Significantly negative 
correlations between DMAs/MAs and DMAs/iAs ratios in BECs and the risk of diabetes 
were observed (OR 0.62 and 0.72 per inter-quartile range, respectively, p < 0.02). These 
data suggest that As metabolites retained in BECs are sensitive biomarkers of iAs 
exposure and the risk of diabetes associated with this exposure. 
6.2 Introduction 
Growing evidence suggests that chronic exposure to inorganic arsenic (iAs) 
increases risk of developing diabetes. A recent National Toxicology Program (NTP) 
workshop on the diabetogenic and obesogenic effects of environmental chemicals 
concluded that there was sufficient evidence to link iAs exposures to an increased 
prevalence of diabetes in populations exposed to levels of iAs in drinking water greater 
than 150 ppb (5). Strong associations between iAs exposure and diabetes were found in 
areas of Taiwan (99, 101-103) and Bangladesh (100, 104) where individuals are exposed 
to iAs in drinking water at levels greater than 500 ppb. However, results from 
epidemiological studies in population exposed to lower levels of iAs are inconsistent. 
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The World Health Organization and American Diabetes Association define the 
diagnostic criteria for diabetes as individuals presenting with fasting plasma glucose 
levels (FPG) ≥ 126 mg/dL (based on two independent examinations) or two-hour plasma 
glucose levels (2HPG) ≥ 200 mg/dL after oral glucose tolerance test (OGTT) (97, 207). 
Additionally, levels of glycosylated hemoglobin (HbA1c), an estimate of average plasma 
glucose level over a 2 to 3 month period,
 ≥ 6.5% are sufficient for a diabetes diagnosis 
(98). Recently, concerns regarding diabetes diagnosis and exposure assessment have been 
raised for earlier epidemiological studies assessing the diabetogenic effects of iAs mainly 
in high exposure areas (5, 105). Results from a recent study of individuals in Bangladesh 
primarily exposed to < 300 ppb As in drinking water showed no associations between 
time weighted As exposure or urinary As and self-reported diabetes or glycosuria (106). 
However, glucosuria is not an accepted diagnostic marker of diabetes (208). 
Several recent studies provide consistent associations between As exposure and 
diabetes (70, 111, 112) or gestational diabetes (113) in populations exposed to less than 
150 ppb As. In these studies, diabetes was diagnosed by preferred methods, including 
FPG, OGTT, or HbA1c levels. Notably, in an As-endemic region of Mexico, urinary 
DMAs
III
 concentration was significantly associated with the prevalence of diabetes (70). 
Additional epidemiological studies with improvements in study design, including 
increasing population size, conducting more accurate exposure assessment, and using 
consistent diagnostic criteria for diabetes are likely to strengthen the evidence for an As-
induced diabetes even at low levels of exposure.  
Assessment of iAs exposure often relies on urinary As excretion or estimates of 
As ingestion and varies widely among epidemiological studies examining the toxicity of 
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iAs. Because iAs levels in drinking water sources and individual consumption patterns 
vary, measurements of exposure using these variables may not accurately reflect actual 
internal doses. As metabolites in biological samples, including blood, hair, nails or urine, 
can be used as biomarkers of exposure. Although, hair and nail matrices are rich in 
sulfhydryl moieties that accumulate As and are not recommended for As exposure 
analysis (115). Moreover, As concentration in urine can be affected by hydration status 
and normalization techniques have limitations. Recent reports indicate that urinary 
creatinine is associated with total urinary As (116) and increased urinary DMAs excretion 
(117). Furthermore, creatinine adjustment in diabetic individuals was shown to 
overestimate urinary As levels (118). Specific gravity may also be used for adjusting 
urinary As levels to hydration status. However, abnormal urinary glucose and albumin 
excretion associated with certain disease states, including diabetes, would result in the 
overestimation of urine density (119, 120).  
Measurement of As concentrations in target tissues or body liquids other than 
urine may more accurately reflect iAs exposure. While these biomarkers have not been 
widely researched, exposure assessments have been performed in bladder exfoliated cells 
(BECs) (85) and saliva (121, 122). In BECs from 21 individuals living in an As-endemic 
region of Mexico, the retention of speciated As did not correlated with urinary As (85); 
however, As species in saliva samples from individuals exposed to As in China correlated 
with iAs concentrations in drinking water (121). Our optimization of an analytical 
technique for oxidation state specific As speciation can be used to examine As retention 
in target human tissues and assess the adverse effects of iAs exposure.    
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The hydride generation-cryotrapping (HG-CT) methods for the oxidation state 
specific analysis of As metabolites are uniquely suited for complex biological matrices 
because no sample pretreatments or extractions are required, thus limiting loses of the 
unstable methylated trivalent species (146, 149). In a pilot study conducted using BECs 
collected from 21 individuals residing in Zimapan, Mexico, As metabolites were 
analyzed using HG-CT-AAS, but oxidation state specific speciation was not performed 
(85). Recent optimization of a HG-CT-inductively coupled plasma-mass spectrometry 
(ICP-MS) technique provides limits of detection (LOD) between 0.04 and 2.0 pg As 
compared to 10 and 26 pg for HG-CT-AAS. This system has been successfully used to 
quantify iAs metabolites in murine pancreatic islets exposed ex vivo (136). Here, we 
aimed to examine the retention of tri- and pentavalent metabolites of iAs in BECs 
isolated from residents of an As-endemic region of Mexico and determine the 
associations between diabetes and markers of As exposure in BECs and urine. Our 
findings indicate that As metabolites retained in BECs are sensitive biomarkers of the 
diabetogenic effects of iAs exposure. 
6.3 Methods 
6.3.1 Study Population 
Study subjects were recruited among residents living in Chihuahua, Mexico for at 
least two years. The study area is located in eastern and north-eastern regions of 
Chihuahua state where As levels in drinking water range from <10 to 800 ppb. 
Recruitment was carried out in collaboration with local public health and municipal 
authorities. Residents were initially approached in their homes and invited for a brief 
screening interview. The interview informed participants about the purpose of the study 
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and determined eligibility to participate. Pregnant women and subjects with kidney or 
urinary tract infection or those using medication for this type of infection were excluded 
because these conditions could affect the urinary pattern of iAs metabolites. Individuals 
with previous occupational exposure to As were also excluded. Subjects enrolled were 
transported to Chihuahua University to undergo a thorough evaluation, including a basic 
physical exam and a medical exam focusing on skin lesions and other pathologies 
associated with exposure to iAs. The body weight, height, body mass index (BMI), waist-
to-hip ratio, and blood pressure for each subject were recorded. 
6.3.2 Sample Collection 
Individuals provided drinking water samples for As analysis and spot urine 
samples were collected at Universidad Autónoma de Chihuahua between 8 and 10 am. 
The containers were immediately stored on ice and divided into two 50 mL polyethylene 
tubes. BECs were isolated by centrifugation at 700 × g for 10 min at 4°C. Cells from each 
donor were then transferred into a single conical 1.5-mL Eppendorf tube, washed with 1 
mL ice-cold phosphate-buffered saline (PBS), and centrifuged at 700 × g for 10 min at 
4°C. Cells were resuspended in 1 mL of PBS, and 10 µL was removed to perform cell 
counts. This aliquot was incubated with an equal volume of 0.4% trypan blue exclusion 
dye for 3 minutes and cells were counted using a hemocytometer. Urines contaminated 
with yeast or bacteria were excluded from the study. The remaining urine aliquot was 
pelleted by centrifugation and stored at -80°C. The BEC pellets were packed in dry ice 
and air-shipped to UNC-Chapel Hill once per month. Here, the pellets were analyzed 
within three days for tri- and pentavalent As species. Aliquots of urine were stored at       
-80°C and shipped with the BECs to UNC-Chapel Hill for analysis of total tri- plus 
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pentavalent species. To assess hydration status, urinary creatinine and specific gravity 
measurements were performed. A multi-well colorimetric assay kit was used to determine 
urinary creatinine concentration (Cayman Chemical Company, Ann Arbor, MI), and 
urine density was measured using a digital Atago PAL refractometer (Atago USA, 
Bellevue, WA).    
MAs
III 
and DMAs
III
 are not stable in urine; however, we have shown that in the 
cellular environment, these trivalent arsenicals in cell lysates from an As methylating 
urothelial cell line are stable for at least 3 weeks at -80°C (193). Moreover, in a simulated 
shipping experiment, DMAs
III
 in cell lysates was stable for at least two days when packed 
in dry ice (Figure 3.9). Based on these results, the concentrations of MAs
III
 and DMAs
III
 
in exfoliated urothelial cells isolated in Chihuahua should remain unchanged if the cells 
are frozen at -80°C immediately after collection and shipped in dry ice to UNC-Chapel 
Hill.   
6.3.3 Diagnosis of Diabetes 
Fasting venous blood was collected during the medical exam, followed by an 
OGTT where individuals were administered 75 g of glucose and samples of venous blood 
were collected 30 minutes and 2 hours into the test. All three blood samples were 
collected in EDTA-vacutainers. Plasma was isolated from freshly collected blood by 
centrifugation at 4°C and stored at -80°C. Plasma glucose levels were measured by 
Prestige 24i Chemistry Analyzer (Tokyo Boeki, Tokyo, Japan). To assure accuracy, the 
analyzer was calibrated prior to analysis of plasma samples and reference human sera 
with normal and elevated glucose levels were used for quality control. FPG and 2HPG 
levels were used to identify diabetic subjects. Study participants were classified as 
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diabetic if they presented with a FPG level ≥ 126 mg/dL, 2HPG ≥ 200 mg/dL, or if they 
reported a doctor’s diagnosis or use of anti-diabetic medication. In participants not taking 
anti-diabetic medication, FPG and 2HPG levels correlated well (r
2
 = 0.42, p < 0.01).  
6.3.4 Analyses of As in Urine and BECs 
As species in BECs were analyzed at UNC-CH by HG-CT-ICP-MS using the 
previously described method (136). Briefly, iAs and the methylated arsenicals in the 
BECs are reduced to their corresponding arsines (arsine, methylarsine, and 
dimethylarsine) in a reaction mixture containing 1% sodium borohydride (NaBH4; 
Sigma-Aldrich, St. Louis, MO) and a 0.75 M Tris(hydroxymethyl)aminomethane (TRIS)-
HCl buffer (pH 6; Sigma-Aldrich). The gaseous phase with generated arsines is separated 
from the liquid phase by gas-liquid separator and dried by a polyethylene cartridge (100 
mm long, 17 mm i.d.) containing approximately 25 g of NaOH pellets (Sigma-Aldrich) 
(172). The arsines are cryotrapped in a Ni80/Cr20 wire wrapped capillary U-tube (total 
resistance of 15 Ω, Omega Engineering, Inc., Stanford, CT) filled with approximately 0.9 
g of Chromosorb WAW-DMCS 45/60, 15 % OV-3 (Supelco, Bellefonte, USA) and 
submerged in a Dewar flask filled with liquid N2. After sufficient time for arsine 
generation and cryotrapping, the Dewar flask is removed from the U-tube and upon 
electrical heating, arsines are separated by their boiling points. The CT outlet is 
connected between the spray chamber and the torch of the Agilent 7500cx ICP-MS 
spectrometer (Agilent Technologies, Santa Clara, CA). The HG and CT steps were 
controlled by a FIAS 400 flow injection accessory (Perkin-Elmer, Norwalk, CT).  
To determine both tri- and pentavalent As (As
III+V
) species, one aliquot of each 
sample is measured directly to determine As
III
 species and an additional aliquot is 
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measured after pretreatment for one hour at room temperature with 2% L-cysteine 
(biochemistry grade, EMD Chemicals, Inc., Gibbstown, NJ) to determine As
III+V
 species. 
At pH 6, trivalent arsenicals (iAs
III
, MAs
III
 and DMAs
III
) selectively generate arsines 
directly without sample extraction or pretreatment, while L-cysteine reduces the 
pentavalent arsenicals to trivalency, allowing determination of both As
III
 and As
V
 species. 
The concentrations of iAs
V
, MAs
V
, and DMAs
V
 are determined as a difference between 
signals obtained for cysteine-treated and untreated sample aliquots. Aliquots of urine 
from individuals providing BECs were also shipped to UNC-CH for analysis. Here, 
samples were measured only for As
III+V
 species by HG-CT-AAS after 2% L-cysteine 
pretreatment due to the rapid oxidation of MAs
III
 and DMAs
III
 in this matrix (70). 
Calibration curves for the quantification of tri- and pentavalent As species in this 
study were generated using aqueous solutions of the pentavalent standards, (iAs
V
, MAs
V
, 
and DMAs
V
) treated with L-cysteine. We have previously shown that the slopes of the 
calibration curves for the L-cysteine-treated As
V
 standards prepared in DIW are identical 
with the slopes of curves generated for the trivalent arsenicals in the absence of cysteine 
(149). We have also shown that the slopes of the calibration curves for the L-cysteine-
treated aqueous solutions of As standards do not significantly differ from the slopes of 
curves prepared for liver homogenates spiked with these standards and treated with L-
cysteine (149). Moreover, our results indicate that trivalent arsenicals are stable in these 
matrices when stored at -80°C for at least 3 weeks and when shipped in containers 
packed on dry ice for at least 2 days (167, 193). The quantification of individual As 
species was made by determining peak areas for arsine and the methyl-substituted 
arsines.  
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6.3.5 Statistical Analysis 
Continuous variables were analyzed using means and standard deviations, and 
their distributions were assessed graphically. Categorical variables were described using 
frequencies. For As species below the limit of detection (LOD), LOD/√2 values were 
used for statistical analysis. The LOD ranged from 10 to 26 pg for urinary As 
measurements by HG-CT-AAS and 0.04 to 2.0 pg for BEC As measurements by HG-CT-
ICP-MS. The associations of the diabetic phenotype with iAs in water and As species in 
BEC and urine were assessed using logistic regression to estimate odds ratios (ORs) and 
95% confidence intervals (CIs). To control for potential confounding, age, sex, and BMI 
were included as covariates. Associations of FPG and 2HPG with measures of iAs 
metabolites and the sum of speciated As were analyzed by linear regression. Age, sex, 
and BMI were included as covariates in these models. The assumption of linear exposure-
response was assessed graphically and found to be adequate. ORs, regression 
coefficients, and CIs are reported for a one interquartile range (IQR) increment of 
exposure to facilitate comparison because of the different concentration ranges of As in 
BECs, urine, and water. Analyses of urinary metabolites of iAs were conducted both with 
and without urinary creatinine concentration and specific gravity adjustment to assess for 
possible effects of variation in hydration status. Chromatograms from HG-CT-AAS and 
HG-CT-ICP-MS analyses were exported and peak areas were integrated in Microsoft 
Excel. All statistical analyses were performed in Epi Info 7 version 1.0.6 (Centers for 
Disease Control and Prevention, Atlanta, GA) and graphical representations were 
generated using GraphPad Instat software package (GraphPad Software Inc., San Diego, 
CA). Statistical significance was considered at the level of p < 0.05. 
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6.4 Results and Discussion 
6.4.1 Study Population Characteristics 
We isolated BECs from a cohort within the NIH population study, 
“Environmental arsenic and diabetes mellitus,” (n = 378). Individuals participating in this 
study lived in As-endemic regions of Chihuahua, Mexico for at least the previous two 
years. General characteristics of this cohort are presented in Table 6.1. Enrolled subjects 
included both males (n = 123) and females (n = 255) ages 18 to 90. The average BMI of 
the population was 29.2 ± 6.1 with 41% presenting as clinically obese (BMI > 30). FPG 
and 2HPG levels were measured in 374 individuals. Samples of drinking water collected 
from 300 individuals contained iAs concentrations ranging from 0.01 to 275 ppb. 
The prevalence of diabetes in the cohort examined in this study was 18% (n = 66), 
and consisted of 44 females and 22 males. Glucose tolerance was within normal or pre-
diabetic ranges (FPG < 126 and 2HPG < 200) for six individuals that reported taking 
anti-diabetic medications. Four subjects reported a previous doctor diagnosis but had 
normal FPG or 2HPG. Moreover, one individual reported a previous diabetes diagnosis, 
but FPG or 2HPG data was unavailable. Logistic regression analysis of the associations 
between diabetes and markers of iAs exposure were performed with and without these 11 
subjects. 
 
Table 6.1: Characteristics of the study population 
  Population Diabetic
a
 Non-diabetic 
 
Mean SD Mean SD Mean SD 
  (N) (%) (N) (%) (N) (%) 
Population (N, %) (378) (100) (66) (18) (308) (82) 
Female (N, %) (255) (67) (44) (67) (211) (67) 
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Age (years) 49.0  16.0  56* 12.0  48* 16.0  
iAs in drinking water (ppb) 54.9  52.7  60.0  50.9  53.7  53.2  
BMI 29.2  6.1  30.8* 5.4  28.9* 6.2  
BMI > 30 (155) (41) (31) (47) (124) (40) 
FPG (mg/dL) 95.9  39.5  155.7* 62.8  83.2* 12.1  
2HPG (mg/dL) 118.6  60.4  204.9* 86.0  100.4* 31.1  
Sum As Urine (ng/mL) 73.6 73.3 82.0 74.9 71.8 72.9 
Sum As BECs (pg/10,000 cells) 126.4  357.9  90.3  202.1  134.0  382.6  
Creatinine (mg/dL) 128.4 90.1 127.1 85.7 128.7 91.1 
Sum As Urine (ng/mg creatinine) 65.8 66.8 73.1 77.9 64.2 64.3 
Specific Gravity
b
 1.014 0.007 1.017* 0.008 1.014* 0.007 
Sum As Urine (ng/SG unit) 109.5 102.2 92.6 62 113.1 108.5 
a
 Diabetes classified by either FPG
 ≥ 126 mg/dL, 2HPG ≥ 200 mg/dL, self-report of 
doctor diagnosis or use of anti-diabetic medication. Previous diabetes diagnosis, FPG or 
OGTT data are not available for four individuals and are excluded from the diabetes 
stratification analysis. 
b 
Specific gravity was measured in 377 samples. 
* For continuous variables, a significant different between diabetics and non-diabetics by 
Student’s t-test, p < 0.05. 
 
For some variables, significant differences between diabetics and individuals free 
of diabetes (non-diabetic) were observed (Table 6.1). The average age of diabetic 
individuals was 56, while non-diabetics were an average of 48 years old. However, those 
classified as diabetic ranged in age from 24 to 84. Moreover, individuals presenting with 
diabetes exhibited a significantly higher (p < 0.05) average BMI (30.8) compared with of 
non-diabetics (28.9). The average urinary specific gravity was significantly higher (p < 
0.05) in diabetic individuals (1.017) compared with non-diabetics (1.014). Impaired 
kidney function associated with the diabetic phenotype can result in the excretion of 
glucose or protein in the urine, which will overestimate urine density, leading to the 
underestimation of urinary arsenicals in these individuals when adjusted for specific 
gravity.  
125 
 
6.4.2 Markers of iAs Exposure 
The concentration of iAs in drinking water and metabolites of iAs exposure in 
BECs and urine of individuals participating in this study were measured and are 
presented in Table 6.2. The levels of iAs in drinking water obtained from 300 study 
participants ranged from 0.01 to 275 ppb. Urinary As was measured for total tri- and 
pentavalent As species, iAs
III+V
, MAs
III+V
, and DMAs
III+V
. Trimethylarsine oxide 
(TMAs
V
O) was not measured because this arsenical is lost during 2% L-cysteine 
pretreatment (146). MAs
III+V
 and DMAs
III+V
 were measured in all 378 urine samples, 
while iAs
III+V
 was below the LOD in five samples. DMAs
III+V
 was the predominant 
species present in urine, accounting for an average of 76% of speciated As. iAs
III+V
 and 
MAs
III+V
 represented approximately 9% and 15% of speciated As, respectively.  
In BECs, oxidation state specific analysis of As species was performed and the 
following six arsenicals were quantified: iAs
III
, iAs
V
, MAs
III
, MAs
V
, DMAs
III
, and 
DMAs
V
. For individual As species, concentrations greater than the LOD were observed 
in 94% to 99% of samples. All BEC samples contained measurable quantities of As for at 
least three As species. Notably, iAs
III
 was the predominant species retained in BECs, 
representing on average 36% of the sum of the total speciated As. Notably, only small 
amounts of DMAs
III
 were retained in BECs, representing on average 2.4% of the sum of 
As species. DMAs
III
 is the least stable trivalent arsenical in aqueous (14) or cellular 
matrices (193) and under these HG conditions, up to 5.9% of DMAs
V
 has been shown to 
form dimethylated arsine in this matrix (unpublished data). This suggests that some, if 
not all DMAs
III
 measured in BECs is likely in the oxidized form.    
Table 6.2: Descriptive statistics for exposure to iAs in drinking water and iAs 
metabolites in BECs and urine, n = 378. 
126 
 
BECs (pg As/10,000 cells) Min. 25
th
  Median 75
th
  Max.  Mean SD 
iAs
III
 0.04 2.05 8.12 17.65 1807 23.82 102 
MAs
III
 0.01 0.44 1.76 4.02 151.7 4.14 11.16 
DMAs
III
 0.01 0.16 0.40 1.47 141.3 2.7 9.53 
iAs
V
 0.001 1.27 4.52 22.46 728.7 34.45 85.86 
MAs
V
 0.0003 0.19 0.85 4.87 776.2 12.98 52.21 
DMAs
V
 0.001 0.66 1.86 13.67 2303 48.67 199.7 
Sum As
III+V
 0.78 9.94 24.91 74.5 3773 126.4 357.9 
MAs/iAs ratio 0.01 0.15 0.2 0.28 3.64 0.26 0.28 
DMAs/MAs ratio 0.04 0.55 1.10 2.87 51.47 2.14 3.63 
DMAs/iAs ratio 0.004 0.10 0.20 0.50 35.0 0.77 2.5 
MAs+DMAs/iAs ratio 0.02 0.29 0.40 0.78 35.63 1.03 2.66 
Urine (ng As/mL)               
iAs
III+V
 0.02 0.92 4.61 10.21 119.2 7.4 10.4 
MAs
III+V
 0.03 2.21 7.31 15.97 131.1 11.1 13.0 
DMAs
III+V
 0.36 12.24 40.38 82.73 307.2 55.12 53.8 
Sum As
III+V
 0.52 15.62 53.23 108.4 492.5 73.61 73.27 
MAs/iAs ratio 0.10 1.28 1.64 2.12 199.4 4.90 19.1 
DMAs/MAs ratio 1.73 4.09 5.18 7.05 86.2 6.22 5.25 
DMAs/iAs ratio 0.41 6.43 9.25 12.45 2117 31.0 144.4 
MAs+DMAs/iAs ratio 0.51 7.96 10.94 14.59 2317 35.94 162.6 
Drinking Water
#
  0.01 5.88 48.41 83.72 275.4 54.9 52.7 
#
 iAs in drinking water (ng iAs/mL) was measured in 300 samples. 
The As speciation profiles for urine and BECs are depicted in Figure 6.1 and 
suggest that the urinary profiles of iAs metabolites are not an accurate reflection of actual 
As retention in target tissues. iAs
III+V
 represented 65% and 9% of sum of As species in 
BECs and urine, respectively. DMAs
III+V
 was highly excreted in urine, representing an 
average of 76% of total speciated As, but it only represented an average of 22% of total 
speciated As in BECs. These results are in agreement with a previous study examining 
the effects of iAs
III
 on urinary bladder cell proliferation in mice. The authors report 
accumulation of iAs
III
 in bladder tissue with primary urinary excretion in the form of 
DMAs (209). High affinity binding of iAs
III
 species to intracellular sulfhydryls, including 
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glutathione (210) and protein thiols (211) may drive the retention of this As species in 
BECs. 
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Figure 6.1: Differences in composition of As species in BECs and urine. (***) 
Significant difference in percent of total speciated As between BECs and urine performed 
by one-way ANOVA, p < 0.05. 
 
To assess the sensitivity of As species retained in BECs as biomarkers of iAs 
exposure, associations between log-transformed arsenicals in BECs and urine were 
compared. While a pilot study examining the retention of As in BECs of 21 individuals 
residing in Zimapan, Mexico showed no correlation between arsenicals measured in 
BECs and urine, results of this larger population study show significant positive 
associations (Figure 6.2). The trivalent As species, iAs
III
 and MAs
III
 retained in BECs 
were highly correlated with iAs
III+V
 and MAs
III+V
 in urine (ß = 0.67 and 0.79, r
2
 = 0.45 
and 0.49, respectively). The strongest association was observed for sum of As
III
 species in 
BECs and sum of As species in urine (ß = 0.88, r
2
 = 0.55). For the 300 individuals that 
provided drinking water samples, iAs concentrations were compared to urinary excretion 
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and BEC retention of As species. Figure 6.3 and Figure 6.4 display scatter plots of log-
transformed iAs in water and As species in urine or BECs, respectively. Significant 
positive associations with iAs in water were observed for all As species in urine 
regardless of adjustment for hydration status (ß = 0.32 to 0.41, r
2
 = 0.41 to 0.75) and for 
As species retained in BECs (ß = 0.21 to 0.43, r
2
 = 0.07 to 0.54). The strongest 
associations between iAs in drinking water were for sum of As
III+V
 species in urine (ß = 
0.40, r
2
 = 0.68) and sum of As
III
 species in BECs (ß = 0.42, r
2
 = 0.54).  
The positive associations between arsenicals in BEC, urine, and drinking water 
are in agreement with previous assessments of the relationship between iAs exposure and 
population-derived biomarkers, including As in urine (212), blood (213), saliva (121), 
hair (214), and toenails (215).
 
However, unlike previous reports, the present study 
directly measures As species in cells originated in a target tissue.     
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Figure 6.2: The correlations between logarithmically transformed concentrations of iAs 
(A,B), MAs (C,D), DMAs (E,F) and sum of As species (G,H) in urine and BECs. Results 
of linear regression analysis are presented as slopes (ß) and coefficient of determination 
(r
2
). All slopes are significantly non-zero, p < 0.05.  
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Figure 6.3: The correlations between logarithmically transformed concentrations of iAs 
in water and iAs (A,B), MAs (C,D), DMAs (E,F) and sum of As species (G,H) in BECs. 
Results of linear regression analysis are presented as slopes (ß) and coefficient of 
determination (r
2
). All slopes are significantly non-zero, p < 0.05. 
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Figure 6.4: The correlations between logarithmically transformed concentrations of iAs 
in drinking water and As metabolites in urine. Results of linear regression analysis for 
iAs (A), MAs (B), DMAs (C), and sum of speciated As (D) in urine compared with iAs 
in drinking water are presented as slopes (ß) and coefficient of determination (r
2
). All 
slopes are significantly non-zero, p < 0.05.  
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6.4.3 Gender Differences in BECs As Retention 
Significant differences in numbers of bladder cells exfoliated and As retention 
were observed between males and females in this study (Figure 6.5). Cell counts from 
BEC samples obtained from males ranged from 450 to 2,128,000 cells, while samples 
from females ranged from 1,800 to 9,717,000 cells. BECs from females contained on 
average 10-fold more cells than samples from males (Figure 6.5A). Notably, when As 
retention in BECs was normalized for cell counts, significant differences in the sum of As 
species between males and females are observed. The sum of speciated As in BECs from 
males and females ranged from 0.78 to 3773 pg/10,000 cells and 0.83 to 2367 pg/10,000 
cells, respectively. However, average As retention was significantly lower in BECs from 
females (39 ± 162 pg/10,000 cells) than males (307 ± 541 pg/10,000 cells) (Figure 6.5B). 
Anatomical differences in the urinary and genital tracts of females may contribute to the 
presence of vaginal epithelial cell contamination. Moreover, the vesical trigone area of 
bladders from adult female bladders is increasingly susceptible to squamous metaplasia, a 
phenomenon rarely observed in males; this finding in women decreases with age (216). 
Notably, regression analysis reveals a significantly negative association between age and 
BEC counts from females in this study (ß = -11,287, r
2
 = 0.04).  
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Figure 6.5: Gender differences in cells counts (A) and As retention (B) in BECs. Values 
are presented as mean ± SEM, n = 378. 
 
While cells were observed microscopically and assessed for viability by dye 
exclusion during cell counting, cell types were not characterized. Because distinguishing 
between epithelial cells of urothelial or squamous origin is not easily achieved using 
routine visual or staining techniques, immunohistochemistry has been used to 
characterize squamous metaplasia in bladder cancer (217) and interstitial cystitis (218). 
This approach was not possible in our study due to only limited numbers of cells 
collected from subject urines. The lower As retention for female BEC samples could be a 
dilution effect; however, log-transformed scatter plots of cell counts and sum of As 
species in BECs for males and females presented in Figure 6.6 suggest a more prominent 
dilution effect for males (ß = -0.70, r
2
 = 0.54) than females (ß = -0.35, r
2
 = 0.12). 
Additional differences in As retention and cell exfoliated counts may arise from 
differences in the characteristics of urination frequency (219) and urine concentration 
(220) between genders. 
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Figure 6.9: The associations of cell counts with sum of As species retained in BECs for 
samples obtained from males (A) and females (B). Results from linear regression analysis 
are presented as slopes (ß) and coefficient of determination (r
2
). All slopes are 
significantly non-zero, p < 0.05. 
 
The percent composition of As species retained in BECs or excreted in urine of 
males and females were compared (Figure 6.7). In BECs, significant differences between 
males and females were observed for all As species retained in BECs except DMAs
III
. 
iAs
III
 and MAs
III 
represented on average 43% and 10% of total speciated As in BECs 
from females, but only 18% and 4% in BECs from males. These data further suggest the 
cell type composition differs between genders and that iAs  
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Figure 6.7: Gender differences in percent composition of As metabolites retained in 
BECs (A) and excreted in urine (B). Values for each arsenical represent percent of the 
sum of speciated As (mean ± SD, n = 378). (**) Significant difference between male and 
female percent composition determined by one-way ANOVA with Bonferroni’s posttest 
(p < 0.05).  
 
metabolism and retention are dependent on the cell type. Males excreted significantly 
more MAs
III+V
 in urine than females (17% vs. 14%), but less DMAs
III+V
 (73% vs. 78%). 
Differences in urinary As excretion between genders have been previously reported. 
Notably, Basu and associates found that in a population exposed to iAs through drinking 
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water in West Bengal, India, males excreted lower iAs and higher MAs in urine 
compared to female and suggest that animal fat consumption is associated with increased 
urinary MAs excretion (117).  
6.4.4 Associations of iAs Exposure and Diabetes 
Diabetes classified by FPG, 2HPG, reported doctor diagnosis, or use of anti-
diabetic medications was used to assess the associations between iAs in drinking water 
and As metabolites in BECs and urine. To adjust for potential confounding, age, sex, and 
BMI were included as covariates in each model. The logistic regression analyses 
presented in Table 6.3 were performed for all individuals diagnosed with diabetes using 
the above criteria (Model 1, n = 374) and then repeated after exclusion of individuals 
reporting diagnosis or use of anti-diabetic medications, but not exhibiting diabetic 
phenotype based on both FPG and 2HPG measurements (Model 2, n = 363). To facilitate 
comparison between iAs exposure markers, ORs and CIs were standardized to an 
increment of one IQR. Concentration ranges corresponding to the IQR for each marker 
are presented in Table 6.2.  
6.4.4.1 Associations of Diabetes with iAs in Drinking Water 
While, ORs for diabetes classified by FPG ≥ 126 mg/dl, self-reported diabetes 
diagnosis or medication, were significantly higher for subjects exposed to high levels of 
iAs in drinking water (185 – 420 ppb As) in the larger cohort, no significant association 
was found between risk of diabetes diagnosis and current iAs concentration in drinking 
water (OR 1.27, 95% CI 0.96 – 1.68, p = 0.10) when standardized to IQR in this smaller 
cohort. The association did not change after restricting the classification criteria for 
diabetes to subjects with diabetic phenotype (i.e., FPG ≥ 126 and 2HPG ≥ 200) or 
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standardizing the OR to 10 ppb increments. Although, linear exposure response 
assessment presented in Figure 6.8 reveals significant associations between individuals 
with iAs concentration is drinking water in the 25
th
 percentile (0.01 – 7.21 ppb; OR = 
1.00) compared to either the 50
th 
(7.22 – 48.69 ppb; OR 4.50, 95% CI 1.63 – 12.43, p < 
0.01), 75
th
 (48.70 – 83.72 ppb; OR 3.49, 95% CI 1.20 – 10.13, p = 0.02), or 100th 
percentile (83.73 – 275.36 ppb; OR 3.12, 95% CI 1.09 – 8.98, p = 0.10). The absence of a 
significant linear dose-response is likely due to variation in individual water consumption 
habits, which was not accounted for by the analysis. Furthermore, data on As in drinking 
water were available only for a subset of the cohort (n = 298).  
These findings are in agreement with recent epidemiological studies conducted in 
As-endemic regions of Mexico (70) and Bangladesh (221) where diabetes diagnosis was 
based on criteria currently recommended by the WHO. Islam and associates reported an 
OR of 2.1 for individuals drinking water with iAs concentrations greater than 50 ppb; 
however, IQR analysis revealed significant associations for the highest quartile of iAs in 
drinking water (> 262 ppb) compared to the lowest quartile (10 – 22 ppb) (221). Notably, 
even the individuals in the lowest quartile drinking water iAs exposure ingest levels 
greater than 10 ppb, the current recommended maximum contaminate level set by the US 
EPA and WHO. In contrast, the lowest quartile of the present study contains individuals 
with iAs concentrations in drinking water less than 7.21 ppb. A pilot study conducted by 
our group in the Zimapan and Lagunera regions of Mexico, where individuals are 
exposed to similar concentration of iAs in drinking water, revealed a 13% increase in OR 
per 10 ppb increase in drinking water iAs concentration (OR 1.13, 95% CI 1.05 – 1.22, p 
< 0.01) (70). 
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Figure 6.8: Association of diabetes with exposure to iAs in drinking water adjusted for 
age, sex, and BMI. Diabetes is classified by either FPG
 ≥ 126 mg/dL, 2HPG ≥ 200 
mg/dL, self-report of doctor diagnosis or use of anti-diabetic medication, n = 374. (*) p < 
0.05 for the comparison of cases to non-diabetic individuals. The values for each IQR are 
presented in Table 6.2. 
6.4.4.2 Associations of Diabetes with Metabolites of iAs in BECs and Urine 
Diabetes was associated with trivalent As species retained in BECs (Table 6.3). 
For iAs
III
 in BECs, a 57% increase in OR for each IQR was observed (OR 1.57, 95% CI 
1.19 – 2.07, p < 0.01). The strongest positive association was observed for MAsIII in 
BECs, with the OR increasing 63% per IQR (OR 1.63, 95% CI 1.24 – 2.15, p < 0.01). 
Notably, the ratios of DMAs/MAs (OR 0.62, 95% CI 0.47 – 0.83, p < 0.01) and 
DMAs/iAs in BECs were negatively associated with the risk of diabetes (OR 0.72, 95% 
CI 0.55 – 0.96, p = 0.02). When diabetes classification was restricted to subjects with the 
diabetic phenotype (Model 2), associations for As metabolites in BECs strengthened. 
Here, a significant positive association was found with DMAs
III
 (OR 1.49, 95% CI 1.04 – 
2.13, p = 0.03) and the sum of As
III+V
 species (OR 1.41, 95% CI 1.01 – 1.97, p = 0.04) 
retained in BECs.  
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In urine, a significant positive association with risk of diabetes was only observed 
for DMAs/MAs ratio (OR 1.37, 95% CI 1.03 – 1.84, p = 0.03). However, when diabetes 
classification was limited only to subjects with diabetes phenotype, significant positive 
associations were also found for unadjusted DMAs
III+V
 concentration (OR 1.34, 95% CI 
1.02 – 1.76, p = 0.04). Here, significant associations were found for all As species in 
urine adjusted for urinary creatinine (Table 6.3). Notably, specific gravity was positively 
associated with diabetes when classified by FPG or 2HPG only (OR 1.42, 95% CI 1.07 – 
1.89, p = 0.02). This suggests that adjusting urinary As concentration for urine density 
may mask potential associations because this variable is itself associated with diabetes. 
Previously published OR values for the associations between As exposure and 
diabetes varied widely depending on the population, statistical model and method of 
exposure assessment (5). While no studies have used the concentrations of As species 
retained in BECs, in a study of gestational diabetes, women in the highest quartile of 
circulating As concentration in blood were at increased odds of having diabetes compared 
to women in the lowest quartile of blood As concentrations (OR 2.79, 95% CI 1.13 – 
6.87, p = 0.01) (113). A reexamination of the concentrations of As species in BECs 
comparing individuals in the highest quartile with those in the lowest quartiles or 
exposure also reveals significant associations between iAs
III
 (OR 5.63, 95% CI 2.02 – 
15.70, p = 0.001) and MAs
III
 (OR 4.99, 95% CI 2.01 – 12.37, p = 0.001), which are much 
stronger than those reported by Ettinger, et al. For urine, several studies have reported 
ORs examining the relationship between As exposure and the development of diabetes 
(107, 108, 110, 111). In the present study, comparing individuals in the highest to those 
in the lowest quartile of urinary speciated As concentrations (> 108.4 vs. < 15.6 ppb As) 
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also reveals significantly increased odds of exhibiting the diabetic phenotype (OR 3.44, 
95% CI 1.35 – 8.85, p = 0.01). In a population study exposed to similar concentrations of 
As through drinking water, Coronado-Gonzalez and associates reported an OR of 2.84 
(CI 95% 1.64 – 4.92, p = 0.01) when comparing individuals with urinary As 
concentrations > 105 ppb with those having < 63.5 ppb (111).These results are in 
agreement and suggest that even levels below 63.5 ppb may contribute to the 
development of diabetes.  
6.4.4.3 Associations between Diabetes and iAs Exposure Based on Linear Regression 
Analysis 
To further examine the relationships between iAs exposure and diabetes, linear 
regression analysis for log-transformed FPG and 2HPG and markers of iAs exposure was 
performed (Table 6.4). In contrast to the results of logistic regression analysis, FPG and 
2HPG were positively associated with iAs in drinking water (r
2
 = 0.21 and 0.17, p < 
0.01). FPG and 2HPG were also positively associated with concentrations of iAs
III
, 
MAs
III
, DMAs
III
, and the sum of As
III+V
 species retained in BECs (r
2
 = 0.11 – 0.17, p < 
0.01). In agreement with the logistic regression analysis, the ratios of DMAs/MAs and 
DMAs/iAs in BECs were negatively associated with FPG and 2HPG levels (r
2
 = 0.08 – 
0.12, p < 0.04). These finding suggest that increased methylation capacity as indicated by 
higher DMAs/MAs and DMAs/iAs protects against the risk of diabetes.  
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Table 6.3: Association of diabetes with exposure to iAs in drinking water and iAs 
metabolites in BECs and urine adjusted for age, sex, and BMI 
  Model 1
a
 Model 2
b
 
 
OR
c
 95% CI p
d
 OR
c
 95% CI p
d
 
iAs in Water 1.27 0.96 1.68 0.10 1.30 0.96 1.75 0.09 
BECs                  
iAs
III
 1.57 1.19 2.07 <0.01 1.75 1.29 2.39 <0.01 
MAs
III
 1.63 1.24 2.15 <0.01 2.02 1.48 2.77 <0.01 
DMAs
III
 1.13 0.96 1.84 0.09 1.49 1.04 2.13 0.03 
iAs
V
 1.23 0.90 1.67 0.20 1.41 1.00 1.98 0.05 
MAs
V
 1.09 0.79 1.50 0.61 1.26 0.89 1.78 0.20 
DMAs
V
 0.97 0.71 1.33 0.85 0.99 0.70 1.38 0.94 
Sum As
III+V
 1.24 0.91 1.68 0.17 1.41 1.01 1.97 0.04 
MAs/iAs 1.06 0.83 1.36 0.63 1.09 0.83 1.42 0.54 
DMAs/MAs 0.62 0.47 0.83 <0.01 0.53 0.38 0.73 <0.01 
DMAs/iAs 0.72 0.55 0.96 0.02 0.65 0.48 0.89 0.01 
(DMAs+MAs)/iAs 0.77 0.56 1.04 0.08 0.78 0.56 1.05 0.09 
Urine                 
iAs
III+V
 1.18 0.91 1.53 0.22 1.34 1.00 1.79 0.05 
MAs
III+V
 1.13 0.87 1.46 0.36 1.23 0.93 1.63 0.14 
DMAs
III+V
 1.24 0.96 1.60 0.10 1.34 1.02 1.76 0.04 
Sum As
III+V
 1.19 0.93 1.54 0.17 1.31 0.99 1.72 0.06 
MAs/iAs 0.86 0.67 1.11 0.25 0.77 0.58 1.02 0.07 
DMAs/MAs 1.37 1.03 1.84 0.03 1.38 1.00 1.89 0.05 
DMAs/iAs 1.12 0.86 1.46 0.38 1.05 0.79 1.40 0.74 
(DMAs+MAs)/iAs 0.99 0.75 1.30 0.95 1.02 0.77 1.34 0.91 
Creatinine adj.                 
iAs
III+V
 1.19 0.92 1.54 0.19 1.38 1.04 1.83 0.03 
MAs
III+V
 1.17 0.91 1.51 0.23 1.35 1.01 1.79 0.04 
DMAs
III+V
 1.26 0.98 1.62 0.08 1.39 1.05 1.84 0.02 
Sum As
III+V
 1.24 0.96 1.60 0.10 1.39 1.05 1.84 0.02 
Creatinine 1.01 0.78 1.31 0.93 1.00 0.75 1.32 0.98 
SG adj.                 
iAs
III+V
 0.98 0.76 1.27 0.87 1.08 0.81 1.42 0.61 
MAs
III+V
 0.94 0.73 1.22 0.65 0.99 0.75 1.30 0.92 
DMAs
III+V
 1.04 0.81 1.33 0.78 1.10 0.84 1.44 0.51 
Sum As
III+V
 1.00 0.78 1.29 0.99 1.04 0.79 1.36 0.79 
SG 1.32 1.01 1.71 0.07 1.42 1.07 1.89 0.02 
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Abbreviations: OR, odds ratio; CI, confidence interval; FPG, fasting plasma glucose; 
2HPG, 2-hour plasma glucose; SG, specific gravity 
a 
Diabetes classified by either FPG
 ≥ 126 mg/dL, 2HPG ≥ 200 mg/dL, self-report of 
doctor diagnosis or use of anti-diabetic medication, n = 374. 
b Diabetes classified by either FPG ≥ 126 mg/dL or 2HPG ≥ 200 mg/dL. Individuals self-
reporting a doctor diagnosis or taking anti-diabetic medication but not classified as 
diabetic by FPG or 2HPG are excluded, n = 363.  
c
 Units of OR and CI are standardized to an increment of one inter-quartile range. 
Descriptive statistics for iAs in drinking water and metabolites of As in BECs and urine 
are presented in Table 6.2. 
d
 p-value for comparison of cases to non-diabetic individuals. 
The linear regression analysis also found positive associations between FPG or 
2HPG and each of the As species in urine regardless of adjustment for hydration status. 
Notably, positive associations between urinary specific gravity and FPG or 2HPG levels 
were observed (r
2
 = 0.13 and 0.11, respectively, p < 0.01). These results are in agreement 
with logistic regression analysis and highlight the limitation of using creatinine or 
specific gravity to adjust for hydration status in studies examining diabetes. Taken 
together, these data present clear differences in the composition of As species retained in 
BECs and those present in urine. Combined results of the logistic and linear regression 
analyses suggest that As species retained in BECs are sensitive biomarkers of the diabetic 
phenotype and provide additional evidence for the important role of the trivalent 
arsenicals in the development of disease in subjects chronically exposed to iAs.  
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Table 6.4: Association of log-transformed FPG and 2HPG with iAs in drinking water 
and iAs metabolites in BECs and urine adjusted for age, sex, and BMI. 
  FPG 2HPG 
 
βa SE pb r2 βa SE pb r2 
iAs in Water 0.041 0.006 <0.01 0.21 0.031 0.006 <0.01 0.17 
BECs 
iAs
III
 0.056 0.009 <0.01 0.16 0.042 0.009 <0.01 0.14 
MAs
III
 0.062 0.009 <0.01 0.17 0.050 0.009 <0.01 0.15 
DMAs
III
 0.050 0.011 <0.01 0.12 0.039 0.011 <0.01 0.12 
iAs
V
 0.013 0.009 0.15 0.07 0.007 0.009 0.45 0.09 
MAs
V
 0.015 0.008 0.08 0.08 0.010 0.008 0.21 0.09 
DMAs
V
 0.010 0.009 0.25 0.07 0.007 0.009 0.40 0.09 
Sum As
III+V
 0.045 0.011 <0.01 0.11 0.035 0.011 <0.01 0.11 
MAs/iAs 0.046 0.022 0.04 0.08 0.039 0.022 0.08 0.09 
DMAs/MAs -0.072 0.015 <0.01 0.12 -0.057 0.016 <0.01 0.12 
DMAs/iAs -0.032 0.013 0.01 0.08 -0.033 0.016 0.04 0.10 
(DMAs+MAs)/iAs -0.014 0.016 0.40 0.07 -0.009 0.017 0.60 0.09 
Urine 
iAs
III+V
 0.048 0.009 <0.01 0.13 0.043 0.009 <0.01 0.14 
MAs
III+V
 0.062 0.010 <0.01 0.15 0.045 0.011 <0.01 0.13 
DMAs
III+V
 0.078 0.011 <0.01 0.18 0.061 0.011 <0.01 0.15 
Sum As
III+V
 0.076 0.011 <0.01 0.17 0.059 0.011 <0.01 0.15 
MAs/iAs ratio -0.001 0.019 0.95 0.02 -0.032 0.019 0.05 0.09 
DMAs/MAs ratio 0.072 0.036 0.05 0.08 0.100 0.036 <0.01 0.11 
DMAs/iAs ratio 0.016 0.018 0.37 0.07 -0.005 0.018 0.80 0.09 
(DMAs+MAs)/iAs  0.014 0.018 0.45 0.07 -0.009 0.018 0.62 0.09 
Creatinine Adj. 
iAs
III+V
 0.052 0.011 <0.01 0.12 0.053 0.011 <0.01 0.15 
MAs
III+V
 0.072 0.012 <0.01 0.15 0.060 0.013 <0.01 0.14 
DMAs
III+V
 0.093 0.031 <0.01 0.18 0.083 0.013 <0.01 0.18 
Sum As
III+V
 0.091 0.013 <0.01 0.18 0.081 0.013 <0.01 0.17 
Creatinine 0.033 0.020 0.09 0.07 0.005 0.020 0.79 0.09 
SG Adj. 
iAs
III+V
 0.040 0.011 <0.01 0.10 0.042 0.011 <0.01 0.13 
MAs
III+V
 0.055 0.120 <0.01 0.12 0.042 0.011 <0.01 0.13 
DMAs
III+V
 0.073 0.013 <0.01 0.14 0.065 0.013 <0.01 0.14 
Sum As
III+V
 0.070 0.013 <0.01 0.14 0.062 0.013 <0.01 0.14 
SG 10.314 2.070 <0.01 0.13 5.995 2.130 <0.01 0.11 
Abbreviations: Adj., adjusted; FPG, fasting plasma glucose; 2HPG, 2-hour plasma 
glucose; β, regression coefficient; SE, standard error; SG, specific gravity 
a
 Coefficients are standardized to an increment of one inter-quartile range. 
b
 p-value for test of β = 0. 
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6.5 Conclusions 
In this report, we have shown that exposure to iAs through contaminated drinking 
water is associated with an increased risk of diabetes characterized by widely accepted 
diagnostic criteria. Moreover, the retention of the toxic trivalent As species in BECs was 
found to be a sensitive biomarker of both iAs exposure and the risk of diabetes associated 
with this exposure. The compositional differences in the As metabolite profiles of urine 
and BECs indicate that the analysis of urinary As metabolites does not reflect As 
retention in a target tissue. Finally, this study provides further evidence for the 
diabetogenic effects of iAs exposure. 
 
   
 
 
CHAPTER VII  
SYNTHESIS 
7.1 Introduction 
Studies described in this dissertation sought to explore whether the quantitative 
analysis of trivalent As metabolites, produced in the course of iAs metabolism, are (i) 
suitable biomarkers for iAs exposure and (ii) can be used to inform the risk assessment of 
iAs-induced diabetes. The analysis of these metabolites in biological samples and thus, 
the use of these results to assess the risk associated with As exposure, are difficult 
endeavors because DMAs
III
 and, to a lesser extent, MAs
III
 rapidly oxidize in the presence 
of oxygen. Thus, this work sought to answer the following two questions: 
 
1)  Can HG-CT-AAS be used to quantify trivalent As species reliably 
in biological samples? 
2)  Does the concentration of trivalent As species in biological 
specimens predict susceptibility to the diabetogenic effects of As 
exposure? 
 
The oxidation state specific analysis of As species by HG-CT-based techniques was 
validated in cells and tissues. The technique was then applied to both in vivo mouse and 
human population studies examining the retention of trivalent arsenicals in target tissues. 
The findings of these studies contributed a robust HG-CT-based technique for the 
measurement and quantification of As
III
 species in a variety of biological samples that 
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can serve as sensitive biomarkers for the risk assessment of diseases associated with 
exposure to environmental iAs. This chapter recapitulates the major findings, discusses 
their implications, and provides a critical analysis of future directions for this research. 
7.2 Findings and Implications 
Establishing methods for quantifying trivalent arsenicals in biological samples is 
an important step for improving the risk assessment of environmental iAs exposure. 
While previous studies used HG-CT-AAS to detect MAs
III
 and DMAs
III
 in cell culture 
lysates with minimal sample handling and pretreatment (149), the stability of these As 
species in biological matrices was not characterized. Furthermore, no studies have 
quantitatively analyzed MAs
III
 and DMAs
III
 in cells or tissues without performing 
pretreatment or extractions that may facilitate the oxidation of trivalent species. Because 
these toxic trivalent metabolites have been identified in the urine of individuals exposed 
to As in drinking water, it is likely that target organ retention contributes to development 
of As-related diseases and thus, potentially be used as a biomarker to inform the risk 
assessment of As exposure. Using cells and tissues, we validated a HG-CT-AAS 
technique for the quantification of trivalent arsenicals and demonstrated that MAs
III
 and 
DMAs
III
 can be quantified and are stable in this reductive environment. Our results 
describe, for the first time, the quantification of trivalent arsenicals in mouse liver 
homogenates after exposure to iAs through drinking water (Chapter 2). Moreover, MAs
III
 
and DMAs
III
 were found to be stable for at least 3 weeks in cells and tissues when stored 
at -80°C (Chapter 3). These results support the theory that high concentrations of 
endogenous reductants, such as glutathione or protein thiols may preserve these trivalent 
species in biological samples. These studies confirm the feasibility of designing 
147 
 
experiments that analyze As
III
 metabolites systematically in laboratory- and population-
based studies. 
Our analytical method represents a novel approach that has the advantage of 
avoiding harsh pretreatments or extractions during the analysis. However, it has been 
argued that HG-based separations alone are not selective because they quantify arsine and 
methyl-substituted arsines as opposed to the As species present in the sample. In 
response, we compared HG-CT-AAS with a commonly used HPLC-based technique for 
the analysis of trivalent arsenicals using a simple in vitro reaction mixture. Recent 
developments in reversed-phase HPLC have successfully separated six As species in an 
aqueous solution (147), but MAs
III
 and DMAs
III
 have only been analyzed in biological 
samples using pretreatments or extractions that produce low yield and potentially result in 
oxidation of the As species (188). Our data demonstrate that protein binding and other 
reagent reactions interfere with the HPLC separation and detection of trivalent 
methylated species (Chapter 4). In contrast, the HG-CT method for separation produced 
high recoveries of these species regardless of biological matrix. These results strengthen 
the validity of HG-CT-AAS for the oxidation state speciation of iAs metabolites in 
biological samples that can be applied to a variety of studies assessing susceptibility to 
iAs-induced disease.  
To our knowledge, no reports have used the quantification of trivalent arsenicals 
present in biological specimens as a biomarker of diabetes associated with iAs exposure. 
Traditionally, analysis of human samples has been limited to measuring the excretion 
profiles of iAs metabolites present in urine. Moreover, in vivo studies in mice (157, 158) 
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and humans (85) suggest that urinary excretion of iAs and its metabolites does not 
correspond well with their tissue distribution.  
 Our laboratory has previously developed a mouse model for As-induced diabetes 
and shown accumulation of methylated As species in target organs (86). However, this 
study did not characterize the retention of trivalent methylated arsenicals. Our new in 
vitro studies are novel because they assess retention of tri- and pentavalent species in 
several target tissues, including those critical for glucose homeostasis (liver, pancreas, 
adipose tissue, and skeletal muscle). Moreover, the recently developed As3mt-KO mouse 
model represents a novel approach for characterizing the role of methylation in the 
development of disease. We used HG-CT-AAS to compare As speciation in tissues of 
WT and As3mt-KO mice exposed to iAs
III
 though drinking water. MAs
III
 and DMAs
III
 
are extensively retained in tissues regulating glucose homeostasis in WT mice. iAs
III
 is 
highly retained in tissues of As3mt-KO mice, , and these mice retain more total As than 
WT mice. We demonstrate that exposing As3mt-KO mice to 25 or 30 ppm As produces 
equivalent internal As doses in tissues critical to glucose homeostasis compared with WT 
mice that develop the diabetic phenotype after 8 weeks of exposure to 50 ppm As in 
drinking water. Our research analyzing the metabolites of iAs, including MAs
III
 and 
DMAs
III
, in tissues involved in insulin production and glucose homeostasis is a crucial 
step for validating these biomarkers for the risk assessment of environmental As 
exposure.  
To determine whether trivalent As species in a target human tissue could predict 
susceptibility to the diabetogenic effects of As exposure, we characterized the retention 
of trivalent As species in BECs and assessed associations between other biomarkers of 
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exposure, including urinary As species and iAs in drinking water, and the development of 
diabetes. Our work represents a novel approach because our previously described HG-CT 
technique was coupled with an ICP-MS, providing better LOD. The results from this 
study indicate that the composition of As species retained in BECs is significantly 
different than the urinary As excretion profile, but also that the concentrations of these 
species in BECs are positively associated with both As in urine and drinking water. Most 
importantly, we report that the retention of iAs
III
 and MAs
III
 in BECs is associated with 
the risk of iAs-induced diabetes. Taken together, these results indicate that the 
concentrations of trivalent arsenicals in BECs are highly sensitive biomarkers of iAs 
exposure and predict the development of As-induced diabetes. This ground-breaking 
study paves the way for examining the adverse effects of iAs exposure in future 
epidemiological-based studies and highlights the need and feasibility of considering As 
retention in target tissues.  
7.3 Future Studies 
Future analytical method development and optimization should focus on 
developing an HPLC-based reference method to further support the HG-CT separation 
methods presented in this dissertation. While the body of evidence supporting the 
analysis of trivalent arsenicals by HG-CT-AAS and HG-CT-ICP-MS are mounting, 
critics still argue that the method is not selective and question its use for the 
quantification of methylated trivalent arsenicals. While our efforts to optimize a reversed-
phase HPLC-ICP-MS reference method have revealed some critical shortcomings, 
additional studies should explore other mobile phases for this column type or anion-
exchange chromatography methods. Furthermore, future studies should utilize updated 
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equipment comprised of chemically inert parts, including those made from polyether 
ether ketone (PEEK), that do not adsorb metals or proteins. Plans in our laboratory are 
already under way to optimize an anion-exchange HPLC-ICP-MS method for As 
speciation using new instrumentation containing only chemically inert parts. 
Additional concerns have been made regarding the formation of thiol analogues 
of methylated As species, including dimethylthioarsenic acid (DMTA), and their 
contributions to the toxic effects of iAs exposure (181). While our optimization of a 
reversed-phase HPLC-ICP-MS method successfully separated seven As species, 
including DMTA from DMAs
III
, in an aqueous mixture, no research has successfully 
quantified both DMTA and DMAs
III
 in biological samples. Future work should optimize 
an HPLC-based method for the separation of tri- and pentavalent oxoarsenicals and 
DMTA in biological samples. Quantitatively determining both oxo- and thioarsenicals 
will enhance the risk assessment of the adverse effects associated with chronic As 
exposure.    
Our in vivo studies characterizing the retention of trivalent arsenicals in tissues of 
WT and As3mt-KO mice clearly demonstrate the need for additional studies that correlate 
the retention of these toxic As species to disease development. We have shown that 
trivalent arsenicals are extensively retained in several target tissues, including those 
critical for glucose homeostasis. No studies report the oxidation state specific speciation 
of As in an in vivo model of chronic iAs toxicity. While our data demonstrate the 
plausibility of such experiments, future studies should assess whether As3mt-KO mice are 
less sensitive to the diabetogenic effects of iAs exposure and characterize the role of 
methylation in the development of the diabetic phenotype. Using As3mt-KO mice and the 
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doses we determined to produce equivalent internal As exposures compared with WT 
mice, we hypothesize that the methylated trivalent arsenicals, MAs
III
 and DMAs
III
 are 
responsible for the impaired glucose tolerance observed in WT mice exposed to 50 ppm 
As is iAs
III
.  
The biomarker development and validation presented in this dissertation paves the 
way for future studies characterizing internal retention of iAs metabolites and disease 
development. Our results demonstrate the feasibility of measuring As retention in BECs 
and suggest they may serve as more sensitive biomarkers than commonly collected 
human samples, e.g., urine. However, gaps still exist in the epidemiological literature 
examining the associations between low iAs exposures and development of diabetes. 
Recent cross-sectional studies and results presented in this dissertation are unable to 
determining the temporal relationship between iAs exposure and incidence of diabetes. 
Future prospective epidemiological studies should be designed to address this 
association, as characterizing the relationship between duration of exposure and onset of 
diabetes is crucial for informing environmental policy and protecting public health.  
While biomarkers of iAs metabolite retention in target human tissues can help 
elucidate the roles of inter-individual variation in iAs metabolism and its impact on 
disease development, additional investigations should explore the mechanisms of these 
adverse effects. Epigenetic information, including promotor region DNA methylation 
patterns, can provide mechanistic insight into the pathways involved in the diabetic 
phenotype. Studies are already underway assessing the associations between DNA 
methylation and As retention in BECs of individuals with diabetes. The information on 
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pathways involved in As-induced diabetes can then be used to design in vitro and in vivo 
studies examining mechanisms of action.   
7.4 Conclusions 
The aim of this dissertation has been to develop novel biomarkers to better inform 
the risk assessment of the diabetogenic effects associated with iAs exposure. We 
demonstrated that trivalent metabolites of iAs can be measured in a variety of biological 
samples and that these species play an important role in the development of iAs-induced 
diabetes. The contributions of these novel studies include: 
 
a)  A robust HG-CT-based technique for the quantification of trivalent 
arsenicals in a variety of biological samples. 
b)  The use of trivalent arsenical quantification in biological systems 
as sensitive biomarkers for the risk assessment of iAs-associated 
diseases, including diabetes mellitus. 
 
The results presented here support the growing body of evidence that the 
measurement of trivalent arsenic metabolites in biological systems is critical for assessing 
the adverse effects of iAs exposure and have contributed to my desire as a scientist to 
conduct meaningful research that impacts human health. 
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